var title_f32_62_33760="Rx entero endocarditis";
var content_f32_62_33760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50418%7EID%2F64258%7EID%2F66444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50418%7EID%2F64258%7EID%2F66444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of native valve endocarditis due to enterococcal strains susceptible to penicillin, gentamicin, and vancomycin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        American Heart Association",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        British Society for Antimicrobial Chemotherapy",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        European Society of Cardiology*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Adult",
"        <br/>",
"        (for patients with normal renal function)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pediatric",
"        <br/>",
"        (not to exceed dose of normal adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in three equally divided doses for four to six weeks",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          Plus one of the following",
"         </strong>",
"         <sup>",
"          &loz;",
"         </sup>",
"         <strong>",
"          :",
"         </strong>",
"        </p>",
"        <p>",
"         Aqueous penicillin G 18 to 30 million units per 24 hours IV either continuously or in six equally divided doses for four to six weeks",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin 12 g per 24 hours IV in six equally divided doses for four to six weeks",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &sect;",
"         </sup>",
"         30 mg/kg per 24 hours IV in two equally divided doses for six weeks; not to exceed 2 g per 24 hours unless concentrations in serum are inappropriately low",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in three equally divided doses for four to six weeks",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          Plus one of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Aqueous penicillin G 300,000 units/kg per 24 hours IV in four to six equally divided doses for four to six weeks",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin 300 mg/kg per 24 hours IV in four to six equally divided doses for four to six weeks",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &sect;",
"         </sup>",
"         40 mg/kg per 24 hours IV in two or three equally divided doses for six weeks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         1 mg/kg every 12 hours IV for four to six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          Plus one of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Amoxicillin 2 g every four hours IV for four to six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Penicillin 2.4 g every four hours IV for four to six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &sect;",
"         </sup>",
"         1 g IV every 12 hours for four to six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Teicoplanin",
"         <sup>",
"          &yen;",
"         </sup>",
"         10 mg/kg IV once every 24 hours for four to six weeks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in two or three equally divided doses for four to six weeks",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          Plus one of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Amoxicillin 200 mg/kg per 24 hours IV in four to six equally divided doses for four to six weeks",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin 12 g per 24 hours (200 mg/kg per 24 hours) IV in six equally divided doses for four to six weeks",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &sect;",
"         </sup>",
"         30 mg/kg per 24 hours IV in two equally divided doses for six weeks",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenously; IM: intramuscularly.",
"     <br/>",
"     * Pediatric doses (should not exceed adult doses): amoxicillin 300 mg/kg per 24 hours IV in four or six divided doses; gentamicin, ampicillin, and vancomycin dosing recommendations are same as American Heart Association, pediatric.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Alternative for penicillin-allergic patient provided isolate is teicoplanin susceptible (MIC &le;4 mg/L).",
"     <br/>",
"     &Delta; Renal function and gentamicin serum concentrations should be monitored at least once per week. Gentamicin dosage adjusted for peak serum concentrations 3 to 4 mcg/mL, trough &lt;1 mcg/mL when two to three divided doses used.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Four weeks of therapy recommended for patients with symptoms of illness &le;3 months; six weeks of therapy recommended for patients with symptoms &gt;3 months or receiving treatment with gentamicin plus vancomycin.",
"     <br/>",
"     &sect; Vancomycin therapy only recommended for patients allergic to penicillin and cephalosporins; vancomycin dose adjusted for peak serum concentrations (one hour after infusion) of 30 to 45 mcg/mL and trough concentration of 10 to 15 mcg/mL.",
"     <br/>",
"     &yen; Alternative for penicillin-allergic patient provided isolate is teicoplanin susceptible (MIC &le;4 mg/L).",
"    </div>",
"    <div class=\"reference\">",
"     Circulation 2005; 111:3167; J Antimicrob Chemother 2012; 67:269; Eur Heart J 2009; 30:2369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of native valve endocarditis due to enterococcal strains resistant to penicillin and susceptible to aminoglycoside and vancomycin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        American Heart Association",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        British Society for Antimicrobial Chemotherapy",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        European Society of Cardiology*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Adult",
"        <br/>",
"        (for patients with normal renal function)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pediatric",
"        <br/>",
"        (not to exceed dose of normal adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          &beta;-Lactamase producing:",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          One of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24&nbsp;hours IV or IM in&nbsp;three equally divided doses for&nbsp;six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus either",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin-sulbactam",
"         <sup>",
"          &Delta;",
"         </sup>",
"         12 g per 24 hours IV in&nbsp;four equally divided doses for six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         30 mg/kg per 24 hours IV in&nbsp;two equally divided doses for six weeks; not to exceed 2 g per 24 hours unless concentrations in serum are inappropriately low",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          &beta;-Lactamase producing:",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          One of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in&nbsp;three equally divided doses for six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus either",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin-sulbactam",
"         <sup>",
"          &Delta;",
"         </sup>",
"         300 mg/kg per 24 hours IV in&nbsp;four divided doses for six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         40 mg/kg per 24 hours IV in&nbsp;two or&nbsp;three equally divided doses for six weeks",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         <strong>",
"          One of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &yen;",
"         </sup>",
"         1 mg/kg IV every 8 to 12 hours for &ge;4 weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus either",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         1 g IV every 12 hours for &ge;4 weeks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Teicoplanin",
"         <sup>",
"          ������",
"         </sup>",
"         10 mg/kg IV once daily for &ge;4 weeks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          &beta;-Lactamase producing:",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          One of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in&nbsp;two or&nbsp;three equally divided doses for&nbsp;four to&nbsp;six weeks",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          plus either",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin-sulbactam",
"         <sup>",
"          &Delta;",
"         </sup>",
"         12 g per 24 hours (or 300 mg/kg per 24 hours) IV in&nbsp;four equally divided doses for four&nbsp;to six weeks",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Amoxicillin-clavulanate",
"         <sup>",
"          &Delta;",
"         </sup>",
"         200 mg/kg (amoxicillin component) per 24 hours IV in&nbsp;six equally divided doses for&nbsp;four to&nbsp;six weeks",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         30 mg/kg per 24 hours IV in&nbsp;two equally divided doses for&nbsp;six weeks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Intrinsic penicillin resistance",
"         </strong>",
"         <sup>",
"          &sect;",
"         </sup>",
"         <strong>",
"          :",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         30 mg/kg per 24 hours IV in&nbsp;two divided doses for six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in&nbsp;three equally divided doses for six weeks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Intrinsic penicillin resistance",
"         </strong>",
"         <sup>",
"          &sect;",
"         </sup>",
"         <strong>",
"          :",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         40 mg/kg per 24 hours IV in&nbsp;two or three&nbsp;divided doses for six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in&nbsp;three equally divided doses for six weeks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Intrinsic penicillin resistance",
"         </strong>",
"         <sup>",
"          &sect;",
"         </sup>",
"         <strong>",
"          :",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         30 mg/kg per 24 hours IV in&nbsp;two equally divided doses for&nbsp;six weeks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 hours IV or IM in&nbsp;two or&nbsp;three equally divided doses for&nbsp;six weeks",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenously; IM: intramuscularly.",
"     <br>",
"      * Pediatric doses (should not exceed adult doses): amoxicillin-clavulanate 300 mg/kg (amoxicillin component) per 24 hours IV in&nbsp;four or six divided doses; ampicillin-sulbactam, gentamicin and vancomycin dosing are same as recommended by American Heart Association, pediatric.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Renal function and serum gentamicin concentrations should be monitored at least once per week. Gentamicin dosage adjusted for peak serum concentration 3 to 4 mcg/mL, trough &lt;1 mcg/mL.",
"       <br>",
"        &Delta; If strain is gentamicin resistant, then &gt;6 weeks of ampicillin-sulbactam or amoxicillin-clavulanate therapy will be needed.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Vancomycin therapy only recommended for patients unable to tolerate penicillins or intrinsic penicillin resistance; vancomycin dose adjusted for peak serum concentrations (one hour after infusion) of 30 to 45 mcg/mL and trough concentration of 10 to 15 mcg/mL.",
"         <br>",
"          &sect; Consultation with a specialist in infectious diseases recommended.",
"          <br>",
"           &yen; If gentamicin-susceptible (MIC &le;128 mg/L).",
"           <br>",
"            &Dagger; Alternative for penicillin-allergic patient provided isolate is teicoplanin susceptible (MIC &le;4 mg/L).",
"            <br>",
"             &dagger;&nbsp;Four weeks of&nbsp;therapy recommended for patients with symptoms of illness &le;3 months;&nbsp;six weeks of&nbsp;therapy recommended for patients with symptoms &gt;3 months. Intravenous amoxicillin-clavulanate is not available in United States.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Circulation 2005; 111:3167; J Antimicrob Chemother 2004; 54:971; Eur Heart J 2009; 30:2369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of native or prosthetic valve endocarditis due to enterococcal strains resistant to penicillin, aminoglycoside, and vancomycin*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       American Heart Association",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       British Society for Antimicrobial Chemotherapy",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       European Society of Cardiology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Adult (for patients with normal renal function)",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"1\">",
"       Pediatric (not to exceed dose of normal adult)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        <strong>",
"         E. faecium:",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         One of the following:",
"        </strong>",
"       </p>",
"       <p>",
"        Linezolid&bull; 1200 mg per 24 h IV or PO in 2 equally divided doses for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Quinupristin-dalfopristin&Delta; 22.5 mg/kg per 24 h IV in 3 equally divided doses for &ge;8 wks",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         E. faecium:",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         One of the following:",
"        </strong>",
"       </p>",
"       <p>",
"        Linezolid&bull; 30 mg/kg per 24 h IV or PO in 3 equally divided doses for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Quinupristin-dalfopristin&Delta; 22.5 mg/kg per 24 h IV in 3 equally divided doses for &ge;8 wks",
"       </p>",
"      </td>",
"      <td rowspan=\"2\">",
"       <p>",
"        <strong>",
"         One of the following:",
"        </strong>",
"       </p>",
"       <p>",
"        Linezolid&bull; 1200 mg per 24 h IV or PO in 2 equally divided doses for &ge;6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Quinupristin-dalfopristin&Delta; 22.5 mg/kg per 24 h IV in 3 equally divided doses for &ge;6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Teicoplanin&loz; 10 mg/kg IV once daily for &ge;6 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Combinations of antibiotics according to in vitro susceptibility",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         E. faecium&yen;:",
"        </strong>",
"       </p>",
"       <p>",
"        Linezolid&bull; 1200 mg per 24 h IV or PO in 2 equally divided doses for &ge; 8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Quinupristin-dalfopristin&Delta; 22.5 mg/kg per 24 h IV in 3 equally divided doses for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Combinations of antibiotics according to in vitro susceptibility&Dagger;",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        <strong>",
"         E. faecalis&sect;:",
"        </strong>",
"       </p>",
"       <p>",
"        Imipenem-cilastatin 2 g per 24 h IV in 4 equally divided doses for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         plus",
"        </strong>",
"       </p>",
"       <p>",
"        Ampicillin 12 g per 24 h IV in 6 equally divided doses for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ceftriaxone 4 g per 24 h IV or IM in 2 equally divided doses for &ge;8 wks&dagger;",
"       </p>",
"       <p>",
"        <strong>",
"         plus",
"        </strong>",
"       </p>",
"       <p>",
"        Ampicillin 12 g per 24 h IV in 6 equally divided doses for &ge;8 wks",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         E. faecalis&sect;:",
"        </strong>",
"       </p>",
"       <p>",
"        Imipenem-cilastatin 60-100 mg/kg per 24 h IV in 4 equally divided doses for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         plus",
"        </strong>",
"       </p>",
"       <p>",
"        Ampicillin 300 mg/kg per 24 h IV in 4 to 6 equally divided doses for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ceftriaxone 100 mg/kg per 24 h IV or IM in 2 equally divided doses for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         plus",
"        </strong>",
"       </p>",
"       <p>",
"        Ampicillin 300 mg/kg per 24 h IV in 4 to 6 equally divided doses for &ge;8 wks",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         E. faecalis&sect;:",
"        </strong>",
"       </p>",
"       <p>",
"        Imipenem-cilastatin 2 g per 24 h (or 60-100 mg/kg per 24 h) IV in 4 equally divided doses for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         plus",
"        </strong>",
"       </p>",
"       <p>",
"        Ampicillin 12 g per 24 h (or 300 mg/kg per 24 h) IV in 6 equally divided doses for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Ceftriaxone 2 g per 24 h (or 100 mg/kg per 24 h) IV or IM in 1 dose for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         plus",
"        </strong>",
"       </p>",
"       <p>",
"        Ampicillin 12 g per 24 h (or 300 mg/kg per 24 h) IV in 6 equally divided doses for &ge;8 wks",
"       </p>",
"       <p>",
"        <strong>",
"         or",
"        </strong>",
"       </p>",
"       <p>",
"        Combinations of antibiotics according to in vitro susceptibility&Dagger;",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenously; IM: intramuscularly; PO: orally; h: hours; wks: weeks.",
"     <br>",
"      * Decreasing order of preference based on published data. Patients with endocarditis caused by these strains should be treated in consultation with an infectious disease specialist; cardiac valve replacement may be necessary for bacteriologic cure; cure with antimicrobial therapy alone may be &lt;50 percent.",
"      <br>",
"       &bull; Severe, usually reversible thrombocytopenia may occur with use of linezolid, especially after 2 wks of therapy. Monitor hematologic toxicity.",
"       <br>",
"        &Delta; Only effective against E. faecium and can cause severe myalgias, which may require discontinuation of therapy.",
"        <br>",
"         &loz; Provided isolate is teicoplanin susceptible (MIC &le;4 mg/L). Strains highly resistant to vancomycin (vanA type resistance) are also resistant to teicoplanin.",
"         <br>",
"          &sect; Only a small number of patients have been treated with imipenem-cilastatin plus ampicillin or ceftriaxone plus ampicillin.",
"          <br>",
"           &yen; Varying results reported with linezolid, quinupristin-dalfopristin, daptomycin and tigecycline.",
"           <br>",
"            &Dagger; High level E. faecalis and E. faecium resistance to gentamicin (MIC&gt;500 mcg/mL): if susceptible to streptomycin, beta-lactam or vancomycin combination with streptomycin 15 mg/kg per 24 h IV in 2 equally divided doses, is an alternative.",
"            <br>",
"             &dagger; Although an every-24-hour dosing of ceftriaxone has never been formally studied in human trials in combination with ampicillin for the treatment of multidrug-resistant Enterococcus faecalis, unpublished animal model data indicate that every-12-hour dosing of ceftriaxone in combination with ampicillin is more efficacious in reducing the bacterial concentration in infected vegetations as compared with every-24-hour dosing of ceftriaxone with ampicillin.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Circulation 2005; 111:3167; J Antimicrob Chemother 2004; 54:971; Eur Heart J 2009; 30:2369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33760=[""].join("\n");
var outline_f32_62_33760=null;
var title_f32_62_33761="Kaposi sarcoma of gastric mucosa";
var content_f32_62_33761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F87392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F87392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kaposi sarcoma of gastric mucosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gastric lesions of Kaposi sarcoma in an HIV-positive patient who presented with an upper gastrointestinal bleed, endobronchial and skin lesions of Kaposi sarcoma, and a hemorrhagic pleural effusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33761=[""].join("\n");
var outline_f32_62_33761=null;
var title_f32_62_33762="Contents: Pediatric neurology";
var content_f32_62_33762=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric neurology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric neurology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cerebral palsy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/33/29209\">",
"           Clinical features of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/0/4104\">",
"           Diagnosis and classification of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/50/41768\">",
"           Epidemiology and etiology of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/37/15962\">",
"           Management and prognosis of cerebral palsy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cerebrovascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/11/31930\">",
"           Cerebrovascular complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/26/7594\">",
"           Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/31/31226\">",
"           Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/61/23513\">",
"           Ischemic stroke in children and young adults: Etiology and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/37/43608\">",
"           Ischemic stroke in children: Evaluation, initial management, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/27/27063\">",
"           Ischemic stroke in children: Secondary prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/44/3786\">",
"           Moyamoya disease: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/36/7751\">",
"           Moyamoya disease: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/2/27690\">",
"           Stroke in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/16/9482\">",
"           Treatment and prognosis of cerebral venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/9/18584\">",
"           Vascular malformations of the central nervous system",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Demyelinating disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/52/25416\">",
"           Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/22/20838\">",
"           Acute disseminated encephalomyelitis in children: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/58/40872\">",
"           Alexander disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/4/34888\">",
"           Cerebrotendinous xanthomatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/20/1352\">",
"           Differential diagnosis of acute central nervous system demyelination in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/15/9464\">",
"           Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/15/29944\">",
"           Optic neuritis: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/32/12809\">",
"           Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/9/13465\">",
"           Pelizaeus-Merzbacher disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/53/35671\">",
"           Sj������gren-Larsson syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/32/21000\">",
"           Treatment and prognosis of pediatric multiple sclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38392\">",
"           Vanishing white matter disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Developmental and behavioral problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/20/15689\">",
"           Asperger disorder: Clinical features and diagnosis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/52/41801\">",
"           Asperger disorder: Management and prognosis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/18/26922\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/61/32730\">",
"           Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/1/4122\">",
"           Autism spectrum disorders in children and adolescents: Behavioral and educational interventions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/54/16234\">",
"           Autism spectrum disorders in children and adolescents: Complementary and alternative therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/54/872\">",
"           Autism spectrum disorders in children and adolescents: Overview of management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/46/35562\">",
"           Autism spectrum disorders in children and adolescents: Pharmacologic interventions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/41/664\">",
"           Clinical features of autism spectrum disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/33/29209\">",
"           Clinical features of cerebral palsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/3/38969\">",
"           Diagnosis of autism spectrum disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/10/26793\">",
"           Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/8/5257\">",
"           Intellectual disability (mental retardation) in children: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/59/40887\">",
"           Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/57/32665\">",
"           Specific learning disabilities in children: Clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/27/37306\">",
"           Specific learning disabilities in children: Educational management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/6/35944\">",
"           Specific learning disabilities in children: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/18/44329\">",
"           Specific learning disabilities in children: Role of the primary care provider",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Encephalopathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/52/25416\">",
"           Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/62/22506\">",
"           Acute toxic-metabolic encephalopathy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/24/2442\">",
"           Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/14/30953\">",
"           Etiology and pathogenesis of neonatal encephalopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/40/23178\">",
"           Approach to neuroimaging in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/13/34004\">",
"           Approach to the infant with hypotonia and weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/17/14618\">",
"           Detailed neurologic assessment of infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/2/30761\">",
"           Diagnosis of brain death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/54/3946\">",
"           Etiology and evaluation of macrocephaly in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/30/28136\">",
"           Evaluation of stupor and coma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/1/25625\">",
"           Lumbar puncture: Indications, contraindications, technique, and complications in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/5/19544\">",
"           Treatment and prognosis of coma in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Feeding the child",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/30/15850\">",
"           The ketogenic diet",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genetic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/56/33673\">",
"           Adrenoleukodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/6/7274\">",
"           Clinical features and diagnosis of the mucopolysaccharidoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/16/35082\">",
"           Complications and management of the mucopolysaccharidoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/31/31226\">",
"           Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/25/8599\">",
"           Huntington disease: Genetics and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/60/4038\">",
"           Krabbe disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/27/42421\">",
"           Metachromatic leukodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/12/7370\">",
"           Mitochondrial myopathies: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/30/2536\">",
"           Mitochondrial myopathies: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/35/12853\">",
"           Mitochondrial structure, function, and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/49/27414\">",
"           Neurologic manifestations of Fabry disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/46/7914\">",
"           Organic acidemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/0/20489\">",
"           Overview of Niemann-Pick disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/23/8570\">",
"           Peroxisomal disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/29/32218\">",
"           Rett syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/9/8344\">",
"           Spinal muscular atrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/39/4727\">",
"           Sturge-Weber syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/48/14088\">",
"           Tests used in the diagnosis of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/0/24586\">",
"           The genodermatoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/11/23737\">",
"           Treatment of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/38/34410\">",
"           Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/36/32328\">",
"           Tuberous sclerosis complex: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/9/18584\">",
"           Vascular malformations of the central nervous system",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Headache",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/8/35977\">",
"           Approach to the child with headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/44/44743\">",
"           Basilar-type migraine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/21/42327\">",
"           Classification of migraine in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/48/34568\">",
"           Cyclic vomiting syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/37/44633\">",
"           Elevated intracranial pressure in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/3/18490\">",
"           Management of migraine headache in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/8/15496\">",
"           Migrainous vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/25/8600\">",
"           Pathophysiology, clinical features, and diagnosis of migraine in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/59/34744\">",
"           Tension-type headache in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/16/21769\">",
"           Acute viral encephalitis in children and adolescents: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/18/23848\">",
"           Acute viral encephalitis in children and adolescents: Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/51/14135\">",
"           Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/21/10586\">",
"           Viral meningitis: Clinical features and diagnosis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Malformations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/62/11237\">",
"           Anencephaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/4/26697\">",
"           Chiari malformations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/54/5994\">",
"           Hydrocephalus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/14/19688\">",
"           Orthopedic issues in myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/46/26344\">",
"           Overview of the management of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/27/20921\">",
"           Pathogenesis and types of occult spinal dysraphism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/62/33767\">",
"           Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/57/3991\">",
"           Primary (congenital) encephalocele",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/59/15288\">",
"           Urinary tract complications of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/48/34568\">",
"           Cyclic vomiting syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/0/17417\">",
"           Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/25/15769\">",
"           Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/54/41833\">",
"           Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/32/12809\">",
"           Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Movement disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/26/8616\">",
"           Acquired torticollis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/34/10790\">",
"           Acute cerebellar ataxia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/60/23497\">",
"           Ataxia-telangiectasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/36/15943\">",
"           Bradykinetic movement disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/45/13018\">",
"           Clinical manifestations, diagnosis, and natural history of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/49/43798\">",
"           Congenital muscular torticollis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/37/13910\">",
"           Epidemiology and pathogenesis of Wilson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/4/15432\">",
"           Friedreich ataxia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/40/18058\">",
"           Hyperkinetic movement disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/35/37433\">",
"           Overview of the hereditary ataxias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/50/32554\">",
"           Restless legs syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/31/22007\">",
"           Sydenham chorea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/35/29242\">",
"           The spinocerebellar ataxias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/8/22664\">",
"           Tourette syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal neurology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/53/2906\">",
"           Brachial plexus syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/11/6328\">",
"           Clinical features and electrodiagnosis of neonatal seizures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/44/42697\">",
"           Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/6/13417\">",
"           Congenital myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/14/30953\">",
"           Etiology and pathogenesis of neonatal encephalopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/23/41335\">",
"           Etiology and prognosis of neonatal seizures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/46/31465\">",
"           Management and complications of intraventricular hemorrhage in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/60/35783\">",
"           Neonatal epileptic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/10/166\">",
"           Neuromuscular junction disorders in newborns and infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/48/11015\">",
"           Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/7/33913\">",
"           Periventricular leukomalacia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/42/12970\">",
"           Pneumococcal meningitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/2/27690\">",
"           Stroke in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/0/13\">",
"           Treatment of neonatal seizures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurocutaneous disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/50/36650\">",
"           Neurofibromatosis type 1 (von Recklinghausen's disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/39/4727\">",
"           Sturge-Weber syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/38/34410\">",
"           Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/36/32328\">",
"           Tuberous sclerosis complex: Management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuromuscular disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/56/905\">",
"           Approach to the metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/36/21065\">",
"           Causes of metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/16/1290\">",
"           Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/58/21415\">",
"           Emery-Dreifuss muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/63/6134\">",
"           Energy metabolism in muscle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/34/26153\">",
"           Facioscapulohumeral muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/32/15881\">",
"           Limb-girdle muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/26/19882\">",
"           Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/40/18057\">",
"           Myotonic dystrophy: Prognosis and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/10/166\">",
"           Neuromuscular junction disorders in newborns and infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/14/41192\">",
"           Oculopharyngeal, distal, and congenital muscular dystrophies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/3/27705\">",
"           Overview of Guillain-Barr������ syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/43/29368\">",
"           Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/35/31287\">",
"           Pathogenesis of myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/33/32276\">",
"           Patient information: Overview of muscular dystrophies (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/9/8344\">",
"           Spinal muscular atrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/5/2138\">",
"           Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/2/26666\">",
"           Treatment of Duchenne and Becker muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/51/41781\">",
"           Treatment of Guillain-Barr������ syndrome in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuropathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/42/25257\">",
"           Facial nerve palsy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/37/602\">",
"           Hereditary neuropathies associated with generalized disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/59/35770\">",
"           Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/16/43272\">",
"           Hereditary sensory and autonomic neuropathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/60/4038\">",
"           Krabbe disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/27/42421\">",
"           Metachromatic leukodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/49/27414\">",
"           Neurologic manifestations of Fabry disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/0/20489\">",
"           Overview of Niemann-Pick disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/20/33098\">",
"           Overview of acquired peripheral neuropathies in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/24/21895\">",
"           Overview of hereditary neuropathies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/44/12999\">",
"           Fourth cranial nerve (trochlear nerve) palsy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/32/32262\">",
"           Horner's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/15/20726\">",
"           Myopathies affecting the extraocular muscles in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/15/9464\">",
"           Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/15/29944\">",
"           Optic neuritis: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/0/1034\">",
"           Pendular nystagmus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/2/43046\">",
"           Sixth cranial nerve (abducens nerve) palsy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/8/28806\">",
"           Supranuclear disorders of gaze in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/34/40487\">",
"           Third cranial nerve (oculomotor nerve) palsy in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Seizures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/57/921\">",
"           Benign partial epilepsies of childhood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/4/14409\">",
"           Clinical and laboratory diagnosis of seizures in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/28/18888\">",
"           Clinical features and complications of status epilepticus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/2/1063\">",
"           Clinical features and diagnosis of infantile spasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/11/6328\">",
"           Clinical features and electrodiagnosis of neonatal seizures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/62/33769\">",
"           Epilepsy syndromes in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/15/1273\">",
"           Etiology and pathogenesis of infantile spasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/23/41335\">",
"           Etiology and prognosis of neonatal seizures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/9/3226\">",
"           Febrile seizures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/30/15849\">",
"           Juvenile myoclonic epilepsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/1/23578\">",
"           Localization-related (partial) epilepsy: Causes and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/28/30154\">",
"           Management and prognosis of infantile spasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/50/30505\">",
"           Management of status epilepticus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/60/35783\">",
"           Neonatal epileptic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/31/29175\">",
"           Nonepileptic paroxysmal disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/51/24376\">",
"           Nonepileptic paroxysmal disorders in infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/25/21912\">",
"           Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/32/37386\">",
"           Overview of the treatment of seizures and epileptic syndromes in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/32/37385\">",
"           Pathophysiology of seizures and epilepsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/61/43994\">",
"           Pharmacology of antiepileptic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/0/13\">",
"           Treatment of neonatal seizures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/7/19578\">",
"           Vagus nerve stimulation therapy for the treatment of epilepsy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/13/32985\">",
"           Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/19/40249\">",
"           Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/35/10808\">",
"           Intracranial epidural hematoma in children: Clinical features, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/61/11222\">",
"           Intracranial epidural hematoma in children: Epidemiology, anatomy and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/49/29464\">",
"           Intracranial subdural hematoma in children: Clinical features, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/4/21575\">",
"           Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/38/12906\">",
"           Minor head trauma in infants and children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-E56533D49D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f32_62_33762=[""].join("\n");
var outline_f32_62_33762=null;
var title_f32_62_33763="Hexachlorophene: Drug information";
var content_f32_62_33763=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hexachlorophene: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/41/28307?source=see_link\">",
"    see \"Hexachlorophene: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/54/9059?source=see_link\">",
"    see \"Hexachlorophene: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      pHisoHex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      pHisoHex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F179125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F179115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiseptic (Children and Adults): Topical: Apply 5 mL cleanser and water to area to be cleansed; lather and rinse thoroughly under running water.Repeat if using as surgical scrub.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F179119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/54/9059?source=see_link\">",
"      see \"Hexachlorophene: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F179116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     pHisoHex&reg;: 3% (150 mL, 480 mL, 3840 mL [DSC]) [contains sodium benzoate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11507274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Surgical scrub: Wet hands and forearms with water. Apply cleanser over hands and rub into a lather. Scrub hands and forearms with a wet brush for 3 minutes. Rinse. Repeat above for another 3 minutes. Rinse and dry.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cleansing: Wet hands with water. Apply cleanser over hands, rub into a lather, and apply to area to be cleansed. Rinse thoroughly and dry.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3071517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with many metals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F179104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Surgical scrub and as a bacteriostatic skin cleanser; control an outbreak of gram-positive infection when other procedures have been unsuccessful",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       pHisoHex&reg; may be confused with Fostex&reg;, pHisoDerm&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F179124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1%: CNS injury, dermatitis, dry skin, irritability, photosensitivity, redness, seizure",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F179107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to halogenated phenol derivatives or hexachlorophene; use on burned or denuded skin; use as an occlusive dressing, wetpack, or lotion; application to mucous membranes; use as a vaginal pack or tampon; routine use for prophylactic total body bathing",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F179092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebral irritability: Discontinue use if signs of cerebral irritability occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Burn patients: Exposure to patients with extensive burns has been associated with apnea, convulsions, agitation and coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Exposure to preterm infants has been associated with apnea, convulsions, agitation and coma; particularly susceptible to hexachlorophene topical absorption. Do not use for bathing infants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid exposure to eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13892598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Hexachlorophene is absorbed systemically when applied topically. Following use as an antiseptic for vaginal exams during labor, hexachlorophene is detectable in the maternal serum and cord blood (Strickland, 1983). Vaginal use as a pack or tampon and application to mucous membranes is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13892599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Phisohex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (148 mL): $31.72",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aknefug-simplex (DE);",
"     </li>",
"     <li>",
"      Dermisan (ID);",
"     </li>",
"     <li>",
"      Jabon Antiseptico (ES);",
"     </li>",
"     <li>",
"      Phisohex (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Ritosept (HU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F179091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bacteriostatic polychlorinated biphenyl which inhibits membrane-bound enzymes and disrupts the cell membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F179106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Percutaneously through inflamed, excoriated, and intact skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Infants: 6.1-44.2 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Halling H, &ldquo;Suspected Link Between Exposure to Hexachlorophene and Malformed Infants,&rdquo;",
"      <i>",
"       Ann N Y Acad Sci",
"      </i>",
"      , 1979, 320:426-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/62/33763/abstract-text/287398/pubmed\" id=\"287398\" target=\"_blank\">",
"        287398",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lester RS, &ldquo;Topical Formulary for the Pediatrician,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1983, 30(4):749-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/62/33763/abstract-text/6225068/pubmed\" id=\"6225068\" target=\"_blank\">",
"        6225068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lockhart JD, &ldquo;How Toxic is Hexachlorophene?&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1972, 50(2):229-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/62/33763/abstract-text/4625618/pubmed\" id=\"4625618\" target=\"_blank\">",
"        4625618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marquardt ED, &ldquo;Hexachlorophene Toxicity in a Pediatric Burn Patient,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1986, 20(7-8):624.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nagy L and Orosz M, &ldquo;Occupational Asthma Due to Hexachlorophene,&rdquo;",
"      <i>",
"       Thorax",
"      </i>",
"      , 1984, 39(8):630-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/62/33763/abstract-text/6474393/pubmed\" id=\"6474393\" target=\"_blank\">",
"        6474393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strickland DM, Leonard RG, Stavchansky S, et al, \"Vaginal Absorption of Hexachlorophene During Labor,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1983, 147(7):769-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/62/33763/abstract-text/6650599/pubmed\" id=\"6650599\" target=\"_blank\">",
"        6650599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8523 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33763=[""].join("\n");
var outline_f32_62_33763=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179113\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179114\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179125\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179115\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179119\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179116\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179103\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179088\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507274\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3071517\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179104\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179129\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179124\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179107\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179092\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299444\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179097\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179099\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13892598\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13892599\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524630\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038651\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179091\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179106\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8523\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8523|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/41/28307?source=related_link\">",
"      Hexachlorophene: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/54/9059?source=related_link\">",
"      Hexachlorophene: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_62_33764="Pulmonary aspergillosis";
var content_f32_62_33764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Invasive aspergillosis in lung transplant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 339px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFTAboDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3v4m+PtK+HOgQ6vrkN7NbS3K2qraIrvuZWYEhmUYwh7+leY/8NUeBv+gd4i/8Bof/AI7R+2l/ySrTv+wxF/6Jmrzv4MfCnwRr/wAIrjxZ4sS932rXDzPFcFAI4xnp64BoA9E/4ao8Df8AQO8Rf+A0P/x2j/hqjwN/0DvEX/gND/8AHa5Xwf8AC34X+Nvh/qfiHQ7HWbZ7VZ0aG5uvnjkRNwyBkYIKn8a+UaAPtj/hqjwN/wBA7xF/4DQ//HaP+GqPA3/QO8Rf+A0P/wAdr4nooA+2P+GqPA3/AEDvEX/gND/8do/4ao8Df9A7xF/4DQ//AB2vjC0sprpv3afL3Y9BW5Z6TBDhpP3r+/QfhQB9dW/7Tvg24/1WleJCPX7NCB+fm1cH7Rvg8j/jw10f9sIv/jlfJQGBgcCloA+tP+GjfB//AD467/34i/8AjlH/AA0d4P8A+fHXf+/EX/xyvkuigD60/wCGjvB//Pjrv/fiL/45R/w0d4P/AOfHXf8AvxF/8cr5KooA+tf+GjvB/wDz467/AN+Iv/jlH/DR3g//AJ8dd/78Rf8AxyvkqigD61/4aO8H/wDPjrv/AH4i/wDjlH/DRvg//nw13/vxF/8AHK+ShS0AfVtx+0t4QgBLaV4jZfVLaE/+1ap/8NUeBv8AoHeIv/AaH/47Xy9VS7sILoEum1/7y8GgD6s/4ao8Df8AQO8Rf+A0P/x2j/hqjwN/0DvEX/gND/8AHa+OL3SprfLJ+9j9QOR9RWdQB9sf8NUeBv8AoHeIv/AaH/47R/w1R4G/6B3iL/wGh/8AjtfE9FAH2x/w1R4G/wCgd4i/8Bof/jtH/DVHgb/oHeIv/AaH/wCO18T0UAfbH/DVHgb/AKB3iL/wGh/+O16Z4B+IOk+N/CVz4i0mG9isbeSSN1uY1WTKKGOArEdCO9fm3X2p+yfs/wCFGan5ozH9sutwzjjy0zQB103xt8Nw6c989jrH2dZPKyIY8k+37yqx+PfhYQJKbLWsN28iPI/8iYrzPwPoWjeIk8ZNrMmonTNDs4bxLe1nCck3LP25OI1Aq14P0DwP4q1LR9Fn0fxfpq6laNfae9zdxtHNGoyTlGJXr3AoA9K0b44eGtX1eLTbWy1gXMsixrvhjAyffzOlP1f41+GtK1mTTLq01Y3KNsOyGNlJ7Y+fnNfNN5bv4d8VaollK6pZ6pcw2zs25wsdw6Lk/RKf46a4l12PVIpAhGxklGMKQAQcfkaAPorWvjpoGhzSQ6toviO1lRtrJLaxg52hgB+854INZrftIeD0KbrDXgG5z9ni4+v7yvlvxFc6neySW+q3Mtxc2yxhVklLkJjKgH2DfhnFO0llAcMoaYDPzDqvcUAfc2leM7LVZJhY2l7LBHF5vngRlGXbuG3D5JKkEcdCM4rD0D4taDrl3LaW1rqUV6gOLe4jjSSRsZCqN/LHsK+fvhp8Q7rQ2t9NENlcQqkotWuJDD5LMNxBccFSRjB9cZFJ4e0qDVYNR1jU9ct9J1C0BYRMS0ksijgLznqAPyoA9ql+PPhiGVopdP1xJVJVkaCMFSDggjzPWoz+0B4UCgmy1oEkgL5EeeP+2lfP2sIl7fvqdpGYFZUV1cYJbaA7dT1bJ/Gs+Gzd5/PeHaOxYcGgD6Utvj54VuD8tnrK8E/NDGOn/bSmL+0D4TZsLZa0TnGBBHz/AORK8EbSkt4TPdIEib5QPU9cVi3NstvIJOFByRjt9aAPpR/2gvCiH57HWgPUwxf/AByrFp8d/C9ywCWesLngF4YwP/RlfKYQTSE7S319a6TRbb7zYVmAwXzwB3FAH0OPjv4Y+0eT9g1rOM7vJjx/6Mp158d/CtqoJtdWkBIA8uGM5yf+ulfPOq/ZRBc/Z1KloyN46k/4VzsN9NDbRxpEjGFtwbbyeO9AH1XL8cvDMcscZstYLugfAhj4B9f3lEfxy8MyK5Wy1jCjJ/cx/wDxyvlq31N7q7SdHxwASfzrSkWQTeZGSF6kigD6OHx48L7dxs9ZAxnmGP8A+OVYt/jd4ZnGUtdVGOuYY/8A4uvmRYBc3LFJQfkPy+hq5pILMy55xyPfpQB9KP8AGfw0sSyeRqbKTjiJOP8Ax+lX4zeG2BIt9UwOp8pP/i/evna3hLpIsuQqgkH3FTQyKITHjcHxkjGcg0AfSNr8U9CuUdoob87TjHlpz9PmqI/FnQfLLi11IqDg4iT/AOLrxSWBtOWNLc4ChWff2JHas+1ug7zbGCIGLEep9KAPoGP4paFJEXSG/LD+Dy13f+hVbv8A4g6ZY6Ja6pLZ6g1vcOY1VI0LAg45G/A6etfNt5dGKeN4GKuDwD6Cu9l1APpEG2PdHdW5XLLkZ3A8Z6cjrQB7N4V8Waf4mE/2BZ0aE/MsygH9Ca6CvIvghG/2/U51B8qRACe2QRj+Zr12gDwP9tL/AJJVp3/YYi/9EzVyPwnsV8S/s3f8I1Br2m6VJeaiy3T3E4RxbiQM4UepwBzwQTXXftpf8kq07/sMRf8AomaviegD7i8O+HrXwSfGksPi/TtS0nVNO3BJp4lnW4SNlyFQBMFSBxycD618O0U5EZ3CoCzHgAUAIASQAMk9q2tP0jdiS7yB2jH9at6Zpq2oEkuGm/RfpWjQAiqqqFUAAdAKWiigAooozQAUGkooAKKKKACiiigA+lLSUUALRSZpaACs2/0uO4y8WI5fboa0qKAONnhkgkKSqVYetRV195aR3cZWQc9mHUVzF7ayWkxSQfRh0IoAr0UUUAFfZ/7LRx8AdaJ7XN3/AOikr4wr7Q/ZXUN8BdXU9DdXY/8AISUAZPwY+wTWfj7T3v7Wzl1LSbaFJbuURh3b7Wueew3KDjPT3rQ+GHw/i8K+J9B1K48QeEbGPTLeSGdtKuX83UtyhcTl224BAbgdR9CPP9K1uxs5ntbyzicxq0cczRhuD257cmrmp/Da1u/BMniGwOyW7ulgtbLyBmUsQDg9uc49hQBz/iaOC+8Va88U4EcusXx81DuUqbqUhsjtjvVnxLbIfCEEm5c/Z1YoD0wx5/I102oeErrRdL/s++jitb+yCHjBV1PIIP5j6g1m67obX+p6XpsRKW9wkcbzL92MM4XJ+hNAHnlnZCO2W8eOR0lBXexJOe2T+FQ6bbsupIplweVyT049a9V0zw/eP4Q1bV72f7Zo9kg0+wj8vDHbLlG4HH3myevzY6V5td2k8H7ySGSNJDlAykZB6EeooApSRSW94UkT5ojnPY+9dX4Xs9I1BNX/ALZ1FrKaK0eW0PBWWUDhG78joBWDHvCRiTLE/IGxyB71MbKOO4EkcueDwRjnFAHsdj4f06TwRoQjtRNbPbm/luerTXO7YUJ7Kg7d+K19QsrQ6MrywwyRKMBcAc47e1eR2erX+kaULSKe4WzZMBTIcckEkA8DJHbFZF34mu1d4/ttw6SLyN5IH4H+lAFzxFeyz3a28TZt4WOBngE9TWZMoK5lkJJx908VHZzRykkDAPVif0p0rIknyjjuSaAIJUdCGT7o7e1eneEPDesPoapANPuLHWPKtzKG3G1kZspnup4we3zYryuSeSKYvCx2+nY16J4G8f8A/CPa1aT2VsJY2s1tXiuZ8IkhbLOp6KCcH25oA5LUL1xeTWIj/wBUzRuOoyDg1CIFjtpduW2nqOlamr6QumGJZdQsLu5uXla4+yyBxEwfAUkcc9RjtUkdkhtRGobI6n3oA4SUtp9+UwWjU/MBXS6ZqMVxDLbK7AqmY93cf3asXWmRwa6u9ElMsRKoeQTjFYMNqySf6Mj+ahzx7UAWNMuAdX2u7CJ+uPWuutbVzdpNCMxuWVwP4T/nFcU9uyXonmUxAnPAru9Lv1s9k9u4YcNyOAe4NAEd7M0QlgUfNuxkemKr2k4tLtDtVzG6yFT0PPIPtXQPFYaiv2iJwt0wz5R6HFZE+lXEE+5kJyDkj07UAdbrHiBrme7WK2tRHqK5YImfLUHd8vp0xXEwOC0qq7As24enFa+mqWtzAz7XRTsYdQO4rMQiMzW2FJYcseCaALSeTNFIjMfMUZUkdfpXZ6XLNrtn4T0hLxfMkhnj8lI8bBGxKnPdm5/GvO5W8uVXz+8UAADoPrXXeL5m0HUfCFlYEw3FnZLcOQ+SJJmLnntxigD2D4aWraX4oubK3uGfT5bMzIjLtIZXVSD/ALQyQa9Prxz4TpfJ44uTqCyIz6e8gEhOfmkQ5wfXrXsdAHgf7aX/ACSrTv8AsMRf+iZq+J6+2P20v+SVad/2GIv/AETNXxPQAqgsQAMk8AV02k2AtY97jMzdf9kelVtDsdqi5lHJ+4PT3rZoAKKUAnoCasRWNzKu5YiB6nigCtRVt7CRPvsufQVGLOUjgfnQBXoqwLR+5A/OnCzbqXA/A0AVaKuC0QctL+VJ5dsOPMbPvxQBUoq0YIz90sfoQaY8KKfmMij3WgCCipfLjP3Zl/EEUnkN6oR/vCgCOipRCB96Rc+g5p62+4/K36UAV6Kt/Ym/vCj7EccsBQBUozVv7E2MhlNNNnJ22n8aAK+ahu7eO6hMcg+h7g1ba2lA+7+RqHpwetAHIXdu9tMY5ByOh9R61BXV6laC8gxwJF5U/wBK5Z1KMVYYYHBFADa+zv2XGK/s/wCtsOouLwj/AL8pXxjX2h+yxF5/wE1iHOPMurtM/WJBQB4d5d/Ppxu0t5Ht0BkZ0X7q5ALH2yQM+9ddq3jQ6roei2FlJcRNp0ShouAvnAn96uOc4I610Xwp0zT/AO2buw1VkktUtbi2CythW3DI479D+OK8jS3msNVmHK7WKGgD2G31iXX7Syub6/W81K7MsNzCTloVUjYSO2SW6Vj+O9BFppMC3Uz/AGWO4DZB+Yxt1x+Oax/AErRa9GvBF1nbu/2TnArsvi9dJf6Zb/ZRuCxHftOCMHofxNAGLY6lqFh4HvNF0tzMupXUSPtGVjUjhC54DNgcdgK6mSx0zQvDNha366XdT+QIL+O+kY3EHmYc+WBny1QEYx1J9a4nwxask2m6bdwTzfbbpJHjacR20kaKWKNwfnOMA9vxp/ira2s3UEliFmhtpJruRbkugZ8NGd3JKqpRQvrigDmNQFs1zPHbTebbRlgsir98AkA/jxTLaNBHJPKp2KAvPX6mqFjdeWhEgyxUlc8d6018ttJmWNtqFsYY4B555oA2vGGh6fL4C0rVbWcHULdkjuY1U4eOUsY2yTgkYKnH9Kw9M8E3uo6Nquow+V5WnQefMHcKSvfb6nFVdbmng1qLRhefa7PTzsATiMkEsQB3AZm5NdP4f8YJoujauGtNPvJbgGMwXUO4kMMZB/uKRkqcdc5oA86DzCOWaGN2jt1DOUQlYwTgbiOmTWeuoTOpfOVYkECtWzvr+ysdU0y3lKWWpqiXMZB+bawYH2PH5E1iahaCB8wE7e4oAtR3wIGTxViC5Mc8U0aJL5bBij8q2DnBHpWOgyhPTFbGkJEYyZXCknvQBq3Nw0k2oX4t4IRM3nCGJdqISTwo7AdAK6XQbhX09Z5ZVjIwCrfxH/CuejjWeyVlI+UlSvr6f59601h8yOyThW2tJj1C0AWr64Z9RS7B3eWNoHccdazdOWW1vIrkMPJJwdw5IPWrdvICjCRSFl+TkdCe9PtblFxFcR7TE+CvuKAH3yvf3MkVshkVOI1A5+lQWrSQvJY3Q2OfnUkdx2rSsNQaa9a4RAHAIBTjntWzJoX9reE9T1qW5t4ZNNwSXbDSk9AB1zQBkacsUlwGeQxlV+VlPB6Vuxal9os2EmHmiYI4B5UdA9c5Y2/2vQvtMRzKuW2+q+lb3haK00vwwLmSyS9nupGWQ/MZSM5AXsMdaAA2cjMstuep+8D/AErBvElikkEkZBz97+das2uJbarEtnbvFbzDEvmtnb2wPpSXktzDcE3ASeIcrn+IZoAZ4cvdDstVM/iK1lvLMQvmKNsZkx8uenGazdLEk+sW1xdh5oIpU6seVBGFBPbHFWro2d1BLNb2QWXHTdwa29D0W5m8IS+IYL1JZ4rj7KNPEeWJYALt9Scnj0FAHtHgm/stb+IC6ta3IN0+lSQXNrn/AFRWWLaQP7pB/Q16dXjXwK8RR6jqV7Y21qkduIWm3v8A60MGRSCccjn8MV7LQB4H+2l/ySrTv+wxF/6Jmr400q0+1XIDD92vLf4V9l/tpf8AJKtO/wCwxF/6Jmr5X0iwNvZoHG1m+ZvXNAE3RcAYA6VYtbWW5cCMcf3j0FWobdUUMyj6tTpLxY1Kq24+g4FAF5TFZKscIRmX7zkd6rTan8x+Znb9KzZJndsMcDsB2q7oWganrt2INLtZJ27sB8q/U0AQyX0rtlQAfpUZmlc/ebPoBXrmg/CKWNVbWL5FBOWjhGT9M132leDtB0yIJb2EbsON8nJNAHzXFZ3s4/dxyt9FNXYfDWsXGPLtJ3+imvqCO0t4hiO2iQD0UVMg2/cVQPYYoA+YD4M8QYBGmTn/AIDUkPgbxJM2BpVxk+or6eJcnCnOe1Sx2t1IflRvxoA+a4Phh4mlbDWaxj1ZxW3Z/CPV8fv723h9gS1fRNv4e1CcA7Bt92xVseE7ru8XToCaAPnZ/g/dMM/2has3+6RTIfg7d+b+9u7cJ325NfQNx4cvYlLFAw9jms97G6XIMZzQB5lpfwr0q3wbyd529F4FdJa+DPD9vgLp8bf73NdIIJF6o3FR/Mv8JoAxX8J6C550u26f3apXPgLw3cjD6cqE/wBxitdUoLdFzSmNu6n8TQB5dq3wh06ZWbSr+W3k7LKNy15t4m8E694fy91bs8A6TQncp+vpX0yy7T0Jpj4dSrAFT1UjINAHyKly6Dk7ueQ1TFYroHHySYyPevZvHvwzt9RjkvdAVYLofM9v0WT6ehrxS4gns5zFNG0c8TYKsMEGgCu6lG2sMEVh69aDH2mMc9HH8jXUSAXEYKjDdvr6VQkQOjI4yrDBBoA4uvtj9keFrj4KX0KtsaS+uUDehMaDNfFt3Abe4eJv4TwfUV9p/siSGL4LXsgxlL+4bn2jSgDE13TIPCXiXQZZwl7ZXKRu/mDhsHDD9OK4nx1Ywz+JNXk0ss1p5m5C4wcda6XxrfPqOmi2lQf6FGs2BkEFmJbr06j8qwo7kG3S4nzL5hG8A4JA7Z9cUAZdnp11Jf6LDADE7bpd46hecmt+/a3gV3v90xkWTYCTgcLjNdlqtpaX3iyKe0tzY2MFrkQpjA3AADj2Ga5Hx1p/2fT4niZijS7Auc9B1/lQBgwRv4h8TWVkxNrpNqTcTPsyIolALux9CABz3OKzPGOvQ6n4j1O4hkiktLtlUSeUUESjaFCL/sqoGe4zxWcdQaFLmFCQ86hJOudoOcA/hzWdGiSu0YDNnAIA5oA6/wAT6PBYXAhhuobq1RAYLiJ8h1IyGyOmR27VyEt4FVY0IEQPTnBPrViO/uIRLZtGRC6bdjLnb7+1RWNly0u3LNwue30oAL5bKHXnWwnmubdAP3zR+W0xIH8OTtGc++MVNdxRyO00ROSPmjODiop4FguWded+ASO1Oj3SuPLxuU9c/pQBXbLrIxIOMAfhVKZDLu3EZrRmCBnG3Hqe1ZsiN5vcUAWbfSbSfQ729jvIxfWjqz2khC+ZEeN0Z/iYHqvoc9jVSzuow5BiV0I54wRSMgIG5eex96dZtZoLpr03AcwEQeSoI83Ixuz/AA43dOelAG14aAul1KIg4hi89G9twyP1q/c3DR3Fu4yGt0Cj3B5I/WrvwzuHGj+IbRJ4IoruKFWSRRuJ8wAMCecDcc49qxPEkP8AY/iPVrBLpLmO2uXjS5jPEm04z+lAHR2U8XmRySq8hyGRAMDcT2qhr1kVu7hoXyryngVc0ARjTNk53SspYk9jimyWjQ2XnyycMxwD2Xp+tAEGlILSRSsnzkA811gs7fVILxBKyTi2aSCGOPd50gGdp9OM81xlrKgmM0mAuNq89TWvHcbdwglDk4IXOCfpQBQ8JXLW+qtYycRSAsoPat7AieayS5khH3kCn+E9q5DWBtkS5iJSRDz60+81m532l78jPF8pI6MPQigDZv40eyuY5SXurU8HP3xVHS9UlmvLYXZzaxryueg61YhvhdXBu4lIDD5h71WuIGs90rKpEpwjAcFGH9DQB2emXWgB9p3COToPepYfEsmg6gv9mpHnYVhJH+qYjG8f7QyetcPYQtHIhP8Aq+NxxwBUjytPKG27fm5560AfQXwq0mfQPiDc2FwsTedpZu0mjGPMDSJnPvnNeyV4j8Bjrl3e29zqMaSaXb2VxbWtyOXOZomKMc5wMHH417dQB4n+1ratd/DzSkVd2zWInI+kM39cV8uttgJZz5k3p6V9UftWSNH8OLIr1Opxj/yFLXyQWJIP5UASyTPMcuxz+lQ0pbjAGPWuk8A+GJfFGuJbDKWsfzzyf3V9PqaANX4ceBrnxPcfaLrdBpcZw8mOXP8AdX/GvoDStOs9IsktNNgjggUY2qOT7k96dYWtvYWcNpZRiK3iXaqqMVbSJnKhULMfSgBoTJAAy3YCr8emSlMuNvfAPNWrK0NuxIUPN7fdWpLkyQxM8z8noo70AYrQSebtjBar1vpwGDcOF74BqneaotlCzyFVbHSqmh+JYDMLu9b5IySqf3iPWgDt9O0lWx8gjX/a+8fwq7cQtZ5+zW7Ow4DsN36VyulfELTrrUBA86JIx6A/yFdY+rsyh44sJjIJPWgCvFbalcEtK7qC3GTjAq4+mu9p5JuHLk5LE1h6l4kuAfLgCK3tWKdQvZHYqz9c0AdOmj3cTfu7vBz2NXY7Od8C+EUiY5YjDfmK5IavdjLM+CvfvSX/AIqa30uWe8nEVvEuZH9R/jQBc1V/st06x4kizwTVFJUmJyqnNeKeIvi9HqVxdWKRyW1k4Oy6j+aRWHQ49DWBZfEn+wJ4zo5nvGbmaS7J2/RFzx9TQB9O6ZpgugxhdVkTqjD+VJcQSRv5csKZHXIrzD4e/F/T9Wu4odUZNOv3l2xDko2TwM+teu3Oq20zxwX+2KR+I5c8Z9DQBhXWnoeYMqx5KEdfpWS6bdysCrr1Brp7yRbS4MU7bGAyD2I9c1Su4I7qFnjYM4GQQaAMD3FcD8TfBkWu2D31jGF1KFc8f8tAO31rvzznaMAdaiz3BFAHyZEzQzNHKCpztbPUGi8jKybwOD1+tekfGXwstpdLrVhHtt5jtmVRwr+v4158MS4XvjBHqPUe9AHLeIbfKpOo5Hyt/SvrL9lx1j+AGtO5wq3F4xPsIUr5iv4PMgmhYc44+vavpf8AZq4/Z08RZ/563v8A6JWgDhJdWTULm6kkk3tdw4Vjx0AI/wDQcVjJcbrR1Uk4OT7CuJ8MXrypHDNKQYiPL55I9K7HTI40uplBYwupALdu4zQB6p4duXuVtzDgwm1Tc3fcDj+VYvxB+zLoM6+cPtNuxdF67i3asXw5rc9nbsUR2gA2lhztycfzH61l6+8t9rtwb2NolUFgDwGyO9AHFW8c948skalo1bB3YBFT2sc1tdBJYWjZcP8AMCOCOD9DT9A0+81nUxZ6bJDF57BPPnfbFGM4DO3YZwM+pFautadf6Bqx0vxTJsv7cAPmQPhMZXBGeMdvegCpJEZz55ODt2rx6dzWjo04gE+2Lzmli2DAy0ZDA7sfRSD7Gqukym4imeNd0YUsv17H6Vp+DNfuNKtNdjjjjd7qzKOxhDkbuDhj93gk+9AGFPPvll34UFssR0H0p8saIi+QRt2gkk849arpaGQBS+IyxLE+g7CrESCWQA/KMbcZoAqyI7yhY8EMOhrR0G10qS/SLXZLlY3VvntgpZXx8vDcEcdPeq8+xLlSmNiA4x35rRs/JW/srohX2OHK9OnI59aAOUuhMXCkElM8AVLHbGUs4jJHX7vI4rdvYrrUr+4vbmVTPJI8srYC7yTk47Ac1VUi2VCJipPZgf5+lAFnwLrCeHvEH2+FUmlEEkZjkX5eQRgitnx1o+l3eiaZq/hmwkt0a1J1CNHDQxumxGKk8g5YZX3yO9cdcQKZWniY+aykHjg+9dz8NbvTCmqW+u28E9tLbtKIZpNgkkA27VJIXcCwYZ9KAOd0c3EulvJgqFxHvJ6/QUlxdS3mIy2UjG0AGrGiWN4LCAkZs5YZJzJIQAgQ89Dnk4HOMkiqN/drHLBKsXlJOMBl6Eqcc++ME/WgDUtdIEyKwcBAucHipmtY7WUTqG+WImM991ULDVwqM5V1jAwWYcH2qW11OPURO13L5GCNj0AacdrFfacsMiq0oUEL0Oe+TXPzabNp8ksd1G5tzlfp6Vv2lusNuJYbrzYnfAz94c+1dPbrbtCLmJUmW3+WVMZY59u1AHn/AIcaWzvADEzxnkAjhh6fiOK6e8t4ZrOSSxDTWS88j5ogf4T7CptUiaLU1uACnzhSgXgDk4/AD9au6FAv2qWPciRTyqCOucj7pHoaAMTQ42ukkjPyxKpJJ+vSpdU0CSw8P2+opKjRzTvFsGdykDOT2xS39tNpOq3UEfRX2kZ6jtUtzeXd3aCxmnkaGN/NSEH5Q54zj1xQB6D+zPfXaeIdS0wzMbJrVrnyieA4dFyPwY19EV89fs9WskPja+eRSpOnOOR/00jr6FoA8Y/auKj4cWO4ZH9qR9/+mUtfJXBzgY4r60/awGfhvY/9hSP/ANFS18saPpN7rF7HZabbvPcSdh0A9z2FAFS1t5bu5it7aNpJpWCoijJJNfTPgHw0nhbQI7ZgpvZf3lw47t/d+grN+H/gK08Kp9qumF1qzLgyAfLFnsn+NdqeTQA9cDnBJrf0uERW4ZsBnGWNY4hKxLJLwpp02oTyAohCR4wBQBpXWpJEdkI3PnFUfEFydNso579sSMCyp6CrnhnTUmla9u+LWH5izdCa8O+OXjo6r4hntNOci2iAjyDwcdaAIfFPi77TcOBJ8gPY1xc/ia7ecmN2RBwvPSsMtI4BOWz6Uing7gT7UAW4NRuo75blJ2EyndkGvSrH4uaiUSGaIZwF3A15WjElV4z1zj+dPhfZ3G7tmgD6g8H3b6pYR3Uysyy5OenFdlp9nZm1uJ0muGSE/c8sA/Qc81w3w/uIR4E0dYZQ7SR5Y56HJyPwrtImMdrsTI5z9aAKepBH2mNCqNzz/WvPvirM1t4Q1BFAVGTJPXoRXprqsijIB9RXD/E7RftnhbUUUsR5DlMf3uuPxxigD5S+tJmrmj6ZfavqUWn6fbvPeSEhY1HPFdjr/wAK9f0bRJNRu1i2xKGeNTkgfhQBwasQQykgg5BFe76Hqt9f/CcSNcXEl/E5CNKck4OcqfpXi+gaTc6zqUNpbIxMjAMwHCjua9+8UyW2jeDItPtCbdbeMRRqBuYnuSfegCt4C+Jbag8Gi69+9cNshmPJGexP1r0kpJZTCS3JaJuq9jXgHgOxSM3d7coSV4iLDkE969K8J+KZIJEsdWcHcco59PSgDsvJEmXgOe5Unk1VkjyuQu2rz20jQi9s+YT1ZeQKpsVaPccls0AZup2NvqNjNYXkfmW867XHp7ivmnxdotx4a8Qz2EpJEZ3RSY4dD0NfT0hNcV8T/Ch8S6THLZgf2naA+XnjzF7p9e4oA8IZo7lAxGJV64719I/ACHyPgJ4oQA486+Iz7wLXzRd21zp9y0N3DJBMhwVcEGvp74GNu+APiJs5JN5/6JWgDwX4deD7i40eDXp5IRazi4jhXqwaPaCSP+BfpW0Wt4tPKRMzueGyMfU1wnw51bVYLs29ml1d2lvHJcSW8ZJWNMDfJjtwBk+1epeFNRsxrVnBMtvN57KFSaQIj7x0LduuM0AcZ/aN9ZQSLauwViGwB97npUd9fSXfkrPKEV+HZieF75+ldL4zvLDTdV/syW3OnyrMqyFoyTEmeW29Tx+dctqVtHfa5fNZWs1nZqPMjjuny6REgBiffIP40AdN4/0aLwfpcFnoGsm7stZtkkuCtuU3hSDgMeq7ucD0Gav/AAo13S4fCPjiPxJpEmpSC1V/trRef5YPyIrE/d+Ygj6H0FY3xIv77XtK0m7k1COezsLOOABcM0IJChWYAAsdpbb1UY9aw/hlp8Op+LtP0jUZ7xdO1KZVuUhk2FlUFgx7YGMknoM0AXdJmeG3YQmN4CvlsNuMHNdFptnbXWlXUcMc0Ou6jK01rDBHhGVjs8rnsQSQc4G3msbw1oZu7rWItHZ7mzDzvbMTy0Me4iT/AL5FXpWnhbRTbsWkubdI4znk8YABP3ee46c0Ac/OrW0YhfJlVQDg9/SiztRGztIenX6+ldT4m8O/2VoujasJ0k/tEzAqWDENG+3t04xxzgg1iwWUhtpXlV2RVw2z39aAMqO5SYSEJ0+UemOtE0qoVXJH4dTS30Pk26zxfJFISdhHPGOlV7eF5pA8gxGq5JPtQBO8xeNfMYog5x3qZYkd1MQLAgck9BVaRAx4ymDwGq9pGZ7iGziXfNIwRBkKGYnjk8CgBRCBncA3HFQ7ylvLbSxpJBIOQw5U+oPrzXSa/oV9o1rZXF9EiwXqF4ZEkDq/TK5HcZGRUWnaAmr2d2bW4H22CMzC12El0XliG6cDJx3oAPDmlWl7a3bNdGCS3g85iZQnmx5CbB33EFgeCOR60/xbpmmW3iNF0qya3sbi3S5hRnMu1SBnLDrk/kcjtWUmh362T6g9pIbKGVY2lKfKjkbgD9R/OoLyS+1BZbTTp/KDWbu6PluIlZ2jjwCRu+YgdBnk8ZoA1BqGkrDFBPZzTWW+QSQs4CgspCurDncp5GRXEi8tLbUJoreeR7XdhfOj27vqMnBrHFzJhQrEKP4c1oabpdxqlzcuzbBHEZ3coSAMgdvUkUAb1ndW/mq6t5UeeApyD+NdLoGpm2vJ70K0rIvK5+//AInFc3Y+E1fSLy+j1O3kkiCukUYJ3JnBOf6V1Gl+Gb+DW7/T7No7w2dubpnhcFZYwAd6evDA468n0oA3Ly/guQtwZZJUYo0aY+X/AGs+4yazLuznju3NoWMcbgsBwSvUGm+ba2+myRSR7kc7g4OGRvVf61f0G6USW8kkwklDLFKCOo6ZNAEviRlvIob5QAXTZIV7nOB+NR6VHGl20pO5VQAA9c11NrpUX2KfS/LV5JJSItx6FhwRXMS6XNpzFLsnKsRn6HkUAesfBLUbmXxDe2fm7rQWzS7QBjfvQZH4E17NXhXwF2/8JTe7Fbb9ibkjj/WJXutAHCfGPQLTxF4as7W/L+RHepMQnViEcY/8erjNG0mw0e38nTLWO3Q9So5b6nrXp3jaF59JjWNdxEwOPwauCMbRyhXBB9KAE5z1FPAyxJ6UbQD0zTZSDjnt0oAdLI8jAZJA6CiKOSadIVU73IUD3NJJKigCFdoxye5qzY3kOlJ/aF0fliBcZ9hxQBzvxu8Zjw1pcXh/SpNty6/vWX9a+ZXdpJWZ2O4nJJra8Y63L4h8R3moTyFvMkOCT2rDYAZ+bNAEiMRyC24dMelCkDkjC9x61JGswiOwMFxkntioyVxhevr60AW7a6S1vkmtoguxgyiU7/z7GoZXMjs5k3FiSflx1qSVbZbeEwecZsHziwG0c8bfw65qO5gltyizp5bsu4Keu09DigD274GyNdeF7mFPma2nOf8AZBAI/rXqdpdpPGAsill4IBr5i07V7nTPhnq0WnyNFLc38UU8iHB8vYxA/Ej9K6L4D+LpLfxGmiajK8kN9hIWc52Sdh+PSgD6ITpUWqWY1HSrqyY48+JkBHUEjirckRjcq3X0pUBGPWgD5e02+/sPxE0l20tlrFjL5IuYVBMgzgq6nhgR3616j4w1rTtX0q80/UNTay8mDz5rdFw84IyFz2zweOa8z+N1g2nfEC9fny7pVnTHbIwf1Bri7q7mnuVuZpGd9oAJPPTGKANBNWjUBI7G2iiBBUxMykc9evJ+td1rnjLTbrw9IkWRePgYK5PA65ry4yGR84A9utSobbyZPPEpkI+QqQAD70AdxpHiKO/gjgumKSKNoxwCKi1acK+YpDkc8nkiuHgl8qVWU5wfzrqLW9ivZEjucebJzuxgUAe5fs7+Jo9X0u/0O/YPNEQyKx+8h61s6hD9h1S4t1Pyo5A78V4r8HZn0r4nWyo4KyI6nHcYz/SvcfEsyyatJMg+8SRQBmzYzwgGfSoHX0I981YeZmxv5444q/p9pBKu+UBie1AHGeItD0/XbbyNUt1cEfJKBh0+h/pXR/DjQX8OfBrxNYtIJU/0ySNxxlDCMZ9+Ku6tpcfkl7cYI5K1q6SufhlrysesFyP/ACFQB8OfDzWP7Bu9QvUv7izuvsUsMCwwiTz3cbdjbuAuCST1445qW18yK0iMskihfu4ODn2NNsLKOFGRY8seQWqxeozxxqgG4fh+lAFtpJZ3e5nZpZpOTLOxd2PqSeTUUl2ZnmkmkcyFQCxb7w44/SoQ2YQisWb+Kp0gkywABLDp7daAOz8S+IvB3/CKPpfhrTdZM05RzHdXf7qOZcAy+WOGJXcOvfpXDW2n30dwk6zGFyCMqxBUHg9OemRWja6Pdx6PLrUVrI9qk6QPMCPkdgSB+IFbkMFuZxcqswhdVdI5HVnTrkEjryPQfSgC7pdymhafaXCTb85ie3GRkHI2H1BHJ9jU94qzrotvpi3M9yq7Fi37mAd22xjH+yQCPU1neKdEurTUoI5ZFa3mt0nhkhfeGDDpx/FwcjrVeOa40O/tr6CXy7m1lSWFZONzKcjd7cUAa+ryyRxwaTewKt9Zyys82c+b5jAkntkbSOOuajvLSCLV5IdCubm5sidqTToULgAZyO3O78q2vEWt6frmsR6lJpzIHhTNtvxh+MjI+8Mcds9etZF5PPd6tJYaPZMWdDOYoAW8pcbiPXgUAQatC9xI0Us3mCNQi5A6DoAfSsS782OLyd+MDOAOR+NSrdF5A7N+5GcnufQ4NVxl33LcqpPOAM9u9AFaOB3xv5APTNXbEz2V9bz26bZInEi7lDDIPGQeo9qoKZVZnk6E9ulTm6kSRSshA4xQB65faFb+JfA+oeKdPR9Is7FzLc6cy5t5ZkA+aE5yoYNgiuP8OXs2larFrFtDLE7zf6FbiNnS5BO149x56NjuecdaxZNa1D+ynslvLgWkrbngWQhGx0yvTtXoVppI8T6JpS+G7wqNBsA0ivkFrpnMhSMd2Of/AB2gDnJfFOq6Z/aunqzLFeMY7iyuk3qmBtVTu5BQYAP+yK5K5WSSBZIRLHJ8yiXJG4YwcH8efY11/icLf341K5lWe4vVEk2WBeNx8rBh2I28Z7EVy97vaMRhyVQn5c8DsSB+VAHN3mjkeWLdi8z9lXj6fWljur+wRoCJYjKoU4ONwzkA+vNdDBO8LCOQjcOA306H3pbu5mu9jahcAywrshjhiA3DPOW7n60Ab0FnNpELQ31rbC6gdFcxPuG1l3bSBw2cjkemKjtb1NNnsrvw9dqZZpJTJbxbk+zx5+SN2zycpux7DOanstZ8nT9+ns9rqdrNHJbYAdTj+8COvTHYYNZOmW3lQGGRRLvYvKV67jxQBDbTJd3U9vfTm3SUFkkZjhX4IJAHPQjt1q5Z3j29xE0xYpgB2A5A9/XFRT6eJJGYxMFDkBiOoHSrTAXE0kd1IHiIUeYg+chegVug9DxQB21nqLtJB9ok2tgeW56PzkHNW4rn7Xql0ZZY7eBmBCyKXU9ifxNZOjSRWscVpewm40vZ5y3EZ3SWoJwFfgZxxkjjmtDWnl06aIqiSWMiDbJnt7GgD1X4QxqL2cm1WKQQsA69HXcvSvUq8n+B8Ujxz3byMoZXjEOfu4ZecepxXrFAGV4jBNgoU4JkH8jXn+pK4u/KTc5I+teg+I222Ct6OP5GuXUSPOjpGGZvlAAyaAMtNPnEHIYE9VzVG4iliOHQr6V1pOZCi8uOq9xUd3As8Oxlzn1oA5OPDOveuK+OGsyWGjW9nE2DPnOPSu5eIxXJiOQVNeX/ALQsZ8zTG/h2kUAeNgc8U5VO7H86dGNu3oQf0p6hI5R5hLJu5xwSPb0oAckDN0kQn+6WxxTmsrgJvMLiMH7204z6Zpkmx3JjGxTxgnJ/OtbRrmOzLvcXLtEg+W2Rjh29/QUARXmjzWui2GoiWN4rwuoQHlGU4IYfrUF1Z3KW6Xt4jhJiVjd+fMK8HB9uKguJXLkO5Kq5IAPAzVm6v/OtLO38tdkG7qc7txzQBZ0a4t1tNR028bZa3qofNA/1UiHKtj8SD7Gt/wCHvgHWG8XaXfPGP7Ptp1nNzGwZGCnIAPviuQkNv/y77l45VuoP17iut+HPja78K34SXM2lysBLEedv+0voaAPqQTmXDOPnPX60FsHg1VsbiK7s4by1YPBMN6MO4NPySKAPEf2i7Yfb9HucfM8bxk+wIP8AU15fYwac+kak19dtHdxKps4wvEjE/MD+HNeq/tDzh9R0y3A3GONmOPfFecHw5Pc6DFe2MctyYRi78tSwhycjOPbrQBz0SowI6P6n+tNZcc5yO2KcsamdV8wKpOGbqB71PqUNtFOVsbprmFQP3jR7MnvxQBWRiHBGOOeRxU800zzid2JJ53YwKqgEfjU6SsMAEFOBg0Adv8KH+0eP9Mf+MB8k/wC6a991lMqjnqMjmvHP2dtHOq+P/NYEw2lu8j/j8oH619B31lCt+6kbghIUHtQBy9pbTyEsi9R36VdsbOdLgm4VdnYg966GO0nePdFCzL0AHeoNStbm0ePgHeucH+VAFfZxz34INWbdBH4B19V6CK57f9M6zbu9SFULA/NyB3q7YyeZ8Otek/vQ3Jz/ANs6APiET4fbtIPapCZcg45Pcr2qCBkK7rg4xgnmtiPXl8gottDII4jDEHUgpls7+vLfXj2oAoNEy7QBjcMknikdlRx8zF/epbicOZJpHAJ5OOK0vD+kjU7W8vfOjjS1tnuHMhwMAgBR7knAoAqpeM1vcQQXQiQASGMlsSkHACgA5I3E5PQZ5ra0CTT0jZtVluESRMRPEM7ZMj5iO4xnj3rqfCPh9PGOg2eheHohBdxSebqN2ttuLoxOAz5yFVV4A+8W6cZqGz0aDxdY3h0rS9RfxJHcqhtbSyKWsaj5Su8nauFXJzglm9KAKI1PUYfD0VpPbj7I1w08EjqfvY2tsPTHTPvWHPCdYuYkYrLczE/PM4UKqgk5Y8dq9q0v4Ta/eaDa6d4q1ay0rTEnM8cCESyqxXDBTwBkc4BPTNV5bv4X+EruK2sNIufEepIm4SzjMQHqS2F/JTQB5n4c0DV9TuLePRtNutQKRfeiQlAc8Zb7o/E17h8HfhtfaSmoyeN9P0x5bp1ktsOHuIzghwWHQEbeAx715/r/AMZ/E9/bXEGgCz0i2ifykS1i3OOM/ebj24UVxGk+ONd03xTa6011Lc6hBuUveO0n3lKnOT056dOKAPVfj5pHgbQbd1s9Mc+I7lcpFbTsqQj/AJ6SLkjtwMc/ma+e4z1xn/aI9K19U1G61S+uby7uZJbqWQvJKxyzE96glitJLJ5DLJ9tEgAjC/KVI5Yt65xxigCTefsxjYR7WxwnOKrsyhQBhogeD3H4VXjUnJ8wDbwMVppHH/ZlwGFsL2znxIHnGZlb5QEUDB2kEkg9GoA7XTPEPg618MRzppEj+I0gktn3/wCp3bSFmAOckdxxya5rQdeuNJtnkhNsXMLxKSvzqXP+sBHO5ccHPGaoay3+gadLGtsF2sP3Ue0glskN6kcYPpWRAd+9gGOB0HSgDWSaWVyi7jK+D164PWtFrYiXyv8AlrKu1ST0HVjUOhwm51u3tlliEtyViSdz8i5I+Y+wzXWeONN0fSrqWPQ7l70WcCwvMW4knJJZ19uQPwoA5uWaD+y2t3tFNz5ySQ3AOGUAYZCO4PB9iKgAgh06S4S6I1D7Wq+QRkeU0ZYOPowI/EV1Hh2LSLJNS/tp3YCwZLZRFvzcFcKSf4cdc+1YotNNVrSQzs12ZJBcoo4RAFCc+p+agCC2nvDvmnCiPBCYXlj68Vc0q8/suxmlkVGnnxsIGSi55wffp9KTUL8Xc0aWzLDAm5QFAyQfU96zbiyVg0ULyyYTgL29KAJF1C4DyRy+b5bMWfAwqfQVoWH2W9dlM7IvTYwxu96wUg1ASZO91yE3HknHFatlastwRM6kg7VKg596AOtW02iNmKbEXg5PI9xU0+oXUpkaZlvreZi0lsyABeMbl9CfQCqVo0CrEIEaZkILd/wxW7BrlnYQ6gYYgmoXC4jkT5fJ9cL0OemKAO7+Bosl1SRbESKBaPuVmJ6un4V7PXhXwEv/ALV4nvomC7ls2O5RjPzp1/OvdaAMPxfII9MjLZwZQOPoazrCUQzpLtDbe1WvHZxo8X/Xdf8A0FqwdKuTLb7G4ZAPxFAHWxajCbkIItu44EnHX3rK1hzHfyqBxwQPwqqH2sgbpmrmujbfb8feQEUAc3q0H7+KVR1OGrzj9oTTpG8P2N5sOxHxn8K9YCrLGwK4z60viDQIfFngS+0mUDztjGJupVxyv68UAfF0LbSrnJAPT1pkyMH3OGG75hnvT7u3mtLqa2uFZJonKOp4wQabmSSPOGZEGAT0HtQAinAHOfYUAKCT+lEZ27hnAPFW7C3S5cR4IblixYYAAzQBCMyMBtyWOBip5HshGUe2bepwJI36/hVZiMgqNv41IiKgCsu55Eyue3NADA0YH7tXz6mrNhZ3eo30VpYwvNczHakajJP/ANao7K3uNQu7ezs4jJcStsSNBySa+t/hJ8M7Pwjpq3F3Gtxq0yjzZSOn+yPQfzoAyPDZl8NeE7C31UqhtYQr7TxmnXfjCySy8+KSPay7gSwrc+NfhW51zwRfLow23ke2URj/AJaBeSB74r45W4uSvlNLIMHaVYng+lAHWeO9Zk1vW5LkyF1BwpzkVb8H+IW0TRNWSR5THcsieWjYycHJ/KuNYqqgMdzegPSlVyUK7sA88+tAEtzGhAmh+4XK7ehHfJ/OmW9rNdTCC1R5pGPyqg5NMUESAsDiprIT/aV+ys6vngqSCKAK7jy2Kn7y8N9aQodoXpzmtO70S8jVpDGXXqSvNVvsE7TwwRxu00rBFHqT0FAH0P8Asq6ULbQNY1eUYNxMsSsf7iAk/qf0r0a6nM08kmMbmJrL8FWC+HfB1rpMZ+cKA/8AX8zmtAkBcngdKANw6gLK0tolTc5jDZJ4Gayry8e4lZ5WyAOg6AVNqa/JaE8N5QBB+tZV9IIrGZmIyFIFAHMTyGeVmPPzECum0aZJvh74kiThoEuIn/3vJDf+zCuVgxhNzbUBy5PYdz+VQ/BnVjrfwl8baoOVub/UJEH+z5S7R+WKAPmTS7G2jdX1O6e1sirK9wkIlYNtJCqmRknGM9Bms63V2ClosDGTjr+NMiWW4kUyHOT+A+la9qiLA+4jzHb7mcHAoAfofhnWPEE/k6Npd7qEgOD5MRKKf9pug/E163onwH1AwLd+K9VtNCtUTzHiVhI+AMsSchRj8ayPAvijxw2gTaB4PmWK0tA9xK8aKZI1Y8gM3AGc8/XmqT6xDpmk3Op69Heanq2p2k1pBJeXDS7Du2tJzjA44HJPfFAHd6lcfDf4WautvaadqGveIU2kPLLhI2IBXJ4UdQeFJFUJvij438T3NnZeFbCDSrO6LpDHZqryHaQGJY8KAWHOBXJat/wh0XhzwlcTwXF/qEyzTanFDMVZg2QmWPQhgCB6ZzWEnim6ggsItNtxptvDZC0uEtiT9p+fe7OSOrMBnHYYoA7fW/EgsrNbaW/1PxCbS53ySXEhW2FweNysPnYYDAAkDgkVyGm7tSvWMsuGT5SxOPlxu/pWTr+s3Gp3cl7KwlkmkMrbFCruJJ4UcDr0roobL+ytCiecmPWLx5S1u67Wt0UbVDg8gsSx+gFAHLW6usJkLFEZnmbb3P8ACKvaisMmliNhJ/aMewoBjBXB3A9y3Q/nV+9zKsixRLiDyooogvJPPXHXGSc+gFc9PIzDejOCeQ2efXNAFG2uC87FsbQCMjsKZcyShiCOGGRj0rR8Z6VN4fv7aCURLJdW0VwFjfeEDrnBOOvqO2aqfMqowUHA6etAFMS73C5CHHNT6ZqVzY/a1tvK2XULW0qyoGypIPGehBAII5pWEbzKyqCO2OuarXVmzMSY2TjJ20AdP4SZJ5HcWy313ayrcxWbR7luAOXRsdBtUt+FZNjtzIrfKCSygdqg8PNcWd5ujkeMupCuhwenT+n41o3UXlLCYzE2QSdvUEnv+X60AeufDCSxmkli0a0t7i8zbmI3e1Hj2wP57fLk7c9PUkd6h17SV1a9muNOSGOeESTXlgcq+yKQAMq+hUoffBNch4QuLzT3gurKWOKaIs24Llh0BDeqkdq17jxNruieMH8VWsVjNdXG5mVgSmHyCMZyO9AFHxLdS28Fnp8WoC6t5FW+mjSPb5UpBUqfUgAe3NO+D03h1vEcY8VofI3M4llceUMK3DjHIJIwfUD1rntf1VpIzMwjFzMS2I1wBnrgelYIvBFB5ecn270AbM1xHHJKkLIY/MJDf3gDxVnQJWWC7u5TwMHn+Vc7brJdGIRZzkk/0qr401CXTZodIgY/IFluCvdiudv4A0Ad1pOuI900r28YuMs0ZYZUnsMetP028WZnS4i2SMxJ7HJ7Vx8mv6Sba1+yZ87Z8+48pWxaa3a6kuydxFcHADjHJHf60AdcsAhZZUxtJxuQ4OanM0F6r+ZJmWM42yL1/HrXNz6uNPt981xBKqkbcN8x/CnW+qwTSCQ5COOvegD2z4D2Yg8V3koAAaxYYDZ/5aJXutfPX7O1+LjxhfQB2YLYOwz6eZH/AI19C0Ac944G7SIx384Y/wC+Wri7C4NvdKxI2sMGov2kPET+FfDfhvV0yUg12ESqDjdG0M4cfkTTWeOTbPbuslvKodXByCCMgj6jBoA6f5XUY+ZTyK0YmivIUt5n2Tr8sbn+IehrlrC/MBEch/d9j1rYBWVQVdSD0xQBJcwtbyGNwAw547/Sizu3sJfNQbh/EueoqzHMs8QguT/1zc/wn/CqMqlGaJx8wODmgDxL49+DAb9/FGjJut7j5rmNeqN3OK8WBPlY3d847V9gzQqyy2tyA0bggg8gj0NfPvxO8Ef8I9dteWYY2EjHj/nmfSgDgkiLo0nVQedvOPrT1dSCEG1Ap5J6miC4ktpVkhkKMO47/WonJILE5yeeKAFXaODx608535J7ZBpsZCKxZVORjntXofw++Fmu+MQlwUGn6Txm6nXlx/sL1b69KAO2/Zt8FpdpL4kn2syyGGFWH3V/iI9z0r6QAwBWF4Q0bTvDOjWmkaaCsUa8b/vue7H61HJrz7nESJgE43E5oA6EgHqM18f/ALQHhT/hHfFy3dvAYrTUQ0gweN4PP07Gvq3RtSa9MiSqodRnK9CK4r40+FF8U+HDAF/fope3kz92QcjP+8MigD44UM2Mc81d0iDz7+OMqWLHp04qvLFLaXTw3KFJYSVZGGCGHGKm0+RluE2DJPAyfWgDs/sVq7w45WNhu44I7gVPGqWMsqxxK8LHKhl5A7c02xuYYYJGk2lwNoUc5NSXmogWO9xtYghcdRQBpRXCyRom3Zx0PQ11Xw88MiS9/tu/QAR5W2jI793/AMKx/hV4UuvFlyC+9dPiP72UjGTnIAr2+/02CykgtLXJRFy3HA9BQBFbqSCT1PTNa8FpHbRLPfd+Uj7n61DZ222RJ7kGKBOQD1c9gKp6tqgLlnYFj0XrigB15cebI1xNgZ/AAdq5rVb03IEUa4jz+dF1dNMcysSO+RgCqoZpHIiQ4HJJOMD1oA5L4sa2nhv4eavcJj7VcJ9jiz/ekyDj6LuP4VN+zGAf2edfBzjzr3p/1xWvFv2jfFEOqa7ZaLp9yk9np6b5HjbKtM/Ue+0YH4mvaf2ZP+TeNfx/z2vf/RK0AfP9rBCkYYHBBx7V1Xw6sFv/ABdZxm3knCkzSJDy4VeSQfYc1ytmg+zqzPlsdR3r1LwbfWcOnabZG8ishJHM8zWvzz3BJCiJwMHPzfLk7Tuxzg0Ac5oWproE08WlSxyX8t41o1rPGwnuY2IAH91OMnnqW5HFP8XWui3mm6tdWVywmjv0toFmuPNeQbCZcDHTcc7jgHgDvV3Xrm006yhE0Vsmv+HX+xop2/6TAwI3MRwzo7DI9CR2NeZT37idWVUYAnpx39P89KAJ4M284JXfER09BWiuJYy6OVDELj0rOsnW5WZnO1gvy7Rxx61PbJIYtrMdr524PWgCxaxFZTG6h17beK3raVZrHULm9Wae8kdCLh5SSpB5z65GPpiue06Zlc+ceVOOa6m2KJoRQNmQyyuUPTGBz+goArG7tI9TjuppTBaW9u9xII3YNcSbQoQHHBJP04Nc1Zg3QjWSUQIxG6TBJ/ACus0Cxv7jV5odMZDcGMlmYKyCNozuXByCT29/Sue1SUWmqXqeQkWNzIqsDzkjccdM4JxQBT1BjctI93NJO448x2LHPfJP1qrbGRiYnOJF6A9/elMUkqKsYyT0J7k/5NTwQFpIzKpZQcEr2GKAK8MJS4O5wrZ3fh1q1dXw2mONFZ27+lONub64zAkhjXj6/wCArcsNMgUxqY8t3Y0AYU6y22m+cVCtu3ADqK247EajpceowyRtlkXyujEk4IH0/rVrVY7YRusyb88Ig9fWk8HmW0spWxtUSCSMDswJ5H5CgD0bxx8OLnwXpy6nBMs1iyRJLk4ZJTwePTP5ZrzWdzJJ5jHIzyO3Wu98ffEK68T+HbTTr+HE1vMZnmU4WUbSACvqCa8v1O6MFlALdd0jfO2eiDpQBT1e2mbUWViqgKowT04zWctsPPKk5IPXtVhEN3JmVvnPOe5rX0vS0Eu+U4UcY7k0ASWHlaXbvf3Kjyohnaf427LXA6i7311NdXPzTSuWY+5NdX8QJ2SaCzRwI0QPtHqe9ciW+T1oArNahuQKctttIIZgfZqsBhzinKOeKAGW8bRzJNyxRtwyc16LoGpaP5Jd28qcsSFcZAzXDwqOOKtLGCRxxQB9P/s7+QfFl88EkbbrFjtU9P3kdfQVfJ/7Ja4+IOp/9gt//RsVfWFAHgf7aX/JKtO/7DEX/omauJ/Z58X/ANteFX0S6ctfaWuE3fx25Py/98k4+hWu2/bS/wCSVad/2GIv/RM1fIXg/wAR33hXxDaavpjgTwHlWGVdDwykdwRQB9ugZ4BOPQ06KaWAnY+K57wp4t0jxVYxXOn3KJMygtETyp7j1GP8mt7JVsSHHvzQBsWWprKQkow54yDxW2kP9oQfIc3MY2kZ++vY1xYjLHMbH2rs/Duqadb24ErtFcFcPv7/AEoAgsyLa9Q3cOcfKysvT3q/4m8Mab4g0ya3uIQVdMDb/hVptf03cP3gJz1K1V1ecwCCa1leNZx/CeMigD5i8V/CXUrKaaTRiZ4VP+pk+V1Pp71ylj4F8V31yILTQ7ySTp9zA/EnivrG2EMl8ZdQaV+ewzn610n9rWNvERD820Z2omKAPE/hj8DBZ3sV/wCM3gnkT5o9PjbcoPXMh7/7o49+1e63YEcUcSMY1ACgRrz7AdhWA+sy3sLGArbr0OPvfn2pL3VpVtRGWxIQAZA2CR7UAbdgojnkV0jjYgDJk3SMff8ASs3U9EkM5ktMMrHlScbT9a5+YK8pKOSwG7eMk5rptF1USadM10f3tuMv6sMcH+lAF3TNOSwhJyHlYfM3r7CpysVzA0Eo68Mh6iuSub6S9CzTuUQnCp0C1padekIVuJsJgbJMZYe2fSgDzL4sfCWHWN2oaeRFe55mxww9HHr/ALVeF3/gnxPpMrA6ZLKO0tuPMU+4Ir7Gv9ct7dVjDeaWXDFTj8RWf5Gkud8glDtycALigD5AtbLW/OSGLTr1pg3TyW/wr2zwD8KLnVmS88TJ5MAwwtwefoa9ctJ9HgK+Xbyu2fvMuau3Wslflt4v+BP/AIUASwQWHh/TY7aygjgiQYSNBj8TWTNMY/3rKDdSfMWYcRr2wPWrK3dlFCr3sonnf5mXG7Ht7Vg+IdUW7uP9EUxxEYJPBb8KAGX+qszbRIXf++x5/CsaWU5JLbn754oCytnylPPU1zfirxfpnhq3kElysl8V+SNBuwfUj/GgDoJkEcRnvWWGBRuJY/yFeP8AxD+J0dvb31tYOklmRsWKPjef9t+pyew4ri/EHizUtXMsZmlSCRtzqXJZz6sf6DivNNevvtM/lRnMUZx9T3NAGfczPcTyTSnMkjFmPua+xv2Yv+Tete/67Xn/AKJWvjSvtX9k02w+CF/9vGbQ39wsowTlSkYI4570AfNsPlxrhmPXK81oQ3NjZ2V0xidr8lGgnWTAiwck4HU9APSvo25svgvBaRzXNjHHA7eWpYXI59DzxSQQfBmeWOG30wyvICVVI7k5A696APli5uJJ5Hll273Yu2euetQxObhhmPnHH0r6xOifB1oHup9IEKKCWMwuU2geuTVG4b4IWyoxsVbK5AjS5YgZxyAaAPmGPIVtpI+bn0IqWzuSJOX4UkAEdK+qP7P+D6NGP7Jcb+QfKusD688VWl0f4KK/mS6WqszHki66/nQB87okTsZEA3KRx6+9bFoyPBPG0pSJFy3HcivdriP4M6asbS2ccYc7U4uDn9aPtfwcjup7VLJmmVBLIiw3JIXA5/LFAHz/AA3y2fh66RI8XrTGJ5ueFwpUD8Qfzrn5U3T5Yk5UgsByTjivqGG4+DFzpUsiQRG1jfzpFxcAqwGMkZz0oig+DdzbiVLAGM4blLkH+dAHy9atK6LGreVMOGJXkg9MVvQFVijWNvLmLbXwO2MHFfRa2/wj3Kw08ZxkHZcf41Itt8JVHmixUH/duMn8M0AeJ+TBb6WvzbGJy4zyT71jy6otuwcfO/3QvYV75qV58HrMIL23VTJyq7LglvoBVe4b4NW9sk82nsqOwCgxXWST0460AfPf20SySSXAwqg85710Ph6aGPQsSozTcuR7HmvXDP8ABOW5Nq1ifNwW2mK6GQBknP0FdBpFp8L760M9jpzeSy4BZJ13L7AnkUAfMOqX7LG8lwQGZvujua597l5JmM53MRu/HoK+rJNO+D91qK276Sz3RGceXcjGPXnFUby2+CNvqbW02nL9rVhkBbk4P54oA+eNCiS1zJcfewT83b2q+t60qNc8RxjoW4wK+il0/wCENzHMV05XEJCuNtxkZ/Grp8MfCy8s0U6QrQHoMzj+tAHxfq16b/UJJ+cHhc+lUxj0zX2fZeDfhBeRNJDoa7ASp3G5XkfVqhtPC/wau7y5tYNHRri3AMqf6SCoPTvQB8bfrU0Sk19hQ+Gfg08xjj0ZTKFLFf8ASc4H41Kvhr4O+ZtGjoD3/wCPnA+pzQB8ixrg1aUbRX1pD4Z+D0zEQabbyMOoWSc/+zVBeaV8HrS4ME2jvv27xsjunBHsQaAOA/ZMI/4WDqf/AGC3/wDRsVfV9ecfDe08BW2tSt4P097W/ktSWZo513Rblz/rOOu33r0egDwP9tL/AJJVp3/YYi/9EzV8T19sftpf8kq07/sMRf8AomaviegDa8M6zPpV6rRTyQjPDo2Ch9a948J/Fe4gjS212Pz4ugnQcj6gfzFfNtbuh6mE221wcL0Rz29jQB9f6Z4p0fUUWSCYop/jHzqPqRyv4gVvo7Om6LbKh5DodwNfI9tPNbSiSCV4pAeGRiprpNN8da7YkYuRMB/fGG/76GDQB9KLKQfmQitCC93Kgyh2jChjjFeAWnxb1JABcQl8ekmf/Qgf51pw/F9T/rbRv++FP+FAHuiXcefndF+hzTzqFser5P0zXhw+LsGcm2yPQwD+jVYj+L2l9ZtOk+qLj/2agD2IXdpHuaIfN3wOtU5bpZ2PmeYR6A4ArzKP4taA3D2dyn4f/XrQtfib4Ylxummi/wB7P+FAHoETwbSsbyxk9yMirUZ2zyOj/u3UA4bg4rhIvHnh6T7l3uX181B+hIq4njHw2ybn1SKPH8LMuf0NAHTzKkrMpuAqbs4FSQzQ26gLJK6+hrhNV+Ivh2ziBsLmK7nzjDybVA9eAaxpfi3paIv7iLdjlYldxn2JxQB6sZrMuXaMFj1J5qY3Nqy4DLgdiK8WufjPYquLXRWdvV5NoP4c1kXPxo1N8i102xiHbcCxoA+ghewKuAST7ConuQ+cRzsPToK+b7n4teJpQfLmtoP9yIf1rJn8Z+K9VfYupXsjN/DBkf8AoNAH0lqOo29pGftU0VsmMlc84rh9Y+JGhadKw4uMdFjfezH8OB+JryqLwd4w1YGaewvFiPPnXr+Uv5uRUv8Awh+m2POueKdLtz3is911J9Pl+X9aALfib4o6vqyvDYAafbHjEfLn6muVtdH1HUXEroVWQ/62Zsb/AKDq34V0S6n4T0dWGkWF9qNz3ub0qgH+6ozj+dc/rvxG1DTmZtMEFneuMB4l3SKPUu2T+RoAxPHQi0If2ajzHUmGZgybBEp6DB5yffHH1rgqlubiW6uJLi5leWeVi7yO25mY9ST3NRUAFfZv7Lkrw/AXU5I/vrfzkc4/hj718ZV9h/s4I8v7OutJEAZGvLgDPrtjoAoeA/Ca+LdW8RJqes3GnWWnWttOHjWJ0dZDPudi6kYAiHT3qx4L8NeHtV1azt9C1bxlHb3rOtpqUmkxJazlVZjtkMfTCtjIGcVJ8BNFn1a0+Ivh6+vEZbnSrWxW4hTAVJFuxkA9SC7fXFelfDRPG2i2Og+GtY8P6dFp2mQC1m1SK/DiaOOMrGY4toYMSEzu/wBo9xQB85eMzPqU174aeS9uWt7+6tprlVCgxxXDopYAAZwgPHFbXh7wknh3Q5b7+0I7xyAIiYgpjBOOTnqOlV4TqkvxM8SRm1kOmjVb8LIM7T/pcpOfXnI/CrfiHSNSQQESt/ZrEie2jGGcds9qAI1/tN9VSSOT/QlTMpYFgSTxk/hU2u3tnpsD3WoNbxxghUWQZ3E+g56jNZlv/a/hq1uIVUalpjndx1UDpjuP1H0qKHTbDVrSS8Mk00jSB0hul4ifnG3sf5cUAN1Gzs9UulnvdW+y6atuzrcFdrliRjaOvTBqGQXmuStcabDItvb23ki4mbEtzjvn8K2dM0GCRmvdUH2y6Y7UWUZ2gdT6elXP7Ys5NTbSNPjzdwLudChCJjtu6UAcHdWjSWd7HqcJQyFIY93ymJTkkse/Heul8KXWoPo1iZILKONisQkmkyzAcfdHfHrUniy1utRihlR42aEtvQAfdHUc+mKTV4ptQSyj0qKOPyLZZVXIyScDH5UAbMzrGZPs7q6qTwD973FZ9/4jtobbyYIRJeKCMKdwH1P9K5afU7+1ZYblRbNIoQQpzIBnsPfrW1YJDpFvHfGT7PNj5vNG5mz29/pQBzwvB/b0d9ra4RkLDzBwuOnH9KtlNYv7/SNThdFjuLphbQyD5CAv3j69/wAau2OmyXl1uSwMluZjcKbv5grYxlV7DHaus1sS65FoTW4WOGzndrgj5dpC4XaPQn8qAMazml0nxFd2dwsW3UIyYjnp2Zf1rpPDVmqWrw2UknyAKFkbPA5IH51TezjlETTRmV0bKv6ke9SWetDSCoWxaUzORkfwnHGfxoAr+N57uB4rezf94QN4B5PocenXnPauR0+6hhuA5txPqMzCOB2GFGTySfyrd1vxRY3QvGe2NvqwUJFGCSHz/UZpNLnR54rFLSKXy0bzJGPCOMEgfiaAMW1El/fX+nm4Bincxzy2zYUgZBKn8a9FsZjpemmxsjI8kUSpEZOTwOv171y2lM1pbyTaraR26RkBVjUAvjkk49yBWLqsmv6sHu4gbaJZB9nt0zub/a459OT/ACoA6xDqCZDzS7y/Cg9+tay2VxpQvdYsbSW6v7xY1aBWABwMcE9BjmszxJbzx6SlxHck6isaTBQuAWUfMD9ea3ob5tU0q3mVwYZUDgRdcGgDl9dvf7Lje5u0eJpiokIOdmccZ7irNyweGCAkkEAvz19P0ql46uYIbKC0uwTFOfKklAztUc5x6/4Vn/8ACOLe6XZXAvWvYiqomG2sQDjqehA7UAS3+p2OkSWyajKbV3zglTlxnHarWsJHNrNrcWElxbyxW/lzsGwJlIBAIPTGa5q0tBPqr2l/a36NabiEbBBTPUHpk/SvRfD/AIy8Pa/dNaadDI13Ah8yOeHBG0evc8UAdP8AAx0bxddhLhpytgwIY52nzE969yrxz4M2lrD4kvbnT7WGCK4t5Gl5O8vvjx9Bgt+Nex0AeB/tpf8AJKtO/wCwxF/6Jmr4nr7Y/bS/5JVp3/YYi/8ARM1fE9ABS0lFAHoXhH4iNp9jFpmtaPpOq2iDbHLcwYljHp5ikMR9c4rsF1jwZeqDdeF7m2DDO+w1A4/AODXh1X9N1SexICnfD3Q/09KAPYjaeArn/V3/AIgsSf8AnrbxzAf98sDSHw14Zl/49PGdup9Lqxlj/UZrh7G/gvUBhbD90PUVazigDrP+EJhkP+i+LPDcg7brh4//AEJBR/wr3U3P7jVPD03+7qkI/mRXJE0hxjkUAdaPhv4hZv3Y0yT/AHNSgP8A7PTv+FZ+J/8An1sz/wBv8B/9nrkPwooA64/DfxGv+sh05D/t6jAP/Z6cPh5rCj99eaDCP9vVYP6NXH0YHpQB2I8ClP8Aj48S+GYQOv8Ap28/+Og0DwroUR/0vxtpY9Rb280p/wDQRXH9KTNAHYf2X4Ht+Z9f1a8PpbaeEz+Lv/SlF34Etf8AU6LrV+w6fabxYl/JFz+tcfSd6AOyHi/TrU/8SnwjosGOjXAe5Yf99tj9KZN8QvEroY7e/WxiP8FlCkAH/fIBrkhRnmgC5faje377768uLl/WaVn/AJmqoqKeaO3jLzOqJ6k1zeqa7JMGjtMxx9C38R/woA0dZ1hLUNFbkPP0J6hP/r1yskjSyM8jFnY5JPemnrSUAFFFFABX2T+zKHP7P2rCMMXN9PjaMn7sdfG1fZv7Ls4tvgJqczNtCX85zjOPljoA8wuPB9pbWn27Xr29gnRVV4wwBYdQSRk4Gay9P0eC4nOpeXdHTEP7i0ErGW456n29q9A1hYNV0udrhhJHMh/eA/iCCKg8FW8Wn+H7c6mRPdwOxjKcBMfdz680AV7QW9/4evIPDssdtcp80S+X9x87ipU9CSevrzRe6jrFpYWbXxga5YKkoZsKGyMYIrpNAuIb2zWe6uIJrySYo0sUe0Ow7EgAE+9T6rpEUu4SSxgL8xVhnGaAMS61KPT4YbbUdOltoyMJLGN0cmecgj607P8AbU7JYqBbqynIbBf3LdvpUOhaNb6RdukF7dT6aQd1pM2+MH2yf/r1sW+lQeZJ/ZUr2yvglAPlNAHOGTW7XxH9jhsbM6W6kRurAOgA5AGefcYqqNJt4JdXKN5V1cz+cLhhnGABsx6DmuguvCz3tyks+oOGhYlEjGNvrg561Rm0yzivZUluJp5VGZAHBfnuc5x1oAyIJ9YbQbqCe1tjeea0cEq8LKDwT+RqDw4t9e6PcQQsqXYcRyXJGQgUcDHfrWpql1Hf63pNhbRtGihnIY5OFHBP61bsp7bQtTmheVGsbr+FT9x/7pHuaAMLTbBfDazvrMZnv5vnMsSlyRn7oJrnLrVE0u/illRr+OSTiO5P76LvjjjH4V6Pr1wyae1zBAJHi+cwtnOB1xXCFbG61P8AtKK2Mun3BDGRT88UgIzkfl9RzQB3Hhi8R7GVo4HSF23FJexPPB9Ku/ZomRhE2wkgMVP8PpiqNtLHHC7uUWIr/F8q/UGrNtd2rRJNAgcMxX5WznH/AOugCzPH5LYgcjAyoP8AP2quB5q8qdxPOD3q5dsYoEnVQ44+7/D/AImo7sTJbN9nUJIT8s6rkdPyoAwfEFrpqy28t7s8yA70BO3BPf1rlLCWw1S9mkeb7LYq/wA0ik5fB46Vd8U6jPqOoTaC9pGZpYllilK/MR/EM/5711emWVnDZWVlBaxyEKEaNkBLt1LH6nNAHIT37X/iO20yx2/YoFEjtnIK7hx9eld3FCks4ZwVCcgnqKyNZ8MWGlX4uGt2LT4BVGKqoWtK0gmk/dW3LRjjJ7Y6ZNAEOuanBaQZnjeSJQCTHyR6/Wo9O1zQl0yGC2mRbdhgImEdc8ng/Wpb2J7qZTajbNFlScgKPUDPvWd4m0u0uNOufs1tayaiIhiRgNpcdefzoAo+G0h1HVvENtPEtzBDdRsiyHghgWVvr0rp9XiMi/ZcJFGhBAjA+UnmuM8MeG7y1ktzcTvaalv3OYGJXHYYPBwO9bWiXkV9bxXlvJLMLsExiXhtucc9s5BoAv3pkgitoxG9wBhWwRu5P3s9xitdbW2sgnksFlI/1ijJOeef8K4rWvE0p1aG30bT5p0tHKXhlOwKRySp9PerWnai3ifTtUbUBFb2ty5itp7Y4lTaRnPOD2+tAHrvwcjP/CS3TuQStrIF+hePn9BXsVeD/s/Wt7pWvzabfzx3S/YXkhnXOXUSoMEHoRkfnXvFAHgf7aX/ACSrTv8AsMRf+iZq+J6/Qr4+/D+/+JHg210fSru1tJ4b5Lpnud20qsci4G0E5y4/I14B/wAMo+Kf+g7on/kX/wCIoA+dKK+i/wDhlHxT/wBB3RPzl/8AiKP+GUfFP/Qd0T85f/iKAPnSivov/hlHxT/0HdE/OX/4ij/hlHxT/wBB3RPzl/8AiKAPnZHZGDISrDoQcGtqy1+aPC3S+av94cN/9evb/wDhlHxT/wBB3RPzl/8AiKP+GUfFP/Qd0T85f/iKAPLLW/trr/UyqW/ung1ZPFelf8Mo+KQf+Q9on5y//EVdtv2ZfGtvgJ4j0YqP4WMpH/oFAHlHSkzXs0f7OPi/H73WdCPuplH/ALJUn/DOHij/AKDOjfnL/wDEUAeK7qMmvaj+zh4o/wCgzo35y/8AxFH/AAzh4o/6DOjfnL/8RQB4rn1oznpXtX/DOHij/oM6N+cv/wARR/wzh4o/6DOjfnL/APEUAeLYor2h/wBnHxXj5NY0TP8AtNL/APEVTm/Zr8bSjA8Q6HGP9jzR+uygDyCeeK3XdPIsY9zWLe+IEUFbNNx/vuOPyr2l/wBlTxXIxZ9f0VmPUkyn/wBkpv8Awyj4p/6DuifnL/8AEUAfPVzczXMm+eRnb37fSoa+i/8AhlHxT/0HdE/OX/4ij/hlHxT/ANB3RPzl/wDiKAPnSivov/hlHxT/ANB3RPzl/wDiKP8AhlHxT/0HdE/OX/4igD50or6L/wCGUfFP/Qd0T85f/iKP+GUfFP8A0HdE/OX/AOIoA+dK+zv2WQp+A+pBwCv2+fOen3Y688/4ZR8U/wDQd0T85f8A4ivcfhd4Cvvh58KtR0TU7u2uZ2nluBJbbtoVlQY+YA5+U9qAPMdCuNP1HTrloYxFpcErwh+zYxkqB7mr1kNFW3aCIubZjl1mHJzVHQ9Og07w01jGjXOn24Ltg5Ycls4HU/4VoW9jb30FtdWLBLV0DfOvzEe9ADLrTIrGKCDS0VLYbpI40+7n+pourGeSzM9xMyHZv35Hb6nHHJ59KsWkSWc9x588j2rcR7usbc9B29M1DdSRTIljl2t+dyuAdxoAwtE1VtQhmaFlmhgYIZEA2u3dh9a7GytZpLNzZzBJGHysw/SuLu/CmnrLIlgZ7KSUkM0Eh8vc395B2+mKl8L6/eaCxtNa33mnICsU8A8wIM8g9D+fNAHTWGozXenXDGMLfW8vlTIADg+v071x+uaP/Z2sf2rb5F7dIYgjY3b24Bx1x/hXZadqvh4atcXdlqcUbXMSo8TfKCQeG574OKualpqXt/b3aMkpUAqwG7p3BoA8u0vQ9RnuJJ5tXey1OGUwzPjftIP3cd+oOelbmpeG5tR0149SlR9TjHM0S7RIv8Jx6/Suw/4RxYZL64Dee93IsjKRgBgMZH4Vy+tXWo6JfC4mQTaXgmVhwU64JPpQBBcCXT9Ijurx5YzCg3MqbicHGTjv0rJ06XSZFnlsbd1S6kCFJF8sMSfvAfWuh0PUbfVZYp7K7RrUyFZkcZ/D29axPHogutcgj0p45b94jE5SQlIEzx0+XPJ96AMTUtDvlu4EhVdRfHyWu4jhexOQAPeulsru6s/D8kusaSlvLEMpbWfLAZHOM46c9ay9J0bUJ0Dx6/8Au3+TPl/M5GeCc9M112mWosl8m7vHu5AwO5z+lAEOk3kF3BG8DLJC/fd39/Q10WhlZfOty4EfUKD056CuZh0TTtJ1AzKzRvcOdvmPxk9AB+NXruWPTYpLieQQxbfvbc89eMfQ0AZuqWUF74uivFheJrGKSEIRnzAe/wDOsXT/ABWlv4ngQKyWybkeSOIusj44T27c1ufb7fxBGLm13okgKhyCp+vPerOi2h0e2iSNU8gEkoh5ZjzuP5UAD389/BM17H8x5VOfkFCW0ohNy6kxNxkHjj1/OqWoX4stVtGnDyLeylGKjhRkdfz/AENXLzXdS0eZ47W1sZ9I3D5XZ1l29zkAj8MUAVdQWR9NdLc+W5YjcvJT0b3pLCOYNDBIvnSsgBkfrwOp/rWnql5o0Orw28McrPcI7lY5QFRQOpHoc9qp6rqFvY2wsrd50triF3lOPnAwcsCPQDt/WgDLu/Egjum097n7LfXKPHbKwyWGMZB7Drx7Vc0DT0t/Cb2yxqphhW3SULhgD1b69cVQPhS11SLR72x1WS4+zHzIp2QBiPTPXI6Vpm5ubkanodle2q6o0DFIZW5Ut91selAFLw/o4toJdNtwzxeUVQu2SxJ7nvnNVU0jTre0s4p2EE5mbESfKDtxnIx6ml8O6/baHPb6R4muBFeRKu+7zuCsTnBHXGeAa63V9XEd8Jp4LS5gwTCSBgj2P86AOr+C6KPFNyWdnkFkxU5IADPGTx+Ar2ivnb9n+71qf4laqNRljmsn053RljC7WEsYCj6AnvX0TQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUNdRZNIu0f7pQg1fqjriJLpN0ki7kZCCM4zQB8s3uoy+Fbia1kiuElkztYrmORPVTn65BqsviYvGrWA3XIYytbFMeYoHKr7966yewuNW0W8sGuIxcW0uYnlj37VxwpzyeOM1T8OafaWNu11e2cSahFlSiAMFOcbgfQjFAHNS68fENg15pd29nLG3lkMu5VY84Yd+nX61Nb3ev2/7y80mG5UKD5tpKBu/wCAmsa/sls/F1vHbuq3OpOWW3ThZR3IGcdf1rrfGV1c+G/D9vPPHEzMfKiReSzckE+w60AZWpeJpoLbbp1rLa6hMdqC4UEhvX8qteFdJurTS7o3USm5M7MVHOARzj1+op3hzQlVY77XZlTVWPmiN2AC5HQ9tx9K6xbP7U0d+JVjjjOCg9R0FAGf4j0yEaFbyy2P2hYFzKTGCQvUn1wK5zwdZKlleTabrF9bxRzZQ/eDbucbTjgDFehjUY5Yp1mRiqjCjsxPFcXptncaXqctpMscdteyF4iVI5HUfXB/SgChrGreKra/uXnnkFndQ/Zbdrc7RGc/63HOG7fjW3dyHUvC7JLB9p1JIQHgkYEy44JyOue9autWUsmkqUPMR2gdh71zvhKwS8uLXXbcH7ZLGbeVTJwhU4bC9s+vpQAmkeGVl0qeGEjT76eHy5QnIX/64FU9T8KXGk+H7j+zFUNEyyFzwHxxkn6c12Gp3CRagj2zJvU8gH731q07wa3pkiXCEBWwyK5BA96AOA8IWxmsrezSKZLgo0okHzRPzk4bseehroJ9J1OyaO7BjltYzmeFTl2X1B9R6VU8Nxp4euZLWIly/MSyMcH1H071t6sNTuLmGKO8htbRwWkYcs2D0HtQBymp6rDqPipZoZo2tNPjHl5PymVvX1wKzPHWo6xp1gt3bE/YscMqh1cdyevr3rT8K+GjDf6m1xFvt5ZSIHLgq4PU7e3OOKu3UlrpFvIb+0Mlmv7qRSu4c9iDQBi2fi2ddFhmi063c7AzMZ0VTx6dvpXQ6Pcz6vp8l7f2v2OOPIVQ4YMMZzXJz6Bazamo0bRYVtZQJTIZCFT/AID3+ldJ4U1LUEUx63aGN4hszxskHYrigC9pU+n6pCh02/huAhJJSQEj6jrj61iXun+IdN1GY6e8WoQyyrJH5z7fKXoR9OldTp+n6DHc3l/p623mQZEphjAIPXBwK5a78Yut7OYrcHToGC3M+cGMn2xz26UAb8NksVy1yLdHyp/h557fSs/VbWPUhJbylo4DkbY22so4OM9ulNtbq01S/tdRhvHdYEfEcZwHLAD5h7e9bf2ePVCZc+Ww6sR1/GgDzyy8ManZarPb2l1eLp7Hz4gjEJkHof8Aa4Nb/g7UdOTUryWSRbid4zmfblienLdcYA46Vr67YXMujXkGjTo7yr5KyI/MWepyO+OPxrH8G+H10KxVJjE08a7RMq/OQeu4ntntQA3SNKsdU8YXkt5NZA7FRVdQjtJ1C5PXpzjNQ+K5bwacrXlskE1vOXk8qP5Fi5ySACSenQU7xpDFN9kS4hSfe+8A4BUjgNnqKsWl5bagkttbK3yAGaUnfswfu7s9T0oA7v8AZ+uLGXWsQQXiXD2U7r9oQAqgkhB59GO0j6GveK+c/wBnPRDo/jvUwLuacS2MjsJn3FSZY8YOM4xmvoygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKz/EBddFvDFjeIzjNaFUtabbpV0TnhD060AfP8NpqVvaSS/aEnuWj3SEkDn0GKrQTzRTfao8SMB8yt0IxyD+VZfxEtZ7LQY30V5rb7PN5wCsxGW7nPoT09zWeuk67YWWmanqOrqIXKSukrYAcjo2Oo59fwoAz47XS7jWZ7W7ti9804ne4bKNF3HT7qj2/GuqGoW2q3F3HeRIZNNunSISPnO0A78H8Dj2rZ8M6jZantmeGBbors3sNu9PYnqPavJ/GukrD8RL+CN963iGaFi54IHzL78ZoA0L/UrTxLDM8kj29hb3IRbjaSZCQ3QAde4rq5b6XSdGe9nZv4kdV5yo5Jx61zemNZajDElr9q0+1sU2vaQSlVz1LN6knuaggvLrVPE2lSS2wazkSTcud4xgjk0AeuaPdWd9o0N8rRNC4EgZSDhsd/Qj0rg9Xub7xKdRffHajTI98EquUEjYzuz2AxWn4UtLXSrO90nSdPuVs2YztKH3YlONynPTtWq1jFbwKYyghdGDIx4JI6ECgDG8L+JLy90PZeMsl6sQYbsKHPQA575zznmqekeILe11meK9tf7O2gvJkjaHAHA98VePhiynvJ7tTNAjxxoFRfkQqMED68VzviTwPcm6guYbiJ7ee4VXikOQUPHQ+nf60AMh1ad/EsrahFLHb3hL23HCqP5k81vaFLLHc6nc2TLJKsW62WXgToTyT9MEYp2oaPDLf2ei5Nxug2iULgwlBlSD9OPpW94f8ADh07TrRLqdpru3d2WQHoG42/SgCok1trUVpcXlv5ctsQ21TlTkcjPpVwol1vtMeXEqgqcjLZ649q5i41y4s9UtY59OdLIllYxf8ALVycAU7wrZ3GsapJq8sL2EltIYipJIZR7H2oAtyWmvwie3tdkVtG2VcYy3qc9enoK0pLt7LwxNJcW8l3KQcKBy/51uzfJaud4XIJU9MVkaHqb6jbTwzRxgqCqTYBVz2Pp+VAGB4VunxLcatFDZwKcRo0vJJ6A1aYFLuSa6d5rPkogwhz2GP61T1yG2h09rfVr1XaOZZA8cQjUNjG3od1c3Jq2t6vI8Wl2bBQSollOB9R27UAXvD2rzeGXuWfT5Z7e6nLyCMhgikf0zWpoXibw9DYz2dzEo8yZ3kE0WVkyc++e1UNE8CSXE//ABUVzLJKRkGJ8IPqSOfoMVtz22nQgpBZ2sUMOAJGQEnsMk/55oAztZ0bwxqDNPoWo2+l6gBwY5tin/gP+FSR+GVm0Ke0l1a4uZpsN9occZA4GAeRzUMHhOG+vvttte2pZX/fQhFYMR6YPy8VYs9XePX7bTba1eVlO55QCEjA6g8YOBQBnXega/Y6faQaJewxRpIMfKQ8gxhix5Gc4qee/wBQsIpFlize8ArtwBlsdOhPB4FdxqWpaalr5s0qw9CjA5z1/PmvN9c1GTxLLaxaSf8Aj3mEgnY7AZOyHvQBe0zww3n3t1ql1PNNd7ZPJlOAmBgcf06VoeGvC6WehXVpcOWlmkM3m4CkEdBgcY/xq14pS80vSNKufs6y6g0iQTkNhY4zksc+gqDT7KO01t7walJJc3qqoilkJTIxjAHGTxQB6L8HoUi165wNzi0KlyeT8yf4V65XiXwK1uHV/EV+NjxXUdvIskbjoVlVWGfqB+Yr22gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKq6r/yDrj/dq1VHXAzaRdBPvFDigDxzxJdWcGjXLXjReT5ZY7z8vFcdbayNV0oSwvK6OnmIhj+8FzxtP04rjPF327V9Re1eWf7OkmyYMCMD0A6V6bo+kR6TZ25t5olWK3CJG7cqMZ6mgDl9duhfWFrbOk1nKUVgJYwCGIz8vNc1418PX0Oj2Gt2V1JcS2lwjgEZcA44x35A/D8a7zxBbJ4k0mSC9EcU0JDRToOVYeg7iua1DUvJ0210u6uPMuYn3ROWJEhH8LHtxnBNAGzJ4bGuWbM2rxyWkgEjGKMKD2x2xgZ6/lUngnQpNLlPn/ZP7MgUiEITvJJySf8AD2ql4Iv7KWz1S31SNY7WeTDoxwo4A69+fTvW7LdwwtLb20iT2zDgqd2OKANZ737OufleNvnBU8kZ9R3rJvxq7axKlqIpbWcLyTgxKecn6Crnh1bUW8yzOHVT5gL8KvbrWPr2sx6tBax2Hmx2jyFHdOPMA7KaAK0OqWl9rH9nW1w80ltmN5fmCbs9Mdx6GtbXrKUaDF5cBe5jlDBVyTjucd+1eefFRZfDdzpF/wCFtlnIVJllkGS7HGFbPTivRdMkuPEXhWzv7WUQag0IGPvKHBwefTg/nQBpaJBdw2BaVY1kZAyFlJYE9Q3t0rnm8W3g8S/2VcCFBAoeaVCSp5HAz0zXWywTbgoAffjeSxGPpXGQ+F7u21YyTeQ63DM8sj8MecBRz0oA1PGxsTZ2JluI4ZFmFxFz94gHB9xkio9I1668mQzoszxgtKVUjAzjPTnNclrD+JI9cmm1Cw87S4JjHBHHgSCHjmPPXtwa0NGntBqlzLLfxWttdBd1lcyhbiM4+Ukfw9+D6igDp49YsdatLhpJGjgRAZEJwVB9cVnW2r21kkdtDAkELjZbRE8sO7fXil0eEW+tN9nii2ygCQjBLpnAJHp71Pq9zYw6vZ2uoQwls+bGQnIJPY0AcJ4xW6v9fAKRo7KotYWwNx/vemT713Wl2BfSLWS4maHUDahZIlIID+uPWsnxBrGltqEMljaJcahCCkUbKPlJ9T1/Cq9lqY0O1kvtc8+YCRUJgXcsW7PzE9+lAF3wzfnxDd3Gm3hmZINwd2bk4PYdhgjBqHSrcWWr3dhqnnTWcDieG4LHJjHIyR1KkfjTm8X6fYX0pj0aSO2nUE3kABDZ6McdiO/rV3TNWurTWJA8Ym0+UEJL/FF3waAIhFbafYT3egTwLJOxk865JLSAcYHHrgUljfz2FnBc6xIvmufnCICzA5P8qn8JLaazDfwyy+dZpKyeTPGAVzyTuHv/ACq7pmo6NLZSrpjW0lvZ5jZ5BwoHU5PUUAZuvx6Ve6Cbm2giu76AeZCknysR6D/DrVGz0G0sbCxvJXFhHE6XkkRYE7vcdcZ/OoPEtqDqOlajCS9qs4+0OjfKsJHLe/TH0NVItI+0a7qd5LNbmxuocefM23YqnKrnOMdKAPUfE+l2niDQZLe43tBcR4Dxnacdeted63qMfh6OylKhoYpkiBIyUToD/wDXra8NeLPtkraDeIIb9Y8Q7DlXUD19cDt1rm/EP/E5stY0R7G4jvfK/dO64QsGBHzdiPSgD034G2P2bxTfyJcGSN4rmUJjpvkiP4/dP517fXi3wKhmtdS+z3AzLHpwV39WDIDXtNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVT1lC+l3KqdpKEA+lXKoa/Mlvo13LJ9xIyTQB89a9rWjWurpbXEcklw5RmPkbgcH/JrOk8W2qaveQa9btb6fMClvexqWUHsDjocc1HY6WPE8moeIIbu5nlAMdnCWASNR1XjqxPf3rKTVzLFHHb2hN8FxNa3GFYNnBwD94UAazSXc9hcWekTRNBI2Guf9nvtHvUWp+A4ZNPgeyeTzUIkkC/dbHPT25pbe2htdRkjiU6YrMWHm5UHHdT05x0qfQPF09nd3EesJsCx5iYABXBOQQfXH4HHbmgDkplkiuHEiiWOJzMhVcoy/wB046EdP8iujs5tHv5oNQ0gXEczoYpYd4KRkc/44qroGmXryXmoWc63ME0rO0EyDDgnoR6jA/nTLV1tPEWoQxwCIzQLLHHGMqpGM/zagCHV9Tilf+zLS48xJuHaLOCDngfkavaZ4cW78MxahrOtTWumW2dqDCoiKcZz7/zrnIPscWupFFEM7GjLKcAH3/PrXS6pqFvqWg2nhqxdJbyQg3CFC6KOTjj1yD7e1AHT3WmaRqtna2oaG70+SH5GY+YG44JPeufOrT2M02gvb/ZlhQyRPbqQjp1IFbdr4bvYvCiWNtcwwXsQAjeAEIgB6fTFRfahCFt/EF1btfB9glhXCYAz8xPT3oAp+GtSmtNPlvtRumZyTHDas44HoO5NWIfGUE+pRWN3YzRX7KTsPzbD1AOOvHerVzpGjQW4v9SgiaRiArDJGT0Ix1PfNXLyzmguLWaBFaNVCHYuWP50AUdQiudTZZWj2oBtGG6469azW8P2V5eTSarbQ7FQKJQg39sDPU1BKdYh1mVtPu0aCaX95byDjrzj/wCtithDPciONyIJpNwVJG5bB6AfSgDir0XNr4liTRo2SOJNiS7DslXGQregHT14FSTXuv6qCl7ZfuzKu+5s237PXjqOfcdK6PxJ4d1G41ixa2jkfT4yPlD4KN3Y98ngf4U7w+t/ZalPYJpsi2ofeZPQn19u1AHELcWnha/m+3SXDyNJuEnklwFHYkDivRkvbLVrbzrdYJrKQAsdvykHqCD/ACrbvbWztLWe4dVREBldgfTnH09q8u8I+JtSWC9W6sZL+MNvje3jALDdyCBwOD3oA2Zb2Cwtrq4017EaJZKw+U/MSeQoGc8n2rW8PhF0iyuNTCNdXSGRkBAHzcgAd8CuT8QXNnr13HYW2mm2YussiNEIW3c4DetTXWmX7w2UkNy7tb3Ksse7I6/MvXgjH6mgC94kt7qDydN0qVNurK2WZCNhzjr371G9jb6b4QNhBaJPNGyp5KnBlYn5t3fP/wBas3wddapd3Ewjnee3sLiXyx1yXbgjPPY11XgmWO71PXP7TRPPiud5PZWIIP06UAY+ia7pGmyNp8EU0MsSgTB8NGCTgqT9SBk1Gr2OsWlxoeo6KYrGTLGUzFBnOcKc9f8AOKua9oVjFPcSAwRxSyCNPQknj6nP8qpax4VuYIrxLGOZ5JUTyozyN6Dk+nOOlAD7uy0jQPFmjTHFr9nh+zx+dJksOn3j35rV8ZatHY64tvEBLdTndsHGwY71yms6/a3lpa2mowi4u4IBBKHjDKXHUg+uAP1rS8MaZ5luuoXEoub6clXc9UHTHP060AesfAy+tNYc6nZOTHNbuuGGDw6j+lewV438C1tLfUL2x0+3kt4bNJYSjrjnepJHqpzxXslABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVk+Lbd7rw3qEETmN3iIDDtWtWT4smS38OahLJ9xIiTzigD5T8Byaj4Z8QpY+cbzT9RR8MF2qJ1znH0x+RFd5paaL4iW0uXgWS7s5MJIAVO5ecAjqKx/C+nW914IlP2dpJzK06hh8ylhwVPY4NbeiNDpnhu0itImRUO04GTnv8AWgDF8Y372d49xHbrdaah23MZXcwz3A744+lcy1lFe2jPaS+ZE2Ge1Zvu55+T0PPQV6PrmmvfWc0sSsJCMhSQoP8AhmsPwtpt7pekXc+u2Nta3Es4SMREN8mOp5OO9AGHoM9xb2QFrJJLbId3kNH88Z6Hn0q7o+pQ3fivbqkcNpd2IdoyqfLcwMOn1U9aueIBLok41PTkTzFIL4HDKeCT6+//ANao7WfTdb1e3l1JYbS4hYqEjkztHByTx8p9fegDG8d6dZprsV3o0cjyywtPOI13bQMAHHYDFbPw+vLNbO5Z9rXkkgW4by9rqMdD6jr3qCz04jxbrsrzFLSGNLRZlP8AERnP1HpVvw/4ft9K1WS6GqyT2TxhpUKbUR1JO8kn0OKAI7LxDexahe2erwpp4jvGhs3Vtxkjxnef0596i1uyvtZuHbTLm2W1kXy7lZoN2f8Aazzj6jFdZ4gm0mXSJL2aFbpEG5GjALse20+vSuJstS1GfSru3uNKit7eRyZpI7gFol4I3jJwSD/9agCrfaNqmj2It5dR08xZV4AZWDZB/hUjB69OK9D0J5JdOtXuLhJLiRMsUPG7uP6VwWqWSW2mGe6mnvbKSIsrOcNER0AP4AelTeHtQt5bSJoYLyOEOrbJFIyeSGQ/xUAbfimW80S9gvbO3tJEbIkWUbec8nd2rM0rxFZ61fDNl5epWRLBWwQM8ZUjrmtXW9R/tNZNPtIhLc+XuhaTG0kjqOxA96x/CHhrUtDsHne1jnvVVnCsyq0r9lz6fWgDrI9ejl1WLT4gr3SqHnhVstHkcZHb8at3M0SyN5RAmYkucHgD19K5HTtfsHvHvV0hbHxHMCk4ZcsNvGC3Gegq9e79SeGB1+zCc/v3Q4wvpn3oAwPFmp32u3NrpekfLYSXAjllHViOc/7tO1a18O+FLS+UmeK5uolSWKCQsfUlR2FXtdll0WzElhohn8psJtmA3Lnn5Rzn+dchrWo3PinU7O509ks5rYtJJM43eXxgIeMfnQBTjJtbi0vLTVGubCMBoZW+Yltw+Xnrj09j0rvtQ8TWkml219HbXJ3gq/kwllWQcfXFeepo0F7dR2N59ua/QF4xKwSLOMnZjqOPzFemeLtNtNP0C2RJljS2TCq38Xqx96AMux1C0sfD4hsJUiv7+R/JlEXloJBjgnHXnHPrXWeGbG3sNJZ72WKS5um8y5nA2B3PXHpXm9qr3GoafDfXwGmGdHCgf6yX+EA/Q8+1eo3dlYNp6R3kYbZuKoxOC2KAOY8S+Tc6zp8FsbdYLScSSc5JXHWrPijUX+yx6eun3c01zEQZY5RHsHPOfXArN+zXEpkutK0zyhLEItkg2rjP3/wxmo54Xh1aG9kgmkeONI1aUEKxA+Zl9sECgBIPDlhommxXmozqtoIzhCok2uQe/r71gaRrGoQWiHTbSK70/wAxjlmCuMHnHqPzrpPGYs9U0aO03siJulOOA3GAD+dcx4Osp7TS4LuGUXGmgSpKp6wyAE7gO4IxQB7N8G9VivfEt1CHxOLNmaMcgfOnOfXmvYq8J/Zwa3v7i71K3nWVvKkibam3PzoRn6Y/WvdqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArG8ZoZPC2poq7iYSAPWtms7xFG02h3scYyzRkAUAfK/g7VLzQNUS0vHDWLR7vlYuD8ucA+oPGO1d5p/ibQZ7UGS4W2fbuaGYFSp/HrXG6ta32kaj4e+17JbO4uvKniVc7BgYJPqOa6W21T7Vokp061hvHspcSQ3GBuhz97J749aAL0XivSLqZ7S3uVnfbx5bbs1R8W6lb3FhDbhXa6UiQQkEZXpuz/nrUnhix0e71i71PRp7GVd6rKtvhlGBx04H4daZ8TZo7CzstUiZEubabaCVzkEElSO+fSgDnk1aPTbyOB7G/naRfMEcEPmKQfx+tSa94c0q2sX1K4tzBLsZpNjlcDGccdAayA+oSrp/idkNtZJcP5sKuR8rDjg/iPxr0C6hh1SwgcwqqyKGaOY56joRQBwnhO6k0vwQLS3Y3d5eSmQb13hMkYJJ/2RTNTs9Vn0qdrvUpdrkrsjXavod2O3pXY+JLm78PabHc21nHdRxqFcKBhewIA5NVdG1qfVnie72xWbAEx7CrDjv680AUNP1O20zwvbWd4Wut+fs7RR7QAOOcn1zWl4bttNjgurWQNO15J5k3mYHJGNn0Aqv4l1/T7TS7tdM2S39uN210J2LnrWHa6lrOtRQXFtp9osKOFuJTLiQZ74zz9KAOm8b6HOmki90kr/okBQwEAqYx1IHQEdf84rn7S5udQ8O6dp9u0kM00fzTSZ3KCeFHtjj6VJq2qy2+oaRbpeTHZJ8yLkQyk9I2Pfgd6n8Va+y2arp+ni2uSyxrcMmdhPHA9P6CgC74nt30m20TTtLbZ++2uSAWI7kn3yTx7VpNffY1sxGZPLYHf/EQc9RXm+r28r6haG71Se6mRF3umPkYjOBk9hzXYXniD7J4g0LTIVW7jvISDI5+ZcDBb07Z9+aANOzutQd7q4NrZym3ZirqfmKnnHSqlz4btPElxHfXHPnr5dxArlCq44IweoOK3dI0+G3tLrdkxyg8e1VoLWL7BNC0xiW4yBtO1hgZwPWgChoWhGG+ksrq++3WUQH2bdITIhx8wc/lisPxp4KmuPEsd9pckNsgtwsibiDOQejdunepPC2oT6PqF7bXNv51lAvmQXUDbyQTghx/erqraWfV5xIyF7fGQQMY+h/pQBzED6PqNlqN4zJDe6WDERI20J9Pr09a5wprfiYaVd6tbRzWFyzxNJbkqtuijq2cg/8A1qoXur39tr1zLfaf9iiWcLNE6ZMi/wAJYnqcdK9Ra6019NGiWM0KxyWzII92GUkd898npQBleHNK0m0120ndo9sYMdsXYbWbsRnq1dbrN3FCfKypfqoIzj3rHh8I29z4bs7K8mJNvtcTJwyODkEU/wARWN5dajanTolmR2xcNuAZRjg+4oAj1jxBHptlbwylneRv9ZtyqgHHJ+vFcv4m1LxHa2txqZGnTWhVUt38wjknDLt79zW34oWCwtLXSfKjneZi7AnIVepb6g9K5XT31CLwveW1rIkha6XyvOQExD15oAvxWWqt4Vnvplhmu5wXFsCULKSABnoOOa57wtevqfhrUNJtJorfUGkJSKc7PmPX/Diunudd1DS5Y7TW0MkJiV2uYUxjI6fh74rzyMaSLW7jvRJ9pE2baWM4Z16D6dM80AfQvwD05NIllsxGkb/Z2eQIcgvvXcR+Jr2evn79nXVlu/EVxa/2hHfeXYOVZc5AEkYIPvyK+gaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqlrUqwaVdSPnaqEnAq7WZ4ns57/QL61tcefLEVTJwM/WgD5l1DxALDxCl01pdX9vNIA620IfBPds9MetbE+lyQ31w8Vrt0u5jYSMHypjYfN+GK1G+HvijSvD7Jpelpd6vJDkmW4i8pWGCV5YE57dvWrNvoXj2/jt7XUfDNta2roBNi7iJQ9yuHOfUDFAFzwpp2madpSnSBm3kAw5+8wHTP0qrrWhx34ZpZ+C25Q3KqfWtTwr4P8RadBJbyWrxwp/qxLPG+RnnOG60t94O8RHVlubayHlshWRDOm0/hn0oA53TdHtVtzp15Jb3cTssghU4Cleh/QVp3sbtLHP5TBFXJXbxxWlY+BdYtnJa3VjnhvMXb+Wc10LeH9T2YFuOnZ1/xoA898G6hdXdhJeala/Y45WZ4xISGEeflLA9CetZkmhrN4iGs2motIY4miaJuF5zyBXoV/wCF9avbGSH7IYiy7c+ZGSPcc4rjG8BePdOl+02SW960ZwtuzRxo6HqPvdfegDPk8N2l7BqDWsMbXEq7C3TcwHGT6Zq14N8JXFhpECaxMGuQCWSPhQM9PetjSPB/iy71Y3WoaY2mWkR3pbR3ETGRu+4qxz+ldk/h7U2XabXqOT5i/wCNAHn15LYboxaWkl9NbNkQooLZHf5sD8a5V9TOq+JrV9UuY/scAMkUQQqQ3cScYyMHjNdhc+CfGkHiK6XT7RE0+5QKbkSxbk4/u7geKyvE3wi8QTwxW2lWpCfL5krTx/PjqxBbqTQB574ltr1YpdRsIXis5pHn3eR5gVO/B78GtvSLC4tn0rUL3xF9o84B443txGUUjncT064rpl+EPiJCs6NfLMoUIqXkYCgYGMbsfrSa18MvHV1bpE0VlfxgqT55jRxjsHDUAZNrquq31zcC4uoLXSbJyHuIpMCVd3y89v61Y8bS3AksSLFLiOKPz451l2qp5798itS2+F/iiFphFp0CWl2Ee4tHuEdQw7Kc84654rc8TeA9duY7JLbTDcRxBUMSzRIqjHXlgfagDjvhrFNLbyz3O2OReFA5Lqc9T/hWhpIv9C1yeC5ZpdLfLwDbhozn7uOw/wA+tbvhDwd4phvrv+1NCS0t1O63KXUTZ56EBqzPE3gTxtqmotaQWc404KAty93CD6ngNn8TQBJ4ksbFlkvriCNrqND5DzAkAkdducE+9cZaaPcWGgtqLMUu2J2nywf90g9uK73S/APiQWNpbXWmGNYjtJa6jkOOxzurpr3wrqv2BIoNOdiCTsEkQyeeuWFAHA+AdUj1FX0+RpxdW8QeTzHBJJx1/Ouh04rcXNwY5v30Emxyp59gaqweAvFFt4jg1Cz05YLdYXSZBLFvlz91Sd3Y89e1LoPw88T2t01/dwv51yGW4gSeMKRxtbO773Xp/jQBzPiwXB8TImnRyG9nw8pb7mxRgDJ6DrnHrWf4i8xdRTTtFVPPZfmfqsYI5Yn1r0vVPCXiOVpTDpkb7YisZE8YZiV4Gc+tJpPgPWYdBhE1oqak0QErNIjHOc4zmgDylL25XxENLvJn8qBER7twC8xwDhR0Ax688Vl+KrCSHVV1C7MsunRwlBLFtzk52qPQ816bZ/DPXJtfmvbnRkt4IkMUeLiNnnJ48xjuIAx0FbN58Nb27t5bWazMltgFI3mTbkHPr64oAo/AOxs7TxNctawvG8lgx/ff6zG+PIPpzivdq8h+E3w/1nwx4vvNT1a4lmgeyNtEJHRiuXVjnaevH6V69QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Computed tomography (CT) scan of the chest showing fungal ball with pulmonary infiltrates, (B) gross anatomy on autopsy of the same patient showing mottling of the involved lobe and (C) Grocott stain of the lung tissue of same patient showing multiple acute angle septate hyphae of",
"    <em>",
"     Aspergillus",
"    </em>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14:211. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33764=[""].join("\n");
var outline_f32_62_33764=null;
var title_f32_62_33765="Lacosamide: Pediatric drug information";
var content_f32_62_33765=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lacosamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"    see \"Lacosamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/0/29701?source=see_link\">",
"    see \"Lacosamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6786825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vimpat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11508103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vimpat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F9406528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F9406539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"      see \"Lacosamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Partial onset seizure:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;3 years and Adolescents &le;16 years: Limited data available: Oral: Initial: 1 mg/kg/day divided twice daily (maximum dose: 50 mg); increased at weekly intervals by 1 mg/kg/day up to 10 mg/kg/day (mean: 6.34 mg/kg/day; range: 1.7-10 mg/kg/day); dosing based on an open-label, prospective trial of 18 patients (mean age: 10.6 years; range: 3-18 years) with refractory partial seizures (Gavatha, 2011). A retrospective study of 16 patients (mean age: 15 years; range: 8-21 years) with refractory partial seizures reported a mean initial dose of 1.3 mg/kg/day  and titrated to a mean maintenance dose of 4.9 mg/kg/day; maximum daily dose: 400 mg/day (Guilhoto, 2011); further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents &ge;17 years and Adults: Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 50 mg twice daily; may be increased at weekly intervals by 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance dose: 200-400 mg/day in two divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     When switching from oral to I.V. formulations, the total daily dose and frequency should be the same; I.V. therapy should only be used temporarily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adolescents &ge;17 years and Adults: Titrate dose with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild to moderate renal impairment: No dose adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute): Maximum dose: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hemodialysis: Removed by hemodialysis; after 4-hour HD treatment, a supplemental dose of up to 50% should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Adolescents &ge;17 years and Adults: Titrate dose with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild to moderate hepatic impairment: Maximum dose: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe hepatic impairment: Use is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6790656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vimpat&reg;: 10 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vimpat&reg;: 10 mg/mL (465 mL) [contains phenylalanine 0.32 mg/20 mL, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vimpat&reg;: 50 mg, 100 mg, 150 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6790309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F9590984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-V",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089816.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089816.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9406540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administer over 30-60 minutes. Can be administered without further dilution or may be further diluted with NS, LR, or D",
"     <sub>",
"      5",
"     </sub>",
"     W. pH: 3.5-5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Solution, tablets: May be administered with or without food. Oral solution should be administered with a calibrated measuring device (not a household teaspoon or tablespoon).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F6790528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F9406536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not freeze. Stable when mixed with compatible diluents (D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, LR) for &le;24 hours in glass or polyvinyl chloride bags at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Any unused portion should be discarded.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution, tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not freeze. Discard any unused portion of oral solution 7 weeks after opening bottle.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9406529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Solution, tablets: Adjunctive therapy in the treatment of partial-onset seizures (FDA approved in ages &ge;17 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Short-term adjunctive therapy in the treatment of partial-onset seizures when oral therapy is not feasible (FDA approved in ages &ge;17 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6790305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lacosamide may be confused with zonisamide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Vimpat&reg; may be confused with Vimovo&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F6790444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Syncope (adults; dose-related: &gt;400 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Ataxia, depression, dizziness, fatigue, headache, memory impairment, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Hepatic: ALT increased",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Local: Contusion, injection site pain/discomfort, irritation, skin laceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Gait instability, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision, diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Anemia, atrial fibrillation/flutter, atrioventricular block, bradycardia, cerebellar syndrome, cognitive dysfunction, drug reaction with eosinophilia and systemic symptoms (DRESS), dysarthria, euphoria-like subjective responses, falling, hallucination, hepatitis, multiorgan hypersensitivity, nephritis, neutropenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9406532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lacosamide or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14264748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in hepatic or renal impairment; dosage adjustment may be necessary; use is not recommended in patients with severe hepatic impairment. Lacosamide may prolong the PR interval (dose-dependent prolongation); AV block has been reported; use with caution in patients with conduction problems (eg, first degree, second degree or higher AV block and sick sinus syndrome without pacemaker), myocardial ischemia, heart failure, or with concurrent use with other drugs that prolong the PR interval; ECG is recommended prior to initiating therapy and when at steady state. During investigational trials, atrial fibrillation/flutter, or syncope occurred slightly more often in patients with diabetic neuropathy and/or cardiovascular disease who received lacosamide versus placebo. The oral solution contains aspartame which is metabolized to phenylalanine and must be used with caution in patients with phenylketonuria.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <i>",
"      In vitro",
"     </i>",
"     data has shown lacosamide interferes with CRMP-2, a protein involved with neuronal differentiation and control of axonal outgrowth; potential effect on CNS development cannot be excluded. Lacosamide administered to neonatal and juvenile rats resulted in decreased brain weights and long-term neurobehavioral changes including learning and memory deficits. Studies of the effects of lacosamide on human CNS development are needed before this medication can be recommended for routine use in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9406533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5-100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA requires a Medication Guide for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Potentially serious (sometimes fatal, possibly delayed) multiorgan hypersensitivity reactions [drug reaction with eosinophilia and systemic symptoms (DRESS)] have been reported with some antiepileptic drugs (rare). Monitor for rash, fever, and signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems. Discontinuation of lacosamide and conversion to alternate therapy may be required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dose-dependent dizziness and ataxia may occur during therapy; reported frequency: 31%. CNS effects may impair physical and mental abilities; patients must  be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually (&ge;1 week) to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Lacosamide oral solution contains propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use the oral solution containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6802892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6790314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6790315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Available information related to use in pregnancy is limited; if inadvertent exposure occurs during pregnancy, close monitoring of the mother and fetus/newborn is recommended (Hoeltzenbein, 2011). Two registries are available for women exposed to lacosamide during pregnancy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pregnant women may contact the North American Antiepileptic Drug (AED) Pregnancy Registry (888-233-2334 or file://www.aedpregnancyregistry.org)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     The healthcare provider or patient may contact the UCB AED Pregnancy Registry (888-537-7734)",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9406541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizure frequency, duration, and severity; patients with conduction problems or severe cardiac disease should have ECG tracing prior to start of therapy and when at steady-state; monitor hepatic and renal function; suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9406537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      In vitro",
"     </i>",
"     studies have shown that lacosamide stabilizes hyperexcitable neuronal membranes and inhibits repetitive neuronal firing by enhancing the slow inactivation of sodium channels (with no effects on fast inactivation of sodium channels).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9406538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Completely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~0.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &lt;15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic  (CYP2C19 substrate); forms metabolite, O-desmethyl-lacosamide (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak plasma concentration: Oral: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (95%; 40% as unchanged drug, 30% as inactive metabolite, 20% as uncharacterized metabolite); feces (&lt;0.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Effectively removed by hemodialysis; AUC decreased by 50% following 4-hour HD session; supplemental dose recommended",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F9406542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/0/29701?source=see_link\">",
"      see \"Lacosamide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each new prescription and refill of lacosamide. Avoid alcohol. Dizziness, lightheadedness, excessive drowsiness, headaches, nausea, vomiting, tremors, or change in vision may occur. May impair ability to perform activities requiring mental alertness or physical coordination. Contact prescriber if rapid, slow, or irregular pulse, fainting, or shortness of breath occurs. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self harm. Take exactly as directed; do not increase dose or frequency or discontinue without consulting prescriber. Do not abruptly discontinue therapy (an increase in seizure activity may result). Report worsening of seizure activity or loss of seizure control to prescriber. Notify physician if rash, fever, fatigue, yellow skin, or dark urine occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14264061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Twice daily I.V. infusions have been used for up to 5 days.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatr",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/62/33765/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gavatha M, Ioannou I, and Papavasiliou AS, \"Efficacy and Tolerability of Oral Lacosamide as Adjunctive Therapy in Pediatric Patients With Pharmacoresistant Focal Epilepsy,\"",
"      <i>",
"       Epilepsy Behav",
"      </i>",
"      , 2011, 20(4):691-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/62/33765/abstract-text/21406334/pubmed\" id=\"21406334\" target=\"_blank\">",
"        21406334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guilhoto LM, Loddenkemper T, Gooty VD, et al, \"Experience With Lacosamide in a Series of Children With Drug-Resistant Focal Epilepsy,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 2011, 44(6):414-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/62/33765/abstract-text/21555051/pubmed\" id=\"21555051\" target=\"_blank\">",
"        21555051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoeltzenbein M, Supcun-Ritzler S, Langthaler M, et al \"Lacosamide During pregnancy: Experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy,\"",
"      <i>",
"       Reprod Toxicol",
"      </i>",
"      , 2011, 31(2):259.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shiloh-Malawsky Y, Fan Z, Greenwood R, et al, \"Successful Treatment of Childhood Prolonged Refractory Status Epilepticus With Lacosamide,\"",
"      <i>",
"       Seizure",
"      </i>",
"      , 2011, 20(7):586-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/62/33765/abstract-text/21474342/pubmed\" id=\"21474342\" target=\"_blank\">",
"        21474342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83877 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33765=[""].join("\n");
var outline_f32_62_33765=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6786825\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11508103\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406528\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406539\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790656\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790309\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9590984\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874836\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406540\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790528\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406536\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406529\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790305\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790444\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406532\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14264748\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406533\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299564\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6802892\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790314\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790315\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406541\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406537\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406538\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406542\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14264061\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83877\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83877|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=related_link\">",
"      Lacosamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/0/29701?source=related_link\">",
"      Lacosamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_62_33766="Pancreatic polypeptide, peptide YY, and neuropeptide Y";
var content_f32_62_33766=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pancreatic polypeptide, peptide YY, and neuropeptide Y",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33766/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33766/contributors\">",
"     Rodger A Liddle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33766/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33766/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33766/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33766/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/62/33766/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Originally isolated in 1968 during the preparation of insulin, pancreatic polypeptide (PP) is the founding member of the pancreatic polypeptide family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The PP family of peptides includes peptide YY (PYY) and neuropeptide Y (NPY), which were discovered based upon their chemical structure (possessing a carboxyl-terminal tyrosine amide) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. PP, PYY, and NPY are all 36 amino acids in length and despite structural similarities, they are found in different locations throughout the gastrointestinal tract and nervous system and possess different biological actions. PP is expressed in endocrine cells of the gut and pancreas, PYY is located in enteroendocrine cells of the ileum and colon and nerves of the enteric nervous system, and NPY is found in the central and peripheral nervous system. This wide distribution suggests that these peptides regulate many different physiological processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR FORMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pancreatic polypeptide (PP) peptides share a significant degree of sequence homology that produces a polyproline helix, an amphipathic alpha-helix, and an amidated carboxyl terminus, resulting in a hairpin fold known as the PP-Fold (",
"    <a class=\"graphic graphic_figure graphicRef67136 \" href=\"mobipreview.htm?32/54/33647\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/6\">",
"     6",
"    </a>",
"    ]. Although unusual for small peptides, it is believed that this tertiary structure is important for the peptides' biological activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TISSUE DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic polypeptide (PP) is secreted by specialized pancreatic islet cells (PP cells) that are distinct from those producing insulin, glucagon, or somatostatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuropeptide Y (NPY) is a principal neurotransmitter found in the central and peripheral nervous systems and is predominantly found in sympathetic neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peptide YY (PYY) has been localized to enteroendocrine cells in the mucosa of the gastrointestinal tract and is most highly concentrated in the ileum and colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/11\">",
"     11",
"    </a>",
"    ]. PYY is produced by two different cell types within the intestine, namely, L cells where it is colocalized with enteroglucagon and H cells of the colon and rectum. PYY cells exhibit interesting pseudopod structures that extend from their basal surface (",
"    <a class=\"graphic graphic_figure graphicRef74542 \" href=\"mobipreview.htm?16/0/16388\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/12\">",
"     12",
"    </a>",
"    ]. These extensions contact cells in the mucosa and submucosa and may facilitate communication with other cells such as neurons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biologic actions of the",
"    <span class=\"nowrap\">",
"     PP/PYY/NPY",
"    </span>",
"    family of peptides result from binding to a multitude of receptor subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/13\">",
"     13",
"    </a>",
"    ]. At present, five functional receptor subtypes have been identified, all of which are typical G protein-coupled receptors that have been designated \"Y\" receptors (",
"    <a class=\"graphic graphic_table graphicRef75135 \" href=\"mobipreview.htm?13/54/14187\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. These receptors signal through the GTP-binding proteins",
"    <span class=\"nowrap\">",
"     Gi/Go",
"    </span>",
"    and inhibit adenylyl cyclase. Another mechanism for signaling also involves inhibition of calcium and potassium channels that have been demonstrated in cardiac myocytes and smooth muscle cells. A sixth Y receptor has been found in some species, but its function has not been clearly established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/49/22293?source=see_link\">",
"     \"Peptide hormone signal transduction and regulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PEPTIDE RELEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pancreatic polypeptide (PP) family of peptides functions as endocrine, paracrine, and neurocrine transmitters. Neuropeptide Y (NPY) is a true neurotransmitter, being released from nerve terminals, while peptide YY (PYY) and PP are hormones acting in both a paracrine and endocrine manner. Following a meal, PP is released into the blood from PP cells of the pancreas via vagal-cholinergic stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/20\">",
"     20",
"    </a>",
"    ]. PP concentrations also fluctuate with the myoelectric activity of the gastrointestinal tract. Plasma pancreatic polypeptide levels increase in phase with the periodic contraction and secretion of the gut, an effect that is abolished with ganglionic blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to PP, PYY levels change very slowly and not to the same degree in response to a meal. Moreover, PYY release does not depend upon intact vagal input [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/22\">",
"     22",
"    </a>",
"    ]. Meal-stimulated PYY release in humans occurs primarily in response to ingested fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/23\">",
"     23",
"    </a>",
"    ]. Gastrointestinal diseases that cause malabsorption increase blood levels of PYY. In addition, surgical conditions that increase the delivery of food to the distal ileum and colon including small bowel resection, vertical band gastroplasty, Roux-en-Y gastric bypass, and jejunoileal bypass also elevate circulating PYY levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/24\">",
"     24",
"    </a>",
"    ]. G protein-coupled receptor 119 (GPR119) agonists have been shown to stimulate PYY release (along with glucagon-like peptide 1 and glucose-dependent insulinotropic peptide), indicating that GPR119 may be directly involved in hormone secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physiological actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;PP has a number of inhibitory actions that are believed to be important for both pancreatic and gastrointestinal function. Because many of its actions are local, it has been difficult to assess the magnitude of PP's effects in the pancreas; however, it is well recognized to inhibit pancreatic exocrine secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, PP has inhibitory effects on gallbladder contraction and gut motility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], and may influence food intake, energy metabolism, and the expression of gastric ghrelin and hypothalamic peptides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/29\">",
"     29",
"    </a>",
"    ]. PYY inhibits vagally stimulated gastric acid secretion and other motor and secretory functions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. PYY-producing cells of the ileum are stimulated by incompletely digested nutrients, particularly fats. PYY released into the bloodstream can inhibit several gastrointestinal processes, including gastric emptying and intestinal motility, thus delaying the delivery of additional food to the intestine. This concept is known as the \"ileal brake\" and is believed to be mediated largely by PYY (",
"    <a class=\"graphic graphic_figure graphicRef62927 \" href=\"mobipreview.htm?11/19/11571\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NPY is one of the most abundant peptides in the CNS and is the most potent known stimulant of food intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/34\">",
"     34",
"    </a>",
"    ]. Peripherally, NPY affects vascular and gastrointestinal smooth muscle function by binding to the Y1 receptor and through its G protein stimulates phospholipase C, resulting in the accumulation of IP3 and increased cytosolic calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/6,27,35\">",
"     6,27,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL IMPLICATIONS OF THE PP/PYY/NPY FAMILY OF PEPTIDES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that pancreatic polypeptide (PP) is secreted from the pancreas in response to vagal nerve stimulation has been used as a diagnostic test of vagal nerve function. Cephalic stimulation of the vagus nerve, such as occurs with sham feeding, stimulates release of PP that can be measured in the blood. However, following vagotomy this response is lost.",
"   </p>",
"   <p>",
"    Although possessing a long evolutionary lineage, and many important effects on the gastrointestinal tract, no members of the PP family of peptides are used clinically as therapeutic agents. However, perhaps the most important possibilities pertain to regulation of food intake. An animal model overexpressing pancreatic polypeptide demonstrated reduced body weight and food intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/36\">",
"     36",
"    </a>",
"    ] and protection against diet and genetic obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/37\">",
"     37",
"    </a>",
"    ]. Conversely, peptide YY (PYY) knock-out mice are predisposed to obesity and insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, substantial data indicate that neuropeptide Y (NPY) and its receptor are potential targets for regulation of appetite and feeding and are involved in the pathogenesis of obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Release of NPY and activation of the NPY Y2 receptor stimulate fat angiogenesis, macrophage infiltration, and the proliferation and differentiation of adipocytes, resulting in abdominal obesity and a metabolic syndrome-like condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/40\">",
"     40",
"    </a>",
"    ]. The Y5 receptor has been proposed as an \"appetite receptor,\" however other Y family receptors also play a role in this complex behavior. It was demonstrated in humans that aerobic exercise increased circulating PYY levels while suppressing hunger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal models lacking various Y-family receptors have been studied. Mice produced with an inactivated Y5 receptor manifested late-onset obesity, yet developed normally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/42\">",
"     42",
"    </a>",
"    ], while mice deficient in Y1 receptor expression demonstrated only mild reduction in daily food intake and NPY-stimulated feeding. However, after fasting, short-term feeding was significantly reduced in these animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/43\">",
"     43",
"    </a>",
"    ]. Gene deletion of the Y2 receptor in mice resulted in increased food intake, body weight, and fat deposition, providing strong evidence for the importance of this receptor in regulating ingestive behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/44\">",
"     44",
"    </a>",
"    ]. Targeted overexpression in the dorsomedial hypothalamus increased food intake whereas ablation in this area reduced hyperphagia and obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/45\">",
"     45",
"    </a>",
"    ]. The ability to target specific neural pathways in the brain will be important for dissecting the location-specific functions of NPY in the regulation of energy metabolism.",
"   </p>",
"   <p>",
"    Ghrelin, originally discovered as a growth hormone receptor ligand, has been demonstrated to antagonize leptin action through activation of the NPY Y1 receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/29,46\">",
"     29,46",
"    </a>",
"    ]. Ghrelin is an acylated peptide that is produced in the stomach and hypothalamus and stimulates feeding and growth hormone release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Intracerebroventricular injections of ghrelin stimulated feeding in rats that were deficient in growth hormone and this action was suppressed when the animals were treated with anti-ghrelin antibodies. Similarly, NPY antagonists abolished this effect. Furthermore, ghrelin treatment also enhanced NPY gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/47\">",
"     47",
"    </a>",
"    ]. It appears ghrelin may be clinically useful as a growth hormone stimulant in cases of deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    as an appetite stimulant in patients with cachexia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The PP family clearly has a role in feeding behavior. However, regulation of appetite is complex and involves many interacting components, including a number of signaling mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/50\">",
"     50",
"    </a>",
"    ]. Although the 36 amino acid form of PYY (PYY1-36) was the form originally isolated from intestine, a shortened form lacking the first two amino acids (PYY3-36) also exists and may play a physiological role in the regulation of food intake. In humans, PYY1-36 acts through four Y-receptor subtypes, Y1, Y2, Y4 and Y5, while PYY3-36 is a specific agonist at the Y2 receptor.",
"   </p>",
"   <p>",
"    Both PYY1-36 and PYY3-36 cross the blood-brain barrier and participate in the regulation of food intake and satiety. Activation of the Y1 and Y5 receptors by PYY1-36 has been shown to increase food intake and cause weight gain, whereas activation of the Y2 receptor by PYY3-36 inhibits NPY release from cells of the arcuate nucleus, thereby decreasing food intake and resulting in weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/24\">",
"     24",
"    </a>",
"    ]. A study in lean and obese humans demonstrated that infusion of PYY3-36 decreased caloric intake by approximately 30 percent compared with placebo when subjects were offered a buffet meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, 24 hour caloric intake was reduced. Obese subjects had significantly lower fasting PYY levels and levels correlated inversely with body mass index. These observations suggest that PYY has an important regulatory role in feeding behavior, potentially offering a target for drug development.",
"   </p>",
"   <p>",
"    In a large cohort of extremely obese individuals, a genetic variant in the coding region of the PYY gene (PYY Q62P) exhibiting familial segregation has been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33766/abstract/52\">",
"     52",
"    </a>",
"    ]. Interestingly, unlike wild-type PYY, the mutated PYY protein demonstrated altered receptor binding and failed to reduce food intake when tested in vivo. These data suggest that rare mutations in PYY may influence human susceptibility to obesity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22637512\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pancreatic polypeptide (PP) family of peptides includes peptide YY (PYY) and neuropeptide Y (NPY). PP, PYY, and NPY are found in different locations throughout the gastrointestinal tract and nervous system and possess different biological actions. This wide distribution suggests that these peptides regulate many different physiological processes. NPY is a true neurotransmitter, being released from nerve terminals, while PYY and PP are hormones acting in both a paracrine and endocrine manner.",
"     </li>",
"     <li>",
"      PP is secreted by specialized pancreatic islet cells (PP cells) that are distinct from those producing insulin, glucagon, or somatostatin. It inhibits pancreatic exocrine secretion. In addition, PP has inhibitory effects on gallbladder contraction and gut motility, and may influence food intake, energy metabolism, and the expression of gastric ghrelin and hypothalamic peptides. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tissue distribution'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Physiological actions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical implications of the PP/PYY/NPY family of peptides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NPY is a principal neurotransmitter found in the central and peripheral nervous systems and is predominantly found in sympathetic neurons. It is the most potent known stimulant of food intake. Peripherally, NPY affects vascular and gastrointestinal smooth muscle function by binding to the Y1 receptor and through its G protein stimulates phospholipase C, resulting in the accumulation of IP3 and increased cytosolic calcium. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tissue distribution'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Physiological actions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical implications of the PP/PYY/NPY family of peptides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PYY has been localized to enteroendocrine cells in the mucosa of the gastrointestinal tract and is most highly concentrated in the ileum and colon. PYY inhibits vagally stimulated gastric acid secretion and other motor and secretory functions. PYY-producing cells of the ileum are stimulated by incompletely digested nutrients, particularly fats. PYY released into the bloodstream can inhibit several gastrointestinal processes, including gastric emptying and intestinal motility, thus delaying the delivery of additional food to the intestine. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tissue distribution'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Physiological actions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical implications of the PP/PYY/NPY family of peptides'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/1\">",
"      Kimmel JR, Pollock HG, Hazelwood RL. Isolation and characterization of chicken insulin. Endocrinology 1968; 83:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/2\">",
"      Kimmel JR, Hayden LJ, Pollock HG. Isolation and characterization of a new pancreatic polypeptide hormone. J Biol Chem 1975; 250:9369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/3\">",
"      Tatemoto K, Mutt V. Chemical determination of polypeptide hormones. Proc Natl Acad Sci U S A 1978; 75:4115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/4\">",
"      Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci U S A 1982; 79:5485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/5\">",
"      Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982; 296:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/6\">",
"      Cabrele C, Beck-Sickinger AG. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J Pept Sci 2000; 6:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/7\">",
"      Larsson LI, Sundler F, H&aring;kanson R. Pancreatic polypeptide - a postulated new hormone: identification of its cellular storage site by light and electron microscopic immunocytochemistry. Diabetologia 1976; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/8\">",
"      Wahlestedt C, Reis DJ. Neuropeptide Y-related peptides and their receptors--are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol 1993; 33:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/9\">",
"      Allen YS, Adrian TE, Allen JM, et al. Neuropeptide Y distribution in the rat brain. Science 1983; 221:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/10\">",
"      Adrian TE, Allen JM, Bloom SR, et al. Neuropeptide Y distribution in human brain. Nature 1983; 306:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/11\">",
"      Lundberg JM, Tatemoto K, Terenius L, et al. Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility. Proc Natl Acad Sci U S A 1982; 79:4471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/12\">",
"      Boh&oacute;rquez DV, Chandra R, Samsa LA, et al. Characterization of basal pseudopod-like processes in ileal and colonic PYY cells. J Mol Histol 2011; 42:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/13\">",
"      Michel MC, Beck-Sickinger A, Cox H, et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998; 50:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/14\">",
"      Eva C, Kein&auml;nen K, Monyer H, et al. Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family. FEBS Lett 1990; 271:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/15\">",
"      Rose PM, Fernandes P, Lynch JS, et al. Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J Biol Chem 1995; 270:29038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/16\">",
"      Lee CC, Miller RJ. Is there really an NPY Y3 receptor? Regul Pept 1998; 75-76:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/17\">",
"      Bard JA, Walker MW, Branchek TA, Weinshank RL. Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem 1995; 270:26762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/18\">",
"      Weinberg DH, Sirinathsinghji DJ, Tan CP, et al. Cloning and expression of a novel neuropeptide Y receptor. J Biol Chem 1996; 271:16435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/19\">",
"      Mullins DE, Guzzi M, Xia L, Parker EM. Pharmacological characterization of the cloned neuropeptide Y y(6) receptor. Eur J Pharmacol 2000; 395:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/20\">",
"      Taylor IL, Impicciatore M, Carter DC, Walsh JH. Effect of atropine and vagotomy on pancreatic polypeptide response to a meal in dogs. Am J Physiol 1978; 235:E443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/21\">",
"      Chen MH, Joffe SN, Magee DF, et al. Cyclic changes of plasma pancreatic polypeptide and pancreatic secretion in fasting dogs. J Physiol 1983; 341:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/22\">",
"      Taylor IL. Distribution and release of peptide YY in dog measured by specific radioimmunoassay. Gastroenterology 1985; 88:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/23\">",
"      Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/24\">",
"      Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg 2006; 16:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/25\">",
"      Shah U, Kowalski TJ. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders. Vitam Horm 2010; 84:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/26\">",
"      Lin TM, Evans DC, Chance RE, Spray GF. Bovine pancreatic peptide: action on gastric and pancreatic secretion in dogs. Am J Physiol 1977; 232:E311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/27\">",
"      Hazelwood RL. The pancreatic polypeptide (PP-fold) family: gastrointestinal, vascular, and feeding behavioral implications. Proc Soc Exp Biol Med 1993; 202:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/28\">",
"      Adrian TE, Mitchenere P, Sagor G, Bloom SR. Effect of pancreatic polypeptide on gallbladder pressure and hepatic bile secretion. Am J Physiol 1982; 243:G204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/29\">",
"      Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003; 124:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/30\">",
"      Lloyd KC, Grandt D, Aurang K, et al. Inhibitory effect of PYY on vagally stimulated acid secretion is mediated predominantly by Y1 receptors. Am J Physiol 1996; 270:G123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/31\">",
"      Sheikh SP. Neuropeptide Y and peptide YY: major modulators of gastrointestinal blood flow and function. Am J Physiol 1991; 261:G701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/32\">",
"      Wen J, Phillips SF, Sarr MG, et al. PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon. Am J Physiol 1995; 269:G945.",
"     </a>",
"    </li>",
"    <li>",
"     Mannon P, Taylor IL. The Pancreatic Polypeptide Family. In: Gut Peptides, Biochemistry and Physiology, Walsh JH, Dockray JG (Eds), Raven Press Ltd, New York 1994. p.341.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/34\">",
"      Hwa JJ, Witten MB, Williams P, et al. Activation of the NPY Y5 receptor regulates both feeding and energy expenditure. Am J Physiol 1999; 277:R1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/35\">",
"      Pheng LH, Regoli D. Receptors for NPY in peripheral tissues bioassays. Life Sci 2000; 67:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/36\">",
"      Ueno N, Inui A, Iwamoto M, et al. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 1999; 117:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/37\">",
"      Boey D, Lin S, Enriquez RF, et al. PYY transgenic mice are protected against diet-induced and genetic obesity. Neuropeptides 2008; 42:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/38\">",
"      Boey D, Lin S, Karl T, et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2006; 49:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/39\">",
"      Inui A. Neuropeptide Y feeding receptors: are multiple subtypes involved? Trends Pharmacol Sci 1999; 20:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/40\">",
"      Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007; 13:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/41\">",
"      Broom DR, Batterham RL, King JA, Stensel DJ. Influence of resistance and aerobic exercise on hunger, circulating levels of acylated ghrelin, and peptide YY in healthy males. Am J Physiol Regul Integr Comp Physiol 2009; 296:R29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/42\">",
"      Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 1998; 4:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/43\">",
"      Pedrazzini T, Seydoux J, K&uuml;nstner P, et al. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 1998; 4:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/44\">",
"      Naveilhan P, Hassani H, Canals JM, et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med 1999; 5:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/45\">",
"      Nguyen AD, Herzog H, Sainsbury A. Neuropeptide Y and peptide YY: important regulators of energy metabolism. Curr Opin Endocrinol Diabetes Obes 2011; 18:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/46\">",
"      Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001; 50:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/47\">",
"      Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/48\">",
"      Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/49\">",
"      Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2001; 2:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/50\">",
"      Strader AD, Woods SC. Gastrointestinal hormones and food intake. Gastroenterology 2005; 128:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/51\">",
"      Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33766/abstract/52\">",
"      Ahituv N, Kavaslar N, Schackwitz W, et al. A PYY Q62P variant linked to human obesity. Hum Mol Genet 2006; 15:387.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2595 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33766=[""].join("\n");
var outline_f32_62_33766=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22637512\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR FORMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TISSUE DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PEPTIDE RELEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physiological actions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL IMPLICATIONS OF THE PP/PYY/NPY FAMILY OF PEPTIDES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22637512\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2595\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2595|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/54/33647\" title=\"figure 1\">",
"      Protein sequence PP family",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/0/16388\" title=\"figure 2\">",
"      Pseudopod structures in peptide YY cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/19/11571\" title=\"figure 3\">",
"      Ileal brake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2595|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/54/14187\" title=\"table 1\">",
"      PP family receptor subtypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/49/22293?source=related_link\">",
"      Peptide hormone signal transduction and regulation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_62_33767="Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)";
var content_f32_62_33767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33767/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33767/contributors\">",
"     David G McLone, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33767/contributors\">",
"     Robin M Bowman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33767/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33767/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33767/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33767/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33767/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/62/33767/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neural tube defects (NTDs), are the second most common congenital anomaly, and are the cause of chronic disability of between 70,000 and 100,000 individuals in the United States. Myelomeningocele (spina bifida) is the most common neural tube defect.",
"   </p>",
"   <p>",
"    Myelomeningocele is characterized by a cleft in the vertebral column, with a corresponding defect in the skin so that the meninges and spinal cord are exposed. Because the neural tissue is exposed, it is also known as open spinal dysraphism, or spina bifida aperta. By contrast, occult spinal dysraphism is characterized by a cleft in the vertebral column, without a corresponding epithelial defect, and neural tissue is not exposed. There are many different forms of occult spinal dysraphism, ranging from asymptomatic vertebral anomalies to clinically significant defects in the spinal cord and related structures. Occult spinal dysraphism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/27/20921?source=see_link\">",
"     \"Pathogenesis and types of occult spinal dysraphism\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The embryology and pathophysiology of myelomeningocele will be reviewed here. The management of infants with myelomeningocele, prenatal aspects, and prevention of neural tube defects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26344?source=see_link\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35560?source=see_link\">",
"     \"Ultrasound diagnosis of neural tube defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=see_link\">",
"     \"Folic acid for prevention of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY OF THE NEURAL TUBE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary neurulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central nervous system (CNS) initially appears as a plate of thickened ectoderm, called the neural plate, at the beginning of the third week of embryonic life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/1\">",
"     1",
"    </a>",
"    ]. The lateral edges of the neural plate become elevated to form the neural folds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/2\">",
"     2",
"    </a>",
"    ]. These folds subsequently become further elevated, approach each other, and fuse to form the neural tube (",
"    <a class=\"graphic graphic_figure graphicRef72061 \" href=\"mobipreview.htm?35/47/36598\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/3\">",
"     3",
"    </a>",
"    ]. The fusion begins in the cervical region and proceeds in both the cephalad and caudal directions (",
"    <a class=\"graphic graphic_figure graphicRef81711 \" href=\"mobipreview.htm?20/24/20879\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The cranial neuropore closes on the 25th day after conception. Fusion is delayed at the caudal end of the embryo so that the caudal neuropore forms an open communication between the lumen of the neural tube (the neurocele) and the amniotic cavity. Closure of the caudal neuropore normally occurs approximately two days later. This process is called primary neurulation and forms all of the functional central nervous system, which extends to the mid sacral levels of the embryo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myelomeningocele is caused by a failure of primary neurulation, (ie, failure of the spinal neural tube to close normally by 28 days after conception).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;After closure of the anterior neuropore, but prior to closure of the caudal neuropore, the neurocele (the embryonic central canal of the spinal cord) closes throughout its length. This process, termed occlusion, isolates the cranial vesicles, prevents drainage of fluid from the vesicles, and maintains them in a distended state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/5\">",
"     5",
"    </a>",
"    ]. About 48 hours later, after the caudal neuropore has closed, the neurocele reopens without loss of fluid from the cranial vesicles.",
"   </p>",
"   <p>",
"    Maintenance of the distended cerebral vesicles is critical to normal development of the entire brain and cranium. Failure of the neural tube to close prior to reopening of the neurocele allows the cranial vesicles to collapse, and this is a mechanism for the development of the Chiari II malformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The marked reduction in the intracranial volume results in a very small posterior fossa. The fetal cerebellum and brainstem then blossom into this small fossa. This causes the fetal cerebellum and brainstem to extrude inferiorly into the spinal canal and upward into the middle fossa. Surgical closure of the open neural tube during fetal life can diminish the severity of or reverse the Chiari II malformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Chiari II malformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Chiari II malformation (sometimes termed the Arnold-Chiari malformation, a misnomer) is characterized by downward displacement of the cerebellar tonsils and medulla, in association with myelomeningocele. Associated abnormalities of the fornix and other structures in the fetal brain are probably responsible for the abnormalities in cognitive function that are frequently seen in individuals with myelomeningocele. The malformation obstructs the outflow of cerebral spinal fluid (CSF) through the posterior fossa, causing hydrocephalus. Almost all patients with a myelomeningocele have the Chiari II malformation, and most have associated hydrocephalus.",
"   </p>",
"   <p>",
"    These anomalies have important effects on the developing brain, which distinguish the clinical manifestations of myelomeningocele from those of traumatic paraplegia and other anomalies of the caudal spinal cord. They are the major cause of cognitive deficits, attention deficits, poor executive skills, stridor, and apnea displayed by many patients with myelomeningocele, and are also responsible for most of the increased mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26344?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\", section on 'Cognitive development'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional findings that may be associated with Chiari II malformation are: Luckenschadel of the skull (an ossification disorder in which the fetal skull appears fenestrated), abnormal gyri of the cerebral hemispheres, cerebellar dysplasia, colpocephaly of the posterior lateral ventricles, dysgenesis or absence of the corpus callosum, a large massa intermedia and a small third ventricle, aqueductal malformations, beaking of the quadrigeminal plate, absence or reduction of the tentorium, upward herniation of the upper cerebellum into the middle fossa, inferior displacement of the medulla and fourth ventricle into the upper cervical canal, elongation and thinning of the lower pons and the medulla, kinking of medullary spinal cord junction in the cervical canal, inferior displacement of the lower cerebellar vermis and tonsils through the foramen magnum into the upper cervical canal, and markedly reduced volume of the posterior fossa with an enlarged foramen magnum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. All of this is caused by decompression of the embryonic vesicles including the disorganization of the brainstem nuclei. Despite extensive malformations and disorganization, many of these patients have normal intelligence and function well independently.",
"   </p>",
"   <p>",
"    Chiari described three other malformations of the hindbrain, based on morphology. The four are distinct lesions and essentially unrelated to each other. Myelomeningocele is usually associated with Chiari II malformation, but may also occur in association with Chiari IV malformation, which consists of severe cerebellar hypoplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26697?source=see_link\">",
"     \"Chiari malformations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Secondary neurulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary neurulation describes the coalescence of mesenchymal cells to form a neural rod, which then cavitates to form a neural tube. In the human embryo, this process occurs in the caudal cell mass and forms the tip of the conus medullaris and the filum terminale. Because it occurs below the surface ectoderm, abnormalities of secondary neurulation produce lesions that are covered by skin, and are not involved in the pathogenesis of myelomeningocele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of neural tube defects (NTDs) (of which myelomeningocele is the most common) is highly variable and depends upon ethnic, geographic, and nutritional factors. It usually ranges from less than one to seven per 1000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The highest rates are found in China, Ireland, Great Britain, Pakistan, India, and Egypt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/12\">",
"     12",
"    </a>",
"    ]. Within the United States, the rate is approximately 0.2 per 1000 births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/15\">",
"     15",
"    </a>",
"    ]; rates are much higher in the Latino population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/13,15\">",
"     13,15",
"    </a>",
"    ]. They are higher in the East and South compared to the West. Girls are affected more often than boys. For a woman delivered of a child with myelomeningocele, the risk of recurrence in subsequent pregnancies is 2.5 percent (about 20 times the rate in the general population) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevalence estimates for myelomeningocele in pediatric populations in the United States are proportionately lower, averaging 3.1 cases per 10,000 children and adolescents 0 to 19 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/18\">",
"     18",
"    </a>",
"    ]. These estimates also vary by ethnicity, gender, and region. These prevalence estimates are lower than the incidence estimates quoted above, both because they do not include other types of NTDs and because prevalence is reduced by early deaths. &nbsp;",
"   </p>",
"   <p>",
"    Rates of NTDs have declined where prenatal maternal serum screening programs for alpha fetoprotein and periconceptional",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation and food fortification (instituted in the 1990s) are practiced. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=see_link\">",
"     \"Folic acid for prevention of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of myelomeningoceles are isolated malformations of multifactorial origin. NTDs also occur as part of syndromes, in association with chromosomal disorders, or as a result of an environmental exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/19\">",
"     19",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"     Folic acid",
"    </a>",
"    deficiency has been implicated in the development of NTDs (folate sensitive NTDs) and administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    or folic acid antagonists (including",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/11/42167?source=see_link\">",
"     primidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/43/21173?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/1/1045?source=see_link\">",
"     triamterene",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/8/5255?source=see_link\">",
"     trimethoprim",
"    </a>",
"    ) increases the risk. These factors are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=see_link&amp;anchor=H7#H7\">",
"     \"Prenatal screening and diagnosis of neural tube defects\", section on 'Etiology and risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=see_link\">",
"     \"Folic acid for prevention of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PRENATAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis is accomplished by maternal screening of serum alpha fetoprotein (AFP) levels and the diagnosis is established by ultrasonography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Maternal AFP screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal serum alpha fetoprotein screening for NTDs is performed in the second trimester, between 15 and 20 weeks of gestation. AFP screening is primarily intended for the detection of open myelomeningocele and anencephaly, but can also detect several nonneural fetal abnormalities. It does not detect skin covered lesions (spina bifida occulta). When the serum AFP is positive, it is important to repeat the serum AFP because repeat testing will be negative in many cases, and such findings are not associated with an increased frequency of false-negative NTD diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=see_link&amp;anchor=H13#H13\">",
"     \"Prenatal screening and diagnosis of neural tube defects\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ultrasound findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myelomeningocele can be detected before the 12th postmenstrual week by noting irregularities of the bony spine or a bulging within the posterior contour of the fetal back. After the 12th postmenstrual week, sonographic fetal markers for open neural tube defects include the lemon sign and the banana sign. The lemon sign refers to a concave shape of the frontal calvarium. The banana sign describes the posterior convexity of the cerebellum in the presence of spina bifida (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81929 graphicRef64380 \" href=\"mobipreview.htm?31/57/32664\">",
"     image 1A-B",
"    </a>",
"    ). These changes result from the Chiari II malformation (ie, herniation of the cerebellum and brainstem through the foramen magnum). Other suggestive findings include ventriculomegaly, microcephaly, and obliteration of the cisterna magnum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35560?source=see_link\">",
"     \"Ultrasound diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fetal surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal surgery for myelomeningocele can arrest leakage of spinal fluid from the back, and might therefore prevent or reverse the Chiari II malformation and hydrocephalus. The surgery has been performed at a few centers since the late 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Initial non-randomized trials suggested that fetal surgery improves the radiographic appearance of the hindbrain and reduces the incidence of Chiari II malformation; and may also improve lower limb function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In a retrospective series of children who underwent fetal surgery for myelomeningocele, most had good neurodevelopmental outcomes at five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Management of Myelomeningocele (MOMs) trial was designed to determine the safety and efficacy of fetal surgery for myelomeningocele, and was conducted from 2003 to 2010 at three institutions in the United States with extensive experience in fetal surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/25\">",
"     25",
"    </a>",
"    ]. Infants were randomized to fetal surgery at 18 to 25 weeks gestation versus standard repair shortly after birth. Analysis of outcomes for the first 158 participants revealed that fetal surgery reduced the risk of death or need for shunt placement during the first year of life (68 percent among the group that underwent fetal surgery versus 98 percent among those undergoing surgical repair after birth; relative risk 0.7 [95% CI 0.58 to 0.84]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/26\">",
"     26",
"    </a>",
"    ]. Prenatal surgery also resulted in improvement in a composite score for mental development and motor function at 30 months of age. These benefits occurred despite a higher risk of preterm delivery and pulmonary edema among infants undergoing fetal surgery, and of obstetrical complications including placental abruption, dehiscence of the hysterotomy site, and maternal transfusion at delivery. The randomized trial was stopped early because of efficacy; the participants will be followed into childhood to evaluate the effect of prenatal intervention on bowel and bladder function, sexual function, and cognitive development. Because fetal surgery was associated with significant fetal and maternal complications, the American College of Obstetricians and Gynecologists (ACOG) recommends that fetal surgery only be offered at facilities with the special expertise, multidisciplinary teams, and facilities to provide the intensive care required for these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/27\">",
"     27",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     The newborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myelomeningocele is due to failure of closure of the spinal neural tube and leads to malformation of the vertebral column and spinal cord, and ultimately the skull and brain. The diagnosis of myelomeningocele is usually obvious at birth because of the grossly visible lesion (",
"    <a class=\"graphic graphic_picture graphicRef55354 \" href=\"mobipreview.htm?16/49/17168\">",
"     picture 1",
"    </a>",
"    ). In approximately 80 percent of cases, the vertebral defect involves the lumbar and sacral region (including the thoracolumbar or lumbosacral area), which is the last portion of the neural tube to close. However, any segment of the vertebral column may be involved, and the defect typically includes the entire spine distal to the most proximal malformed vertebra.",
"   </p>",
"   <p>",
"    At birth, the neural plate appears as a raw, red, fleshy plaque seen through a defect in the vertebral column (spina bifida) and the skin. A protruding membranous sac containing meninges, CSF, and nerve roots is under the dysplastic spinal cord, which protrudes through the defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anatomy of the lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the anatomy of this lesion is important for surgical repair. The exposed neural tissue may be flat or elevated by a CSF sac below. Rostral to the open lesion, the spinal cord is closed. There may be an associated split cord malformation, in which case the dorsal portion of the spinal cord is only a hemicord, and the other portion of the split cord is ventral to the lesion.",
"   </p>",
"   <p>",
"    At the superior margin of the lesion in the midline is a small opening that is the opening into the central canal of the closed spinal cord. If the sac has not ruptured, CSF from the central canal of the spinal cord can be seen coming out of this opening. Running caudally in the midline is the embryonic ventral sulcus. On either side of the sulcus are the motor plates with the motor nerves exiting from the ventral surface of these plates. The outer lateral tissues are the sensory (alar) plates and the sensory nerves enter at the lateral edge. At the lateral edge, the lesion is attached to dysplastic meninges and skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     NEUROLOGIC ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic deficits in myelomeningocele are usually present at birth, but may progress if complications such as hydrocephalus or tethered cord develop. Careful evaluation and monitoring of the neurologic deficits and identification of their anatomical origins is important to detect and prevent further deterioration of function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26344?source=see_link\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Spinal cord",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic deficits usually depend upon the level of the lesion, and typically affect the trunk, legs, bladder, and bowel. The deficits usually are severe, resulting in complete paralysis and absence of sensation. The bladder and bowel are affected in 97 percent of patients, resulting in urinary and fecal incontinence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15288?source=see_link\">",
"     \"Urinary tract complications of myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some segments of the spinal cord may retain some central connections and have partial function, resulting in voluntary control of isolated movements or the appreciation of sensation in part of the involved limbs. Often, the distal cord may retain some function, but the afferent pathways to the brain are disrupted. In this case, tendon reflexes or withdrawal to pain may be preserved, although voluntary control of movement and appreciation of pain are absent. Isolated reflex segments can be a problem because they often cause spasticity of the bladder and the muscles of the lower extremities. Aberrant connections in the involved spinal cord may result in unusual findings such as contraction of the contralateral limb when tendon reflexes are elicited. Markedly asymmetrical involvement of the lower extremities on physical examination usually indicates a split cord malformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Brainstem",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with myelomeningocele have brainstem dysfunction, due to the Chiari malformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. This causes problems such as swallowing difficulties, vocal cord paresis causing stridor, and apneic episodes. Strabismus and facial weakness can also occur. Most individuals with spina bifida will have an abnormal ventilatory response to respiratory gases. Weakness in the upper extremities and poor tone may also be caused by severe forms of the Chiari malformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ninety percent of newborns with spina bifida will have enlarged ventricles, indicating some degree of hydrocephalus. This is caused by the Chiari II malformation. The risk of developing hydrocephalus requiring shunting is lower among infants with sacral lesions, as compared with those with a higher vertebral level of involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/31\">",
"     31",
"    </a>",
"    ]. Hydrocephalus often leads to multiple hospitalizations for shunt revisions and the complications of this procedure, and is the major cause of mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33767/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Evaluation and management of hydrocephalus is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26344?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\", section on 'Hydrocephalus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/15/13555?source=see_link\">",
"       \"Patient information: Spina bifida (myelomeningocele) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of neural tube defects ranges from less than one to seven per 1000 live births, depending on ethnic, geographic, and nutritional factors. Myelomeningocele (spina bifida) is the most common neural tube defect. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Incidence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myelomeningocele is caused by a failure of primary neurulation, which is a process of folding and fusion of the embryonic neural plate that occurs during the third and fourth week of gestation (",
"      <a class=\"graphic graphic_figure graphicRef72061 \" href=\"mobipreview.htm?35/47/36598\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef81711 \" href=\"mobipreview.htm?20/24/20879\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Primary neurulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal diagnosis of myelomeningocele is accomplished by maternal screening of serum alpha fetoprotein (AFP) levels and the diagnosis is established by ultrasonography. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=see_link\">",
"       \"Prenatal screening and diagnosis of neural tube defects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Chiari II malformation is a pancranial malformation that causes hydrocephalus and hind brain dysfunction. Downward displacement of the cerebellar tonsils and medulla is just one of the abnormalities in this complex malformation. It occurs in almost all patients with myelomeningocele and is responsible for the cognitive difficulties displayed by many. The malformation can also cause brainstem dysfunction, with swallowing difficulties, vocal cord paralysis, and apneic episodes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Chiari II malformation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Brainstem'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with myelomeningocele usually have complete paralysis and absence of sensation affecting the lower extremities and trunk, depending upon the level of the spinal lesion. The bladder and bowel are affected in 97 percent of patients, resulting in urinary and fecal incontinence. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Spinal cord'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some degree of hydrocephalus occurs in most individuals with myelomeningocele. This is caused by the Chiari II malformation and is a major cause of mortality. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Hydrocephalus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/1\">",
"      M&uuml;ller F, O'Rahilly R. The primitive streak, the caudal eminence and related structures in staged human embryos. Cells Tissues Organs 2004; 177:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/2\">",
"      Ybot-Gonzalez P, Copp AJ. Bending of the neural plate during mouse spinal neurulation is independent of actin microfilaments. Dev Dyn 1999; 215:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/3\">",
"      Alvarez IS, Schoenwolf GC. Expansion of surface epithelium provides the major extrinsic force for bending of the neural plate. J Exp Zool 1992; 261:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/4\">",
"      M&uuml;ller F, O'Rahilly R. The development of the human brain, the closure of the caudal neuropore, and the beginning of secondary neurulation at stage 12. Anat Embryol (Berl) 1987; 176:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/5\">",
"      Desmond ME, Jacobson AG. Embryonic brain enlargement requires cerebrospinal fluid pressure. Dev Biol 1977; 57:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/6\">",
"      McLone DG, Dias MS. The Chiari II malformation: cause and impact. Childs Nerv Syst 2003; 19:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/7\">",
"      McLone DG, Knepper PA. The cause of Chiari II malformation: a unified theory. Pediatr Neurosci 1989; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/8\">",
"      Sutton LN, Adzick NS, Bilaniuk LT, et al. Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging following fetal surgery for myelomeningocele. JAMA 1999; 282:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/9\">",
"      Tulipan N, Hernanz-Schulman M, Lowe LH, Bruner JP. Intrauterine myelomeningocele repair reverses preexisting hindbrain herniation. Pediatr Neurosurg 1999; 31:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/10\">",
"      Naidich TP, McLone DG, Fulling KH. The Chiari II malformation: Part IV. The hindbrain deformity. Neuroradiology 1983; 25:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/11\">",
"      ACOG Committee on Practice Bulletins. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 44, July 2003. (Replaces Committee Opinion Number 252, March 2001). Obstet Gynecol 2003; 102:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/12\">",
"      Frey L, Hauser WA. Epidemiology of neural tube defects. Epilepsia 2003; 44 Suppl 3:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/13\">",
"      Canfield MA, Annegers JF, Brender JD, et al. Hispanic origin and neural tube defects in Houston/Harris County, Texas. II. Risk factors. Am J Epidemiol 1996; 143:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/14\">",
"      Harmon JP, Hiett AK, Palmer CG, Golichowski AM. Prenatal ultrasound detection of isolated neural tube defects: is cytogenetic evaluation warranted? Obstet Gynecol 1995; 86:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Racial/ethnic differences in the birth prevalence of spina bifida - United States, 1995-2005. MMWR Morb Mortal Wkly Rep 2009; 57:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/16\">",
"      Cowchock S, Ainbender E, Prescott G, et al. The recurrence risk for neural tube defects in the United States: a collaborative study. Am J Med Genet 1980; 5:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/17\">",
"      Papp C, Ad&aacute;m Z, T&oacute;th-P&aacute;l E, et al. Risk of recurrence of craniospinal anomalies. J Matern Fetal Med 1997; 6:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/18\">",
"      Shin M, Besser LM, Siffel C, et al. Prevalence of spina bifida among children and adolescents in 10 regions in the United States. Pediatrics 2010; 126:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/19\">",
"      Moretti ME, Bar-Oz B, Fried S, Koren G. Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. Epidemiology 2005; 16:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/20\">",
"      Tulipan N, Bruner JP. Myelomeningocele repair in utero: a report of three cases. Pediatr Neurosurg 1998; 28:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/21\">",
"      Adzick NS, Sutton LN, Crombleholme TM, Flake AW. Successful fetal surgery for spina bifida. Lancet 1998; 352:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/22\">",
"      Johnson MP, Sutton LN, Rintoul N, et al. Fetal myelomeningocele repair: short-term clinical outcomes. Am J Obstet Gynecol 2003; 189:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/23\">",
"      Chen CP. Prenatal diagnosis, fetal surgery, recurrence risk and differential diagnosis of neural tube defects. Taiwan J Obstet Gynecol 2008; 47:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/24\">",
"      Danzer E, Gerdes M, Bebbington MW, et al. Preschool neurodevelopmental outcome of children following fetal myelomeningocele closure. Am J Obstet Gynecol 2010; 202:450.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/25\">",
"      Sutton LN. Fetal surgery for neural tube defects. Best Pract Res Clin Obstet Gynaecol 2008; 22:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/26\">",
"      Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med 2011; 364:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/27\">",
"      ACOG Committee opinion no. 550: maternal-fetal surgery for myelomeningocele. Obstet Gynecol 2013; 121:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/28\">",
"      Nagler J, Levy JA, Bachur RG. Stridor in an infant with myelomeningocele. Pediatr Emerg Care 2007; 23:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/29\">",
"      Holinger PC, Holinger LD, Reichert TJ, Holinger PH. Respiratory obstruction and apnea in infants with bilateral abductor vocal cord paralysis, meningomyelocele, hydrocephalus, and Arnold-Chiari malformation. J Pediatr 1978; 92:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/30\">",
"      Tomita T, McLone DG. Acute respiratory arrest. A complication of malformation of the shunt in children with myelomeningocele and Arnold-Chiari malformation. Am J Dis Child 1983; 137:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/31\">",
"      Rintoul NE, Sutton LN, Hubbard AM, et al. A new look at myelomeningoceles: functional level, vertebral level, shunting, and the implications for fetal intervention. Pediatrics 2002; 109:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/32\">",
"      Dias MS, McLone DG. Hydrocephalus in the child with dysraphism. Neurosurg Clin N Am 1993; 4:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33767/abstract/33\">",
"      Rekate, HL. Shunt revision: complications and their prevention. Pediatr Neurosurg 1991-1992; 17:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6170 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33767=[""].join("\n");
var outline_f32_62_33767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMBRYOLOGY OF THE NEURAL TUBE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary neurulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Chiari II malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Secondary neurulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRENATAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Maternal AFP screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ultrasound findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fetal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      The newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anatomy of the lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NEUROLOGIC ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Spinal cord",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Brainstem",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6170\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6170|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/54/32610\" title=\"diagnostic image 1A\">",
"      Lemon sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/9/33940\" title=\"diagnostic image 1B\">",
"      Banana sign",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6170|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/47/36598\" title=\"figure 1\">",
"      Primary neurulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/24/20879\" title=\"figure 2\">",
"      Cephalocaudad neurulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6170|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/49/17168\" title=\"picture 1\">",
"      Meningomyelocele",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26697?source=related_link\">",
"      Chiari malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26344?source=related_link\">",
"      Overview of the management of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/27/20921?source=related_link\">",
"      Pathogenesis and types of occult spinal dysraphism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/15/13555?source=related_link\">",
"      Patient information: Spina bifida (myelomeningocele) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35560?source=related_link\">",
"      Ultrasound diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15288?source=related_link\">",
"      Urinary tract complications of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_62_33768="Overview of blunt abdominal trauma in children";
var content_f32_62_33768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of blunt abdominal trauma in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33768/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33768/contributors\">",
"     Donna Reyes Mendez, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33768/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33768/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33768/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33768/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33768/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/62/33768/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7146376\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 25 percent of prepubertal children with multisystem injury have significant abdominal injury. Motor vehicle crashes, auto-pedestrian injury, and falls are the major causes of blunt abdominal injury in children; bicycle injuries, all-terrain vehicle injuries, and child abuse also contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19497?source=see_link\">",
"     \"Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mortality of blunt abdominal trauma in children is directly related to the number of structures injured: it is less than 20 percent in isolated liver, spleen, kidney, or pancreatic trauma; increases to 20 percent if the gastrointestinal tract is involved; and increases to 50 percent if major vessels are injured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Children are more vulnerable to abdominal injury caused by blunt forces than are adults. Compared with adults, children have relatively compact torsos with smaller anterior-posterior diameters, which provide a smaller area over which the force of injury can be dissipated. In addition, they have relatively larger viscera, less overlying fat, and weaker abdominal musculature. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3477?source=see_link&amp;anchor=H8#H8\">",
"     \"Trauma management: Unique pediatric considerations\", section on 'Abdomen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation and management of children with blunt abdominal trauma will be reviewed here. The assessment and treatment of children with specific injuries to the spleen, liver, pancreas, or gastrointestinal tract are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/13001?source=see_link\">",
"     \"Hollow viscus blunt abdominal trauma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link\">",
"     \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike penetrating trauma, which is usually apparent upon inspection, blunt abdominal trauma must be suspected from historical information, particularly the mechanism of injury, and careful physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Mechanisms of injury that are associated with intraabdominal trauma include isolated high energy blows to the abdomen (eg, fall from a bicycle on to the handlebar), motor vehicle collisions, seat belt usage, and falls from a height greater than 20 feet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/6,9-11\">",
"     6,9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12106?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention of falls in children\", section on 'Falls from height'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial evaluation of pediatric trauma patients should address life-threatening injuries that compromise airway, breathing, and circulation first (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"mobipreview.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). Assessment for abdominal injury should take place as part of the secondary survey. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H33#H33\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Abdomen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with abdominal trauma and hemodynamic instability unresponsive to crystalloid infusion and blood transfusion should undergo immediate emergent laparotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/5\">",
"     5",
"    </a>",
"    ]. The remainder of the evaluation may disclose other indications for laparotomy (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Laparotomy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variably present signs of abdominal injury include ecchymoses (particularly of the umbilical or flank regions); abrasions; tire-tracks; seat-belt marks; abdominal distension, tenderness, rigidity, or masses; pain in the left shoulder induced by palpation of the left upper quadrant (Kehr's sign); or prolonged ileus (greater than four hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A nasogastric or orogastric tube (in patients with maxillofacial trauma) should be placed before abdominal examination in patients with vomiting, abdominal distension, altered mental status, or suspicion for significant abdominal injury. Gastric decompression may facilitate abdominal examination and minimize risk of aspiration of gastric contents if vomiting occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeated, serial examinations are necessary in children with abdominal trauma because life-threatening abdominal injury may not be apparent upon the initial examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/12\">",
"     12",
"    </a>",
"    ]. Severe intraabdominal hemorrhage in children can be masked by their ability to maintain normal systolic blood pressure with large volume blood loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/59/41912?source=see_link&amp;anchor=H3#H3\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Pathophysiology and classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abdominal injury also can be obscured by concurrent extraabdominal injury (eg, head trauma, thoracic trauma, extremity fracture) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, the examination may be unreliable if the patient's neurologic status is impaired due to brain or spinal cord injury or substance use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/14\">",
"     14",
"    </a>",
"    ], and in children younger than one year of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abdominal wall bruising is indicative of potential for significant intraabdominal injury in restrained children who are involved in motor vehicle crashes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/11\">",
"     11",
"    </a>",
"    ]. Among 147,985 children aged 4 to 15 years who were restrained passengers in 102,548 motor vehicle crashes during a child passenger safety project, significant intraabdominal injury was present in 0.2 percent and abdominal bruising in 1.3 percent. Children with abdominal bruises were 232 times more likely to have intraabdominal injury than those without bruising (95% CI, 76-710). In addition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      74 percent of children with significant intraabdominal injury had abdominal wall bruising",
"     </li>",
"     <li>",
"      99 percent of children without abdominal injury had no abdominal wall bruising",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Associated injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tenderness during palpation of the lower ribs may indicate rib fracture. Among 476 hospitalized children and adults with solid abdominal organ injury, lower rib fractures were associated with splenic or hepatic injury in 31 and 15 percent of cases respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with abdominal trauma should have their genitalia and perineum evaluated during the secondary survey. The index of suspicion for rectal, urethral, and vaginal injuries should be heightened in patients with pelvic fractures or straddle injuries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H34#H34\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Perineum'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35669?source=see_link&amp;anchor=H7#H7\">",
"     \"Straddle injuries\", section on 'Vaginal injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Decreased rectal sphincter tone may indicate spinal cord injury. Additional signs of spinal cord injury include priapism, hypotension with relative bradycardia, and decreased strength and sensation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of children with blunt abdominal trauma varies depending upon the severity of trauma. Children with hemodynamic instability due to intraabdominal bleeding that is unresponsive to crystalloid infusion (40 to 60",
"    <span class=\"nowrap\">",
"     ml/kg,",
"    </span>",
"    maximum volume: 3L) and blood transfusion (20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    or approximately half of their blood volume) require immediate laparotomy; preoperative laboratories, especially a complete blood count and blood type and crossmatch, should be obtained in a manner that does not delay operative care. Other laboratory studies may be obtained as well to have baseline measurements including prothrombin time (PT), partial thromboplastin time (PTT), serum electrolytes, glucose, amylase, lipase, transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]). Of note, laparotomy may not be appropriate if the patient&rsquo;s hemodynamic instability is due to pelvic fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Laparotomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hemodynamically stable children in whom intraabdominal injury is suspected on the basis of mechanism of injury or physical examination findings should undergo emergent computed tomography (CT) scanning of the abdomen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/19\">",
"     19",
"    </a>",
"    ] without waiting for laboratory results. Laboratory studies for these patients should include a CBC and a type and crossmatch. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Physical examination'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Radiologic evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the remainder of children (eg, those with mild to moderate blunt abdominal trauma who are hemodynamically stable, awake, alert, and cooperative), laboratory testing can occasionally identify unsuspected injury. The presence of unexplained anemia, gross or microscopic hematuria (&ge;50 red blood cells per high-powered field) or elevation of serum transaminases (ALT &gt;125",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    or AST &gt;200",
"    <span class=\"nowrap\">",
"     U/L)",
"    </span>",
"    may be the only indication of intraabdominal injury in these children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/15,19\">",
"     15,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Complete blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin and hematocrit should be followed serially (every four to six hours until measurement is unchanged) in stable patients with abdominal pain or tenderness after significant blunt trauma because the initial hemoglobin and hematocrit in a patient with acute blood loss can be normal if equilibration of intravascular volume has not yet occurred. An initial hematocrit of less than 30 percent indicates severe blood loss. Hemoglobin and hematocrit should be measured more frequently (eg, every 30 minutes) in hemodynamically unstable patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinalysis is typically performed as a screening test for genitourinary trauma and to assess the need for imaging. Observational studies suggest that computed tomography of the abdomen and pelvis with intravenous contrast is only indicated in children with gross hematuria, microscopic hematuria &ge;50 red blood cells per high-powered field, vertical deceleration injuries (eg, falls),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical signs of renal injury (eg, flank pain or ecchymosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Asymptomatic patients with microscopic hematuria and otherwise normal physical findings have major renal injuries less than 2 percent of the time and may not require imaging. These patients may be followed as an outpatient to ensure that the hematuria clears.",
"   </p>",
"   <p>",
"    Hematuria is variably present in patients with serious renal injury and may be transient. Thus, the first aliquot of urine obtained from the patient should be tested for blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Transaminases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevation of transaminases in hemodynamically stable children with blunt abdominal trauma appears to be a sensitive and specific indicator of intraabdominal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/19,22\">",
"     19,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective observational study of 107 intraabdominal injuries in 1095 children younger than 16 years who presented to an urban Level I trauma center for management of blunt abdominal trauma, elevation of aminotransferases (AST &gt;200",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      [3.33",
"      <span class=\"nowrap\">",
"       &micro;kat/L]",
"      </span>",
"      or ALT &gt;125",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      [2.08",
"      <span class=\"nowrap\">",
"       &micro;kat/L])",
"      </span>",
"      was independently associated with intraabdominal injury identified by radiologic imaging, laparotomy, or autopsy (OR 17.4, 95% CI 9.4-32.1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another retrospective study of 43 hemodynamically stable children who underwent abdominal CT for blunt abdominal trauma, AST &gt;450",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      (7.50",
"      <span class=\"nowrap\">",
"       &micro;kat/L)",
"      </span>",
"      and ALT &gt;250",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      (4.17",
"      <span class=\"nowrap\">",
"       &micro;kat/L)",
"      </span>",
"      were present in 19; 17 of these had hepatic injury identified on abdominal CT scan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/22\">",
"       22",
"      </a>",
"      ]. In contrast, none of the patients with AST &lt;450",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      (7.50",
"      <span class=\"nowrap\">",
"       &micro;kat/L)",
"      </span>",
"      and ALT &lt;250",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      (4.17",
"      <span class=\"nowrap\">",
"       &micro;kat/L)",
"      </span>",
"      had evidence of hepatic injury on CT scan. Beyond these threshold levels, no correlation was found between the serum enzyme level and extent of hepatic injury visible on CT scan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend that clinicians obtain transaminases in patients who have sustained potentially significant abdominal trauma, are hemodynamically stable and have a low clinical likelihood of intraabdominal injury that will require surgical intervention. We recommend that patients with elevated liver enzyme studies (AST &gt;200",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    or ALT &gt;125",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    undergo abdominal and pelvic CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pancreatic enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated serum amylase (&gt;125",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    [2.08",
"    <span class=\"nowrap\">",
"     nkat/L])",
"    </span>",
"    may indicate intraabdominal injury, but is not specific for pancreatic injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Nor is elevated amylase a sensitive indicator of CT- or laparoscopically-proven pancreatic injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/4,24-31\">",
"     4,24-31",
"    </a>",
"    ]. Similarly, lipase is not a sensitive indicator for intraabdominal injury. In one prospective study of 85 consecutive blunt abdominal trauma victims, amylase and lipase were measured serially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/24\">",
"     24",
"    </a>",
"    ]. Although one-half of the patients had elevation of one of these enzymes, only one patient had pancreatic injury documented by clinical course, operation, or autopsy. In another observational study of 83 children with blunt abdominal trauma and evidence of intraabdominal injury on CT, lipase had a positive predictive value of 75 percent. Thus, some authors conclude that amylase is of no value in the clinical management of patients with blunt abdominal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/32\">",
"     32",
"    </a>",
"    ], whereas others continue to recommend its measurement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/4\">",
"     4",
"    </a>",
"    ]. The author usually measures serum amylase and lipase in children with significant blunt abdominal trauma to serve as a baseline measure for comparison if symptoms of abdominal pain persist after initial evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiologic evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain abdominal radiographs are not routinely employed for the diagnosis of intraabdominal injury because they lack sensitivity and specificity relative to abdominal CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/5\">",
"     5",
"    </a>",
"    ]. Pelvic radiographs are indicated in hemodynamically unstable patients or those with clinical findings suggestive of pelvic fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22650?source=see_link&amp;anchor=H21#H21\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Plain radiograph'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Abdominal CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal CT with intravenous contrast is the preferred diagnostic imaging modality to detect intraabdominal injury in hemodynamically stable children who have sustained significant blunt abdominal trauma. CT is sensitive and specific in diagnosing liver, spleen, and retroperitoneal injuries, which may be managed nonoperatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link&amp;anchor=H14482574#H14482574\">",
"     \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\", section on 'Imaging'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    CT with IV contrast alone is less sensitive in detecting injuries of the pancreas, intestinal tract, bladder, and lumbar spine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link&amp;anchor=H14482574#H14482574\">",
"     \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\", section on 'Imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/13001?source=see_link&amp;anchor=H952288#H952288\">",
"     \"Hollow viscus blunt abdominal trauma in children\", section on 'Imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18425?source=see_link&amp;anchor=H14#H14\">",
"     \"Blunt genitourinary trauma\", section on 'CT scanning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential indications for abdominal CT scan (only for use in the hemodynamically stable patient) include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/4,5,7,19,33\">",
"     4,5,7,19,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal tenderness not caused by minor, superficial injury (eg, bruise, abrasion)",
"     </li>",
"     <li>",
"      Seat belt sign (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/13001?source=see_link&amp;anchor=H7836200#H7836200\">",
"       \"Hollow viscus blunt abdominal trauma in children\", section on 'Seat belt syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      History or mechanism of injury suggestive of intraabdominal injury in a patient with distracting injuries",
"     </li>",
"     <li>",
"      Initial serum aspartate aminotransferase (AST) &gt;200",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      or alanine aminotransferase (ALT) &gt;125",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"     </li>",
"     <li>",
"      Gross or microscopic hematuria (&ge;50 red blood cells per high powered field) in otherwise asymptomatic patients",
"     </li>",
"     <li>",
"      Declining or unexplained hematocrit or hematocrit &lt;30 percent",
"     </li>",
"     <li>",
"      Unaccountable fluid or blood requirements",
"     </li>",
"     <li>",
"      Inability to perform adequate abdominal examination or serial abdominal examinations (eg, children younger than two to three years or those with substance use, head injury, altered sensorium, or planned general anesthesia) in a patient with history or mechanism suggestive of intraabdominal injury",
"     </li>",
"     <li>",
"      Positive focused assessment with sonography for trauma (FAST) exam in a stable patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The accuracy of CT imaging may be increased with the use of oral or intravenous contrast. The routine use of oral contrast is controversial; it is rarely of benefit in the diagnosis of acute distal bowel injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], but may be helpful in the diagnosis of duodenal and pancreatic injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. The use of oral contrast media can increase scanning time and cause vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/41\">",
"     41",
"    </a>",
"    ] although low rates of aspiration have been documented in retrospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In addition, oral contrast may inadequately penetrate the small or large bowel. For these reasons, many trauma centers no longer use oral contrast. Compared with pediatric trauma centers that continue to use oral contrast, those that have omitted oral contrast report similar rates of detection of perforation and other abdominal injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abdominal CT is associated with significant radiation exposure, and this imaging risk must be balanced with the likelihood of finding a clinically important intraabdominal injury (IAI). A multicenter, prospective observational study of 12,044 children with blunt torso trauma has derived clinical features that predict a very low risk of IAI requiring intervention (eg, laparotomy, angiographic embolization, blood transfusion, or hospitalization for two nights or longer) consisting of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glasgow coma scale &ge;14",
"     </li>",
"     <li>",
"      No evidence of abdominal wall trauma or seat belt sign",
"     </li>",
"     <li>",
"      No abdominal tenderness",
"     </li>",
"     <li>",
"      No complaints of abdominal pain",
"     </li>",
"     <li>",
"      No vomiting",
"     </li>",
"     <li>",
"      No thoracic wall trauma",
"     </li>",
"     <li>",
"      No decreased breath sounds",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The absolute risk of IAI for the 5,034 children who met all seven of these criteria was 0.1 percent. However, 23 percent of these patients underwent abdominal CT. &nbsp;The six very low risk patients who did have IAI had other features commonly associated with intraabdominal injury (eg, hematuria, elevated liver enzymes, a distracting injury, or ethanol intoxication). Thus, implementation of this rule, if validated, has significant potential to reduce the number of abdominal CTs in children. The authors note that failure to meet the very low risk criteria derived in this study is",
"    <strong>",
"     not",
"    </strong>",
"    necessarily an indication for abdominal CT and that further validation of these criteria are needed before widespread use can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focused assessment with sonography for trauma (FAST) is a rapid ultrasound examination of four abdominal locations: right upper quadrant, left upper quadrant, subxiphoid region, and pelvis. The primary utility of this examination for the unstable trauma patient is the detection of hemopericardium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraperitoneal fluid secondary to intraabdominal injury (IAI). For example, unstable children with blunt abdominal trauma and intraperitoneal fluid on FAST may warrant operative intervention in lieu of computed tomography (CT) of the abdomen. In the stable patient, the presence of intraperitoneal fluid on FAST indicates the need for abdominal CT. However, a negative FAST does not have adequate sensitivity or specificity to exclude intraabdominal injury, especially solid organ injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H24#H24\">",
"     \"Trauma management: Approach to the unstable child\", section on 'FAST (Focused Assessment with Sonography for Trauma)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Peritoneal lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic peritoneal lavage is rarely indicated in children. Diagnostic peritoneal lavage (DPL) may be useful in the evaluation of a hemodynamically unstable child, particularly if he or she requires emergent surgery (eg, craniotomy), and time does not permit abdominal CT scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/5\">",
"     5",
"    </a>",
"    ]. Some surgeons prefer performance of emergent laparotomy to DPL. DPL is considered positive if [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/5,46\">",
"     5,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More than 5 mL of gross blood are obtained",
"     </li>",
"     <li>",
"      Obvious enteric contents (eg, bile, stool) are obtained",
"     </li>",
"     <li>",
"      Extravasation of peritoneal lavage fluid from a chest tube or urinary bladder catheter occurs",
"     </li>",
"     <li>",
"      Lavage fluid contains &gt;100,000 red blood cells or &gt;500 white blood cells per mm3",
"     </li>",
"     <li>",
"      The amylase concentration of peritoneal lavage effluent is elevated (&gt;175",
"      <span class=\"nowrap\">",
"       IU/L)",
"      </span>",
"      [2.92",
"      <span class=\"nowrap\">",
"       nkat/L]",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abdominal CT is performed instead of DPL in the hemodynamically stable child because DPL is less injury- and organ-specific, cannot detect retroperitoneal injury, and has potential risks, including the introduction of air or fluid into the abdomen, peritoneal irritation, and false positive results that may lead to exploratory surgery when clinical observation would be the more appropriate treatment as children with intraperitoneal blood rarely need laparotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/46\">",
"     46",
"    </a>",
"    ]. Relative contraindications to DPL include pregnancy or previous abdominal surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     STABILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of children with suspected intraabdominal injury should adhere to the Advanced Trauma Life Support guidelines for diagnosis and treatment of immediately life-threatening injuries and appropriate resuscitation (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"mobipreview.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). After the patient has been assessed, resuscitated, and stabilized the patient should receive ongoing care directed by a trauma surgeon with pediatric expertise, when available. Because optimal care and outcomes occur when the critically injured child is initially resuscitated and subsequently managed in a pediatric trauma center (PTC), it is preferable to provide initial care in such facilities from the outset, whenever possible, or to arrange transfer to a PTC for ongoing management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H44#H44\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Definitive care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for immediate laparotomy include supporting evidence of significant intraabdominal injury (based upon history, physical examination, computed tomography, DPL, or ultrasound) and [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Perforation from a hollow viscus injury demonstrated as pneumoperitoneum",
"     </li>",
"     <li>",
"      Intraabdominal bleeding of more than &frac12; the patient&rsquo;s blood volume demonstrated as persistent or recurring hemodynamic instability, despite crystalloid infusion and blood transfusion, especially when accompanied by abdominal distension. Of note, hemodynamic instability caused by a pelvic fracture frequently warrants treatment other than laparotomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative indications for laparotomy include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/1,47\">",
"     1,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing abdominal tenderness or peritoneal irritation",
"     </li>",
"     <li>",
"      Transfusion requirement of greater than 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of packed red blood cells for intraabdominal bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other indications for laparotomy vary according to the specific injury:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diagnosis of hollow visceral injury (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/13001?source=see_link&amp;anchor=H10391032#H10391032\">",
"       \"Hollow viscus blunt abdominal trauma in children\", section on 'Operative management'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Solid organ injury with evidence of continued bleeding (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link&amp;anchor=H14482595#H14482595\">",
"       \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\", section on 'Damage control surgery'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link&amp;anchor=H14482602#H14482602\">",
"       \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\", section on 'Spleen'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18425?source=see_link&amp;anchor=H21#H21\">",
"       \"Blunt genitourinary trauma\", section on 'Definitive management'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pancreatic injury with major parenchymal or ductal disruption (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link&amp;anchor=H14482609#H14482609\">",
"       \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\", section on 'Pancreas'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20953329\">",
"    <span class=\"h2\">",
"     Nonoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful observation without operative intervention for hemodynamically stable children with solid organ injuries from blunt abdominal trauma, in a facility with operative capability and surgical expertise, is a standard practice that is safe and improves patient outcome and resource utilization. In addition, preservation of the spleen in children with splenic injuries avoids the infectious risks associated with splenectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link&amp;anchor=H641878#H641878\">",
"     \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\", section on 'Nonoperative management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characteristics of injuries that ultimately required surgery were reported in a retrospective series from seven level I pediatric trauma centers describing 1818 children with solid organ injury initially managed nonoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/48\">",
"     48",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery was subsequently required for 89 (5 percent) patients with the following injuries: kidney (3 percent), liver (3 percent), spleen (4 percent), and pancreas (18 percent).",
"     </li>",
"     <li>",
"      The reasons for failure of nonoperative management included the following: shock (33 percent), peritonitis (27 percent), persistent hemorrhage (16 percent), hollow viscus injury-related (15 percent), isolated pancreatic injury (8 percent), and ruptured diaphragm (1 percent).",
"     </li>",
"     <li>",
"      Failure of nonoperative management was significantly associated with injury severity, pancreatic injury, and multiple organ system involvement.",
"     </li>",
"     <li>",
"      Need for operative intervention was determined within 12 hours of the injury for 76 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the proven advantages of nonoperative management for solid organ injuries from blunt abdominal trauma, observational studies document that children cared for in general hospitals are significantly more likely to undergo splenectomy than those cared for in children&rsquo;s hospitals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33768/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    We suggest developing strategies to increase compliance with guidelines for the nonoperative management of solid organ injury in children that target physicians and other clinicians in general hospitals, where the majority of injured children receive care.",
"   </p>",
"   <p>",
"    In addition, while preferable, although not always practical, to provide initial care for children with blunt abdominal trauma in pediatric trauma centers (PTC), when this option is not available, consultation with and transfer to a PTC for ongoing management is strongly encouraged. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H44#H44\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Definitive care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SPECIFIC INJURIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20951374\">",
"    <span class=\"h2\">",
"     Liver, spleen, or pancreas injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and management of children with liver, spleen, or pancreas injury after blunt trauma is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link\">",
"     \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     GI tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and management of hollow viscus injuries in children who sustain blunt trauma is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/13001?source=see_link\">",
"     \"Hollow viscus blunt abdominal trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanisms of injury that are associated with intraabdominal trauma include isolated high energy blows to the abdomen (eg, fall from a bicycle on to the handlebar), motor vehicle collisions, seat belt usage, and falls from a height greater than 20 feet.",
"     </li>",
"     <li>",
"      Variably present signs of abdominal injury include ecchymoses (particularly of the umbilical or flank regions); abrasions; tire-tracks; seat-belt marks; abdominal distension, tenderness, rigidity, or masses; pain in the left shoulder induced by palpation of the left upper quadrant (Kehr's sign); or prolonged ileus (greater than four hours). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs of abdominal injury are variable and may evolve over time necessitating repeated serial examinations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Abdomen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory evaluation of children with blunt abdominal trauma varies depending upon the severity of trauma. The most useful tests include a hematocrit, urinalysis, and serum liver transaminases (AST and ALT). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In hemodynamically unstable children, hemoglobin and hematocrit should be followed serially since the initial hemoglobin and hematocrit in a patient with acute blood loss can be normal if equilibration of intravascular volume has not yet occurred. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complete blood count'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that clinicians obtain transaminases in patients who have sustained potentially significant abdominal trauma, are hemodynamically stable and have a low clinical likelihood of intraabdominal injury that will require surgical intervention. We recommend that patients with elevated liver enzyme studies (AST &gt;200",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      or ALT &gt;125",
"      <span class=\"nowrap\">",
"       IU/L)",
"      </span>",
"      undergo computed tomography (CT) of the abdomen and pelvis. Gross hematuria is also an indication for CT. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Transaminases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Urinalysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasonography is useful, when available, for the rapid, early evaluation of hemodynamically unstable children with potential blunt abdominal trauma. Because ultrasonography lacks adequate sensitivity, Abdominal and pelvic CT scan with intravenous contrast is usually performed in all hemodynamically stable patients with clinical findings suggestive of intraabdominal injury regardless of ultrasound results. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Ultrasonography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Abdominal CT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for abdominal and pelvic CT in children with serious blunt abdominal trauma are provided. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Abdominal CT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The general approach to the child with blunt abdominal trauma is the same as for any seriously injured child and is outlined in the table (",
"      <a class=\"graphic graphic_figure graphicRef64241 \" href=\"mobipreview.htm?42/51/43834\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Stabilization'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link\">",
"       \"Trauma management: Approach to the unstable child\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemodynamically stable children with blunt abdominal trauma are usually managed nonoperatively. (See",
"      <a class=\"local\" href=\"#H20953329\">",
"       'Nonoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemodynamically unstable children not responsive to intravenous crystalloid and blood transfusions warrant emergent laparotomy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Laparotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management strategies also vary depending on the type of organ injury. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/13001?source=see_link\">",
"       \"Hollow viscus blunt abdominal trauma in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=see_link\">",
"       \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/1\">",
"      Schafermeyer R. Pediatric trauma. Emerg Med Clin North Am 1993; 11:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/2\">",
"      Cooper A, Barlow B, DiScala C, String D. Mortality and truncal injury: the pediatric perspective. J Pediatr Surg 1994; 29:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/3\">",
"      Wright MS. Update on pediatric trauma care. Curr Opin Pediatr 1995; 7:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/4\">",
"      Rothrock SG, Green SM, Morgan R. Abdominal trauma in infants and children: prompt identification and early management of serious and life-threatening injuries. Part I: injury patterns and initial assessment. Pediatr Emerg Care 2000; 16:106.",
"     </a>",
"    </li>",
"    <li>",
"     Saladino RA, Lund DP. Abdominal trauma. In: Textbook of Pediatric Emergency Medicine, 6th, Fleisher GR, Ludwig S (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. p.1271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/6\">",
"      Taylor GA, Eichelberger MR, O'Donnell R, Bowman L. Indications for computed tomography in children with blunt abdominal trauma. Ann Surg 1991; 213:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/7\">",
"      Holmes JF, Sokolove PE, Land C, Kuppermann N. Identification of intra-abdominal injuries in children hospitalized following blunt torso trauma. Acad Emerg Med 1999; 6:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/8\">",
"      Moss RL, Musemeche CA. Clinical judgment is superior to diagnostic tests in the management of pediatric small bowel injury. J Pediatr Surg 1996; 31:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/9\">",
"      McLellan BA, Rizoli SB, Brenneman FD, et al. Injury pattern and severity in lateral motor vehicle collisions: a Canadian experience. J Trauma 1996; 41:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/10\">",
"      Holland AJ, Cass DT, Glasson MJ, Pitkin J. Small bowel injuries in children. J Paediatr Child Health 2000; 36:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/11\">",
"      Lutz N, Nance ML, Kallan MJ, et al. Incidence and clinical significance of abdominal wall bruising in restrained children involved in motor vehicle crashes. J Pediatr Surg 2004; 39:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/12\">",
"      Saladino R, Lund D, Fleisher G. The spectrum of liver and spleen injuries in children: failure of the pediatric trauma score and clinical signs to predict isolated injuries. Ann Emerg Med 1991; 20:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/13\">",
"      Ferrera PC, Verdile VP, Bartfield JM, et al. Injuries distracting from intraabdominal injuries after blunt trauma. Am J Emerg Med 1998; 16:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/14\">",
"      Boulanger BR, McLellan BA. Blunt abdominal trauma. Emerg Med Clin North Am 1996; 14:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/15\">",
"      Isaacman DJ, Scarfone RJ, Kost SI, et al. Utility of routine laboratory testing for detecting intra-abdominal injury in the pediatric trauma patient. Pediatrics 1993; 92:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/16\">",
"      Shweiki E, Klena J, Wood GC, Indeck M. Assessing the true risk of abdominal solid organ injury in hospitalized rib fracture patients. J Trauma 2001; 50:684.",
"     </a>",
"    </li>",
"    <li>",
"     Greenes DS. Neurotrauma. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S (Eds) (Eds), Lippincott, Williams, and Wilkins, Philadelphia 2010. p.1422.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/18\">",
"      DuBose J, Inaba K, Barmparas G, et al. Bilateral internal iliac artery ligation as a damage control approach in massive retroperitoneal bleeding after pelvic fracture. J Trauma 2010; 69:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/19\">",
"      Holmes JF, Sokolove PE, Brant WE, et al. Identification of children with intra-abdominal injuries after blunt trauma. Ann Emerg Med 2002; 39:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/20\">",
"      Santucci RA, Wessells H, Bartsch G, et al. Evaluation and management of renal injuries: consensus statement of the renal trauma subcommittee. BJU Int 2004; 93:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/21\">",
"      Santucci RA, Langenburg SE, Zachareas MJ. Traumatic hematuria in children can be evaluated as in adults. J Urol 2004; 171:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/22\">",
"      Hennes HM, Smith DS, Schneider K, et al. Elevated liver transaminase levels in children with blunt abdominal trauma: a predictor of liver injury. Pediatrics 1990; 86:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/23\">",
"      Moretz JA 3rd, Campbell DP, Parker DE, Williams GR. Significance of serum amylase level in evaluating pancreatic trauma. Am J Surg 1975; 130:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/24\">",
"      Buechter KJ, Arnold M, Steele B, et al. The use of serum amylase and lipase in evaluating and managing blunt abdominal trauma. Am Surg 1990; 56:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/25\">",
"      Adamson WT, Hebra A, Thomas PB, et al. Serum amylase and lipase alone are not cost-effective screening methods for pediatric pancreatic trauma. J Pediatr Surg 2003; 38:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/26\">",
"      Sivit CJ, Eichelberger MR, Taylor GA, et al. Blunt pancreatic trauma in children: CT diagnosis. AJR Am J Roentgenol 1992; 158:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/27\">",
"      Boulanger BR, Milzman DP, Rosati C, Rodriguez A. The clinical significance of acute hyperamylasemia after blunt trauma. Can J Surg 1993; 36:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/28\">",
"      Akhrass R, Kim K, Brandt C. Computed tomography: an unreliable indicator of pancreatic trauma. Am Surg 1996; 62:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/29\">",
"      Gorenstein A, O'Halpin D, Wesson DE, et al. Blunt injury to the pancreas in children: selective management based on ultrasound. J Pediatr Surg 1987; 22:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/30\">",
"      Smith SD, Nakayama DK, Gantt N, et al. Pancreatic injuries in childhood due to blunt trauma. J Pediatr Surg 1988; 23:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/31\">",
"      Shilyansky J, Sena LM, Kreller M, et al. Nonoperative management of pancreatic injuries in children. J Pediatr Surg 1998; 33:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/32\">",
"      Mure AJ, Josloff R, Rothberg J, et al. Serum amylase determination and blunt abdominal trauma. Am Surg 1991; 57:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/33\">",
"      Sokolove PE, Kuppermann N, Holmes JF. Association between the \"seat belt sign\" and intra-abdominal injury in children with blunt torso trauma. Acad Emerg Med 2005; 12:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/34\">",
"      Timaran CH, Daley BJ, Enderson BL. Role of duodenography in the diagnosis of blunt duodenal injuries. J Trauma 2001; 51:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/35\">",
"      Shankar KR, Lloyd DA, Kitteringham L, Carty HM. Oral contrast with computed tomography in the evaluation of blunt abdominal trauma in children. Br J Surg 1999; 86:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/36\">",
"      Mahmoud M, McAuliffe J, Donnelly LF. Administration of enteric contrast material before abdominal CT in children: current practices and controversies. Pediatr Radiol 2011; 41:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/37\">",
"      Strouse PJ, Close BJ, Marshall KW, Cywes R. CT of bowel and mesenteric trauma in children. Radiographics 1999; 19:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/38\">",
"      Nastanski F, Cohen A, Lush SP, et al. The role of oral contrast administration immediately prior to the computed tomographic evaluation of the blunt trauma victim. Injury 2001; 32:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/39\">",
"      Arkovitz MS, Johnson N, Garcia VF. Pancreatic trauma in children: mechanisms of injury. J Trauma 1997; 42:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/40\">",
"      Kunin JR, Korobkin M, Ellis JH, et al. Duodenal injuries caused by blunt abdominal trauma: value of CT in differentiating perforation from hematoma. AJR Am J Roentgenol 1993; 160:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/41\">",
"      Tsang BD, Panacek EA, Brant WE, Wisner DH. Effect of oral contrast administration for abdominal computed tomography in the evaluation of acute blunt trauma. Ann Emerg Med 1997; 30:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/42\">",
"      Lim-Dunham JE, Narra J, Benya EC, Donaldson JS. Aspiration after administration of oral contrast material in children undergoing abdominal CT for trauma. AJR Am J Roentgenol 1997; 169:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/43\">",
"      Federle MP, Peitzman A, Krugh J. Use of oral contrast material in abdominal trauma CT scans: is it dangerous? J Trauma 1995; 38:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/44\">",
"      Haftel AJ, Lev R, Mahour GH, et al. Abdominal CT scanning in pediatric blunt trauma. Ann Emerg Med 1988; 17:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/45\">",
"      Holmes JF, Lillis K, Monroe D, et al. Identifying Children at Very Low Risk of Clinically Important Blunt Abdominal Injuries. Ann Emerg Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     Pediatric Trauma. In: Advanced Trauma Life Support for Doctors: Student Course Manual, 8th edition, American College of Surgeons Committee on Trauma (Ed), American College of Surgeons, Chicago, Illinois 2008. p.225.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/47\">",
"      Jaffe D, Wesson D. Emergency management of blunt trauma in children. N Engl J Med 1991; 324:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/48\">",
"      Holmes JH 4th, Wiebe DJ, Tataria M, et al. The failure of nonoperative management in pediatric solid organ injury: a multi-institutional experience. J Trauma 2005; 59:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/49\">",
"      Bowman SM, Zimmerman FJ, Christakis DA, et al. Hospital characteristics associated with the management of pediatric splenic injuries. JAMA 2005; 294:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/50\">",
"      Mooney DP, Rothstein DH, Forbes PW. Variation in the management of pediatric splenic injuries in the United States. J Trauma 2006; 61:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/51\">",
"      Bowman SM, Zimmerman FJ, Christakis DA, Sharar SR. The role of hospital profit status in pediatric spleen injury management. Med Care 2008; 46:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33768/abstract/52\">",
"      McDonald LA, Yanchar NL. Management of pediatric splenic injuries in Canada. J Pediatr Surg 2012; 47:473.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6553 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33768=[""].join("\n");
var outline_f32_62_33768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7146376\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Abdomen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Associated injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Complete blood count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Transaminases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pancreatic enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Abdominal CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Peritoneal lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      STABILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Laparotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20953329\">",
"      Nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SPECIFIC INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20951374\">",
"      Liver, spleen, or pancreas injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      GI tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6553\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6553|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/51/43834\" title=\"figure 1\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18425?source=related_link\">",
"      Blunt genitourinary trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19497?source=related_link\">",
"      Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/13001?source=related_link\">",
"      Hollow viscus blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4777?source=related_link\">",
"      Liver, spleen, and pancreas injury in children with blunt abdominal trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22650?source=related_link\">",
"      Pelvic trauma: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12106?source=related_link\">",
"      Prevention of falls in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35669?source=related_link\">",
"      Straddle injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3477?source=related_link\">",
"      Trauma management: Unique pediatric considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_62_33769="Epilepsy syndromes in children";
var content_f32_62_33769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epilepsy syndromes in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33769/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33769/contributors\">",
"     Angus Wilfong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33769/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33769/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33769/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/62/33769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Classification of Epileptic Seizures is used by most epileptologists to classify seizure types (",
"    <a class=\"graphic graphic_table graphicRef53661 \" href=\"mobipreview.htm?0/60/973\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21912?source=see_link\">",
"     \"Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the clinician caring for an individual with seizures, particularly if they are chronic, should no longer be satisfied with the diagnosis \"seizure disorder\" or \"grand mal seizures\" but should attempt to determine if the child fits one of the childhood epilepsy syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The syndrome classification provides invaluable prognostic, therapeutic, and, in the case of familial epilepsies, genetic information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The syndrome classification has proved to be invaluable in clinical situations in which a more detailed profile of the epileptic patient is desired. Genetic studies of families with inherited epilepsies are facilitated when recognition of the epileptic syndrome allows easier identification of the phenotype. As an example, the location of the involved chromosomal and gene product associated with the dominantly inherited syndrome of nocturnal frontal lobe epilepsy (ADNFLE) was found in studies of families in which involved individuals were recognized on the basis of the typical phenotype: complex partial seizures often resembling parasomnias (eg, night terrors), relatively exclusive nocturnal occurrence, characteristic electroencephalogram (EEG) findings, normal development, and neurologic examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the last few years, trials of new antiepileptic drugs (AEDs) have included individuals with epileptic syndromes rather than participants selected solely on the basis of the seizure type. A study of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/60/21448?source=see_link\">",
"     topiramate",
"    </a>",
"    , for example, used a large cohort of children with the Lennox-Gastaut syndrome, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/34/3626?source=see_link\">",
"     lamotrigine",
"    </a>",
"    was studied in children and adolescents with juvenile myoclonic epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The populations are, therefore, more homogeneous and in the future will allow the clinician to tailor the AED to the groups of children with the type of seizures most likely to respond to a particular drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISTRIBUTION OF EPILEPSY SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective study with at least two-years follow-up (mean 9 years) of 182 children with two or more seizures, who were seen in one of several large university-based urban hospitals, classified epilepsy syndromes according to the International League Against Epilepsy (ILAE) guidelines and reported the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The etiology of the syndrome was idiopathic in 25 percent, cryptogenic in 49 percent, and of remote symptomatic origin in 26 percent.",
"     </li>",
"     <li>",
"      In the initial classification, 114 (63 percent) children had a localization-based (partial) epilepsy syndrome including idiopathic in 26 (24 of which had benign rolandic epilepsy of childhood), cryptogenic in 34, and symptomatic in 54 (primarily temporal lobe in origin). Twenty-one (12 percent) children had a generalized epilepsy syndrome, including 19 with primary generalized epilepsy (majority generalized tonic-clonic). Forty-seven (26 percent) were classified as \"undetermined if focal or generalized\". At the time of last follow-up, the syndrome classification had changed in 18 percent of cases.",
"     </li>",
"     <li>",
"      At the time of last follow-up, 144 (79 percent) of the children were in two-year terminal remission and 108 (59 percent) were in remission and not taking medications. Favorable prognosis was associated with the idiopathic and cryptogenic categories and benign rolandic epilepsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SEIZURE SYNDROMES WITH ONSET IN THE FIRST YEAR OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous epilepsy syndromes characteristically have their onset in the first year of life (",
"    <a class=\"graphic graphic_table graphicRef70499 \" href=\"mobipreview.htm?12/17/12571\">",
"     table 2",
"    </a>",
"    ). Several of these disorders are discussed in separate sections and are not covered here (infantile massive spasms, febrile convulsions and neonatal seizures). Most of these syndromes are extremely rare.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign familial infantile convulsions are an autosomal dominant epilepsy syndrome characterized by afebrile seizures in an otherwise normal infant beginning at about six months of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/9\">",
"       9",
"      </a>",
"      ]. Seizures typically abate by two years of age, and psychomotor development is normal. In some patients and families, paroxysmal kinesigenic dyskinesia develops in adolescence or adulthood; the majority of these are found to have mutations in the proline-rich transmembrane protein 2 (",
"      <em>",
"       PRRT2)",
"      </em>",
"      gene on chromosome 16p [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. The phenotypic spectrum of",
"      <em>",
"       PRRT2",
"      </em>",
"      mutations includes what has been called infantile convulsions and paroxysmal choreoathetosis (ICCA) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/13\">",
"       13",
"      </a>",
"      ], fever-related infantile seizures, hemiplegic migraine, and episodic ataxia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/12,14-18\">",
"       12,14-18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/60/17354?source=see_link&amp;anchor=H166228438#H166228438\">",
"       \"Hemiplegic migraine\", section on 'Additional types'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Mutations in the sodium channel subunit gene",
"      <em>",
"       SCN2A",
"      </em>",
"      on chromosome 19q have also been identified in some families with benign familial infantile convulsions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/19-23\">",
"       19-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The familial neonatal seizure syndromes have been linked to chromosomes 20q and 8q. Mutations in two novel voltage-gated potassium channel genes,",
"      <em>",
"       KCNQ2",
"      </em>",
"      and",
"      <em>",
"       KCNQ3",
"      </em>",
"      , have been identified. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=see_link&amp;anchor=H9#H9\">",
"       \"Neonatal epileptic syndromes\", section on 'Benign familial neonatal convulsions'",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      A group of genetic epilepsy syndromes, referred to as \"generalized epilepsy with febrile seizures plus\" (GEFS+), are characterized by multiple febrile seizures, generalized tonic-clonic seizures, and other seizure types including absences and myoclonic seizures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3226?source=see_link&amp;anchor=H6#H6\">",
"       \"Febrile seizures\", section on 'Genetic susceptibility'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NEONATAL SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ohtahara syndrome or early infantile epileptic encephalopathy is a rare epileptic encephalopathy that usually has an onset in the first month of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/24\">",
"     24",
"    </a>",
"    ]. It is characterized by frequent tonic seizures and severe developmental delay with an abnormal neurologic examination. The profoundly abnormal electroencephalogram (EEG) is important in the diagnosis of this syndrome, showing a suppression-burst pattern awake and asleep. Most cases are associated with a congenital structural brain abnormality. The prognosis is poor, and many infants ultimately develop other seizure types, including infantile spasms.",
"   </p>",
"   <p>",
"    Ohtahara syndrome may be confused with a similar syndrome that is usually caused by a neurometabolic disorder (eg, nonketotic hyperglycinemia) and is called early myoclonic encephalopathy (EME). EME is a progressive disorder, associated with prominent myoclonic seizures (which are infrequent in Ohtahara Syndrome). The EEG in EME also shows a suppression-burst pattern.",
"   </p>",
"   <p>",
"    These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=see_link&amp;anchor=H14#H14\">",
"     \"Neonatal epileptic syndromes\", section on 'Early myoclonic encephalopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=see_link&amp;anchor=H18#H18\">",
"     \"Neonatal epileptic syndromes\", section on 'Early infantile epileptic encephalopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MYOCLONIC EPILEPSY OF INFANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonic seizures may begin in the first year of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/25\">",
"     25",
"    </a>",
"    ]. Myoclonus is a brief synchronous jerk of one or more limbs with and without involvement of the bulbar musculature. Jerks may be focal, multifocal, or generalized, and are more likely to be flexor than extensor. They can also be negative, with inhibition of muscular activity. Myoclonus is termed epileptic when it occurs with a cortical epileptiform discharge, usually a generalized spike and wave discharge or",
"    <span class=\"nowrap\">",
"     spikes/sharp",
"    </span>",
"    waves over the motor cortex (the latter may have to be identified by special computer averaging techniques). Epileptic myoclonus must be distinguished from other epileptic and non-epileptic conditions, including infantile spasms, tonic seizures, normal physiologic sleep myoclonus (hypnic jerks), and benign startle responses, among others.",
"   </p>",
"   <p>",
"    Myoclonic seizures in infants can be accompanied by other seizure types, including partial and generalized convulsive seizures. These epileptic syndromes have been divided into a benign and severe form based upon the course, with the latter manifesting psychomotor retardation, severe speech delay, and often ataxia. Some discussion has occurred in the neurologic literature questioning the justification of subdividing the myoclonic epilepsies into individual syndromes rather than considering them as a spectrum from benign to very severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Severe myoclonic epilepsy of infancy (Dravet syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A severe form of myoclonic epilepsy of infancy (Dravet syndrome) is often associated with intractable epilepsy and poor psychomotor developmental outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. A mortality risk in early life as high as 10 percent has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Point mutations in SCN1A, the gene that encodes the alpha subunit of the voltage-gated sodium channel, as well as chromosomal deletions and balanced translocations, have been identified in approximately 70 to 80 percent of patients with this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/27,33-48\">",
"     27,33-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients typically present in the first year of life with prolonged, often febrile, generalized clonic or hemiclonic seizures in the setting of normal cognitive and motor development prior to seizure onset. Episodes of status epilepticus are common, representing the initial event in up to 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/29,33\">",
"     29,33",
"    </a>",
"    ]. Other seizure types, including myoclonic, focal, and atypical absence, develop between the ages of one and four. In a series of 241 cases of SCN1A mutation-positive Dravet syndrome, the median age of seizure onset was six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/33\">",
"     33",
"    </a>",
"    ]. The most common seizure precipitant was",
"    <span class=\"nowrap\">",
"     fever/illness",
"    </span>",
"    (58 percent), followed by vaccination within the preceding 48 hours (7 percent), and bath (2 percent); in one-third of patients, no precipitant could be identified.",
"   </p>",
"   <p>",
"    An atypical and rare presentation seen in some children with Dravet syndrome is an acute encephalopathy characterized by status epilepticus followed by deep coma, often preceded by a viral illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Magnetic resonance imaging in these patients reveals diffuse signal abnormalities that may predominate in either the cortex or deep gray matter. In one series of 15 patients with this complication, 4 died and 9 survivors had severe sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/49\">",
"     49",
"    </a>",
"    ]. Other studies have also reported an increased mortality risk of 5 to 10 percent by the age of five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EEG becomes increasingly abnormal with age. In a case series of 37 patients, the first EEG was normal in all 37 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/29\">",
"     29",
"    </a>",
"    ]. By three years of age, interictal EEG is abnormal in 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/33\">",
"     33",
"    </a>",
"    ]. Abnormalities are variable and include focal, multifocal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    generalized epileptiform activity and changes in background activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatments for Dravet syndrome that have shown some efficacy in small, open-label trials include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/60/21448?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/0/25608?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/4/32839?source=see_link\">",
"     clobazam",
"    </a>",
"    , stiripentol (not available in the U.S.) and the ketogenic diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/54-59\">",
"     54-59",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/34/3626?source=see_link\">",
"     lamotrigine",
"    </a>",
"    have been associated with worsened seizure frequency in patients with Dravet syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/33,60-62\">",
"     33,60-62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=see_link&amp;anchor=H186115#H186115\">",
"     \"The ketogenic diet\", section on 'Specific conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment efficacy is limited, and seizures are usually refractory to standard antiepileptic drugs; developmental delay and persistent gait ataxia and cognitive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behavioral impairment occur in the majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/29,33,34,63\">",
"     29,33,34,63",
"    </a>",
"    ]. In one series, only 6 of 152 patients assessed at age three and older had normal developmental outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/33\">",
"     33",
"    </a>",
"    ]. Predictors of more severe developmental disability include early and severe interictal EEG abnormalities, young age at onset of myoclonic seizures, and young age at onset of developmental delay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While multiple studies have reported an association between vaccination and seizures in Dravet syndrome, both at diagnosis and as a trigger for subsequent seizures, we do not usually recommend altering patients&rsquo; vaccination schedule. A retrospective study that examined seizure onset and vaccination in 95 patients with Dravet syndrome found that 25 patients had their first seizure within two days after vaccination and that this vaccination-proximate group had an earlier age of seizure onset compared to the vaccination-distant group (18.4 versus 26.2 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/64\">",
"     64",
"    </a>",
"    ]. However, there were no differences in clinical outcomes between the two groups, suggesting that vaccination should not be withheld from children with SCN1A mutations. Subsequent studies have also observed earlier seizure-onset in patients with vaccine-associated seizure but no difference in developmental outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/33,65\">",
"     33,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of cases of Dravet syndrome involve de novo mutations, but germ line mutations have also been observed. Genetic testing for SCN1A is available and can be done prenatally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/66\">",
"     66",
"    </a>",
"    ]. One study suggested that confirmatory genetic testing in patients with suspected Dravet syndrome, particularly those patients less than two years of age in whom a clinical diagnosis can be difficult, was associated with a decrease in unnecessary testing, improved access to therapies and supportive care services for families, and increased family satisfaction with care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/67\">",
"     67",
"    </a>",
"    ]. Further information is available at",
"    <a class=\"external\" href=\"file://www.genetests.org\">",
"     file://www.genetests.org",
"    </a>",
"    . Counselling for genetic testing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ABSENCE SEIZURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absence seizures (also called petit mal or generalized nonconvulsive seizures) are a common pediatric epileptic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/68\">",
"     68",
"    </a>",
"    ]. The seizures consist of multiple brief staring episodes with behavioral arrest that may recur hundreds of times daily. They are associated with generalized 3-hertz spike and slow wave discharges on electroencephalogram (EEG).",
"   </p>",
"   <p>",
"    Several epileptic syndromes with markedly different clinical courses and prognoses have absence seizures as the only or most predominant seizure type. The age of onset and clinical phenotypes of the absence syndromes are quite variable and often help to define the particular syndrome (",
"    <a class=\"graphic graphic_figure graphicRef64284 \" href=\"mobipreview.htm?5/59/6078\">",
"     figure 1",
"    </a>",
"    ). The clinical expression of absence seizures themselves may differ from one syndrome to the other; as an example, in epilepsy with myoclonic absences (EMA), EEG spikes are followed by prominent myoclonic jerks that may cause the child to fall, whereas in children with the more common childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE), the spikes are not associated with myoclonus. Although the age of onset, clinical manifestations of the seizures, neurologic status of the children, and prognosis differ among the various syndromes, the EEG patterns are quite similar and the approach to treatment is fundamentally the same, with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/34/2598?source=see_link\">",
"     ethosuximide",
"    </a>",
"    , valproic acid,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/34/3626?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11383?source=see_link\">",
"     clonazepam",
"    </a>",
"    representing the most effective AEDs. A randomized clinical trial compared ethosuximide,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    , and lamotrigine in 453 children with CAE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/69\">",
"     69",
"    </a>",
"    ]. Ethosuximide and valproic acid were found to be more effective than lamotrigine in eliminating seizures; ethosuximide had a more favorable adverse event profile compared with valproic acid. One observational study suggested that while similarly effective over the long term, ethosuximide&rsquo;s onset of efficacy was faster compared with lamotrigine and valproate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The other seizure types that accompany the absences are specific for the particular syndrome. The Lennox-Gastaut syndrome (LGS) and myoclonic-astatic epilepsy (MAE) are more serious epileptic disorders in which children always have other seizure types, including tonic and atonic seizures, as well as developmental delay.",
"   </p>",
"   <p>",
"    The neurologic and cognitive status of the child also varies from syndrome to syndrome. Children with CAE, juvenile myoclonic epilepsy (JME), and JAE usually are neurologically and cognitively intact. Relatively minor behavioral, psychiatric, and cognitive impairments are reported in a minority [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. In contrast, children with the Lennox-Gastaut and MAE syndromes have static encephalopathies with motor and cognitive impairment as well as abnormalities on imaging studies, including evidence of an earlier brain injury and developmental and maturational disorders. Children with EMA fall somewhere in between, with approximately 44 percent having mental retardation prior to the onset of the seizures at 1 to 12 years of age (mean 7 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for seizure remission differs for each syndrome. Childhood absence epilepsy (typical absence seizures with occasional generalized tonic-clonic seizures and an EEG pattern of generalized",
"    <span class=\"nowrap\">",
"     3/sec",
"    </span>",
"    spike and wave activity in a neurologically healthy child) has a reasonably good long-term prognosis with disappearance of seizures in the teen years. The prognostic implication of other EEG patterns are disputed, but a later age of onset of CAE and a family history of generalized tonic-clonic seizures are risk factors for persistent seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/75\">",
"     75",
"    </a>",
"    ]. Juvenile myoclonic epilepsy (JME) is associated with life-long seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Children with LGS and MAE have life-long neurologic deficits and many continue to have seizures into adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LENNOX-GASTAUT SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Lennox-Gastaut syndrome (LGS) is an ill-defined syndrome that is associated with severe seizures in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Patients usually present in the first seven years of life; some begin having seizures before reaching the age of one.",
"   </p>",
"   <p>",
"    The criteria defining the syndrome are relatively nonspecific, leading to the inclusion of children whose seizures have a wide variety of etiologies. The syndrome is characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple seizure types, particularly tonic and atonic seizures, but also including absence seizures (\"typical\" petit mal) and myoclonic seizures (\"atypical\" petit mal) as well as nonconvulsive status epilepticus",
"     </li>",
"     <li>",
"      A slow (less than 2.5-hertz) spike-wave pattern on the interictal EEG that is generalized and of highest voltage in the frontal region (also called an \"atypical spike and wave\" pattern)",
"     </li>",
"     <li>",
"      Mental retardation (occasionally progressive) with or without other neurologic abnormalities. Psychotic symptoms are common. Often neurodevelopment is normal before the first seizure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some epileptologists also require an electroencephalogram (EEG) showing a fast (10 to 20-hertz) polyspike pattern accompanying the tonic seizures, which are often activated by sleep or seen only in sleep. Most children with the characteristic slow spike and wave EEG pattern have a static encephalopathy and mental retardation. The EEG pattern associated with the tonic seizures is similar to the ictal pattern of an infantile spasm, with an electrodecremental response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/2/1063?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and diagnosis of infantile spasms\", section on 'Ictal EEG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This syndrome has many causes, including genetic disorders, neurocutaneous syndromes (eg, tuberous sclerosis), and encephalopathies following hypoxic-ischemic insults, meningitis, and head injuries. Approximately 40 percent of patients have a cryptogenic etiology, although increasingly, these children are found to have genetic disorders, particularly chromosomal syndromes. Up to 25 percent have a history of infantile spasms. Children with this syndrome are often difficult to manage medically and have a poor seizure and neurologic prognosis. Mortality is also higher (SMR = 14) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy for LGS is uncertain and may depend in part upon the underlying etiology. Systematic reviews of randomized controlled trials have concluded that no drug has been shown to be highly effective, although valproic acid,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/34/3626?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/60/21448?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/12/29893?source=see_link\">",
"     rufinamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/25/28055?source=see_link\">",
"     felbamate",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/4/32839?source=see_link\">",
"     clobazam",
"    </a>",
"    may be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    can precipitate drop attacks in some of these children.",
"   </p>",
"   <p>",
"    Two randomized studies have demonstrated that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/4/32839?source=see_link\">",
"     clobazam",
"    </a>",
"    may be an effective treatment in children with LGS. In one trial, 217 patients with LGS were randomized to one of four treatment arms: placebo or clobazam 0.25, 0.5, or 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/84\">",
"     84",
"    </a>",
"    ]. After 12 weeks, a &gt;50 percent reduction in drop seizures was observed in 32, 43, 59, and 78 percent of patients in each respective treatment group; the differences were statistically significant for the two higher clobazam dose groups versus placebo. In another trial, high dose clobazam (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) was associated with greater number of patients achieving a &gt;50 percent reduction in drop seizures compared to low dose clobazam (0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) (83 versus 38 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/85\">",
"     85",
"    </a>",
"    ]. Clobazam is now available in the US.",
"   </p>",
"   <p>",
"    Because seizures are often medically refractory, other treatment options are often considered. The ketogenic diet has been helpful in some children with LGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=see_link\">",
"     \"The ketogenic diet\"",
"    </a>",
"    .) Vagus nerve stimulation also appears to be effective in some patients with LGS, leading to a greater than 50 percent reduction in seizure frequency (particularly for atonic and tonic seizures), as well as shortened seizure duration and reduced number of AEDs prescribed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=see_link&amp;anchor=H6#H6\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\", section on 'Other seizure types and patient populations'",
"    </a>",
"    .) Other surgical options, including corpus callosotomy, may be considered in some refractory cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LANDAU-KLEFFNER SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Landau-Kleffner syndrome (LKS, also called acquired epileptic aphasia) is an extremely rare syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/90\">",
"     90",
"    </a>",
"    ]. It represents one of the best examples of deterioration of higher cortical functioning, in this case language, solely on the basis of frequent epileptiform activity. It has become a major area of concern and debate among parents of children with pervasive",
"    <span class=\"nowrap\">",
"     developmental/autistic",
"    </span>",
"    spectrum disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with LKS develop normally until approximately three to six years of age, when they begin to lose language function. This later age contrast with that of autistic children. The disorder begins with an auditory verbal agnosia; the children behave as if they are deaf. They ultimately have difficulties with expressive language and many have personality disorders and hyperkinetic behavior. They do not develop the striking behaviors associated with the autistic spectrum disorders, and usually they do not manifest a decline of overall cognitive function.",
"   </p>",
"   <p>",
"    Approximately 75 percent of children with LKS have epilepsy, but it is rarely severe. The electroencephalogram (EEG) abnormalities are quite dramatic and are required to make the diagnosis. The typical findings are bilateral centrotemporal spikes and sharp waves that spread widely throughout both hemispheres. The diffuse spread of this bihemispheric focal activity often leads to the appearance of \"generalized spike and wave\" discharges. When the child falls asleep, the epileptiform activity becomes virtually continuous and is classified as \"electrical status epilepticus during slow sleep\" (ESES). The epileptiform activity occupies over 80 percent of the total non-REM sleep time. A similar sleep pattern, continuous spikes and waves during slow sleep (CSWS), can be seen in children with other autism-like disorders, which are clinically distinct from LKS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With sophisticated imaging and nuclear medicine techniques, the epileptiform process can be shown to originate in the language cortex of the dominant temporal lobe and secondarily to spread to homologous cortex in the other hemisphere and beyond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/92\">",
"     92",
"    </a>",
"    ]. No structural abnormalities are typically seen on routine neuroimaging with CT or MRI. However, volumetric analysis of MRI in four children with typical LKS has shown volume reductions of 26 to 51 percent in the bilateral superior temporal areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/93\">",
"     93",
"    </a>",
"    ], regions that correspond to the auditory association cortex. It is unclear if this focal cortical atrophy is the cause of LKS or the result of intractable epileptiform activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The deterioration of language in these children may be caused by an interruption of the normal maturation of the cortex in the temporal lobes during a critical period of development when the brain is making new synapses and removing (\"pruning\") others. The pervasive epileptiform activity is thought to activate and perpetuate synaptic connections that would, in the course of normal development, be removed. There is evidence that cognitive functioning improves if epileptic activity is reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. The involvement of both temporal lobes eliminates the possibility that an uninvolved temporal lobe can subsume the function of the other as so often occurs in children with lesions that destroy the dominant speech cortex early in development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no controlled clinical trials that have investigated treatment in LKS. Anecdotal evidence suggests that early initiation of antiepileptic drugs and control of epileptic activity improves long term prognosis. AEDs with some reported benefit include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11383?source=see_link\">",
"     clonazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/0/25608?source=see_link\">",
"     levetiracetam",
"    </a>",
"    , and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. A trial of corticosteroids is recommended if there is no response to AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One group has pioneered a surgical technique called \"multiple subpial transection\" that appears to offer a rational treatment approach to some of these children, who typically are not helped by standard AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/97\">",
"     97",
"    </a>",
"    ]. Subpial transection consists of closely spaced slicing of the temporal lobe gyri involved in the epileptic process, with interruption of the short cortical-cortical fibers in the white matter immediately under the cortical gray. This limited slice disrupts the epileptic interconnections and stops the epileptiform activity while sparing the thalamocortical fibers that subserve normal cortical function. The results can be quite dramatic, with complete disappearance of the epileptiform activity on the EEG and rapid return of language function. Despite the rather extensive transections undertaken in some patients, few postoperative deficits have been noted.",
"   </p>",
"   <p>",
"    Despite aggressive treatment, some patients with LKS have persistent, intractable epilepsy, and most patients have residual language dysfunction that diminishes their quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Relationship with autism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between LKS and pervasive developmental disorders",
"    <span class=\"nowrap\">",
"     (PDD)/autistic",
"    </span>",
"    spectrum disorder is a tenuous one, at best [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33769/abstract/99\">",
"     99",
"    </a>",
"    ]. The two syndromes initially were linked by two clinical similarities: loss of language after a period of relatively normal language acquisition and seizures. Uncontrolled evoked potential studies purportedly have shown abnormalities in the auditory cortex in autistic children even with normal EEGs and have been used to support the contention of temporal lobe dysfunction in this disorder. Scattered reports describe successful steroid therapy in children with LKS as well as in autism, also uncontrolled. Nevertheless, the two disorders are in reality quite different. The autistic child usually has a plateau or loss of language in the second half of the second year of life as compared with an older age in LKS, the EEG almost always is normal early in the course of autism, particularly at the time of language regression (although it may show epileptiform activity in over 20 percent at a later age), and one never sees the striking ESES pattern in autism. The characteristic social, motor, and communication abnormalities of autism are not seen in the LKS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features of autism spectrum disorders\", section on 'Autistic disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BENIGN PARTIAL EPILEPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign partial epilepsies of childhood are idiopathic syndromes that occur in developmentally and neurologically normal children and have a benign course, remitting prior to adulthood. The best-described of these syndromes are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign childhood epilepsy with centrotemporal spikes (BCECTS) or benign rolandic epilepsy makes up about 10 to 20 percent of all childhood epilepsies and has a mean age of onset between seven and nine years. The most common seizure type is a simple partial seizure with motor symptoms involving the face, but secondary generalized seizures are also common and are often the presenting symptom. Seizures are more common at night and the characteristic EEG abnormality of centrotemporal spikes is also more prominent in sleep recordings. In most cases, seizures remit within two years.",
"     </li>",
"     <li>",
"      Benign occipital epilepsy of childhood (Gastaut type) produces frequent seizures with prominent visual symptoms (hallucinations, blindness). The mean age of onset is between eight and nine years. EEG reveals occipital spikes, activated by eye closure.",
"     </li>",
"     <li>",
"      Panayiotopoulos syndrome presents at a mean age of less than five years with a unique seizure type that has prominent autonomic features including vomiting and pallor. The seizures are usually nocturnal and last more than five minutes. One-third to one-half of episodes last more than 30 minutes. Seizures are infrequent; almost half of patients have just a single seizure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/921?source=see_link\">",
"     \"Benign partial epilepsies of childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     JUVENILE MYOCLONIC EPILEPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile myoclonic epilepsy (JME) is frequently diagnosed in pediatric epilepsy clinics but is often not recognized by referring clinicians. Typically, the patient is a healthy young teenager with one or more of the following seizure types:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myoclonic jerks (often upon awakening in the morning or during early morning hours)",
"     </li>",
"     <li>",
"      Absence seizures (\"typical\" petit mal seizures that often precede the other seizures and begin toward the end of the first decade)",
"     </li>",
"     <li>",
"      Generalized tonic-clonic seizures, which also have a tendency to occur upon awakening",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis and treatment of JME are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15849?source=see_link\">",
"     \"Juvenile myoclonic epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/54/38754?source=see_link\">",
"       \"Patient information: Epilepsy in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/26/419?source=see_link\">",
"       \"Patient information: Seizures in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/5/19540?source=see_link\">",
"       \"Patient information: Treatment of seizures in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16948835\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Numerous epilepsy syndromes characteristically have their onset in the first year of life (",
"      <a class=\"graphic graphic_table graphicRef70499 \" href=\"mobipreview.htm?12/17/12571\">",
"       table 2",
"      </a>",
"      ). These are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=see_link\">",
"       \"Neonatal epileptic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A severe form of myoclonic epilepsy of infancy (Dravet syndrome) is often associated with intractable epilepsy beginning in the first year of life and poor psychomotor developmental outcome. Patients typically present with prolonged, often febrile, generalized clonic or hemiclonic seizures in the setting of normal cognitive and motor development prior to seizure onset. Mutations in SCN1A, a gene that encodes the alpha subunit of the voltage-gated sodium channel, have been identified in up to 80 percent of patients with this syndrome (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Severe myoclonic epilepsy of infancy (Dravet syndrome)'",
"      </a>",
"      above.). &nbsp;",
"     </li>",
"     <li>",
"      Absence seizures are the only or most predominant seizure type in several epileptic syndromes, which have markedly different clinical courses and prognoses. The age of onset and clinical phenotypes of the absence syndromes often help to define the particular syndrome. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Absence seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Lennox-Gastaut syndrome is associated with severe seizures in childhood. There are many causes, including genetic syndromes and hypoxic ischemic insults. Children usually present in the first seven years of life with a syndrome characterized by multiple seizure types, particularly tonic and atonic seizures, an atypical, slow spike and wave pattern on EEG, and mental retardation, often with psychotic features. The optimal therapy is uncertain; some children benefit with treatment from antiepileptic drug therapy; other treatment options include the ketogenic diet, vagal nerve stimulation, and epilepsy surgery. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Lennox-Gastaut syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with the Landau-Kleffner syndrome (LKS) develop normally until approximately three to six years of age, when they begin to lose language function. Approximately 75 percent of children with LKS have epilepsy, but it is rarely severe. Characteristic EEG abnormalities include bilateral centrotemporal spikes and sharp waves that spread widely throughout both hemispheres. During sleep, epileptiform activity becomes continuous, \"electrical status epilepticus during slow sleep\". Early initiation of antiepileptic drugs and control of epileptic activity may improve long term prognosis. Other treatment options include corticosteroids and epilepsy surgery. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Landau-Kleffner syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benign partial epilepsies of childhood (benign childhood epilepsy with centrotemporal spikes, benign occipital epilepsy of childhood, Panayiotopoulos syndrome) are idiopathic syndromes that occur in developmentally and neurologically normal children and have a benign course, remitting prior to adulthood. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/921?source=see_link\">",
"       \"Benign partial epilepsies of childhood\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Juvenile myoclonic epilepsy can include any one or more of the following seizure types: myoclonic jerks, absence seizures, and generalized tonic-clonic seizures. The typical patient is neurodevelopmentally normal and presents after 10 years of age. Sleep deprivation may be required to elicit the typical 4 to 6 hertz polyspike and wave pattern on EEG. Seizures are usually controlled with a broad spectrum antiepileptic drug. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15849?source=see_link\">",
"       \"Juvenile myoclonic epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/1\">",
"      Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981; 22:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/2\">",
"      Farrell K. Classifying epileptic syndromes: problems and a neurobiologic solution. Neurology 1993; 43:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/3\">",
"      Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/4\">",
"      Duchowny M, Harvey AS. Pediatric epilepsy syndromes: an update and critical review. Epilepsia 1996; 37 Suppl 1:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/5\">",
"      Scheffer IE, Bhatia KP, Lopes-Cendes I, et al. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain 1995; 118 ( Pt 1):61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/6\">",
"      Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999; 52:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/7\">",
"      Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996; 5:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/8\">",
"      Shinnar S, O'Dell C, Berg AT. Distribution of epilepsy syndromes in a cohort of children prospectively monitored from the time of their first unprovoked seizure. Epilepsia 1999; 40:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/9\">",
"      Vigevano F. Benign familial infantile seizures. Brain Dev 2005; 27:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/10\">",
"      Cloarec R, Bruneau N, Rudolf G, et al. PRRT2 links infantile convulsions and paroxysmal dyskinesia with migraine. Neurology 2012; 79:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/11\">",
"      de Vries B, Callenbach PM, Kamphorst JT, et al. PRRT2 mutation causes benign familial infantile convulsions. Neurology 2012; 79:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/12\">",
"      Marini C, Conti V, Mei D, et al. PRRT2 mutations in familial infantile seizures, paroxysmal dyskinesia, and hemiplegic migraine. Neurology 2012; 79:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/13\">",
"      Szepetowski P, Rochette J, Berquin P, et al. Familial infantile convulsions and paroxysmal choreoathetosis: a new neurological syndrome linked to the pericentromeric region of human chromosome 16. Am J Hum Genet 1997; 61:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/14\">",
"      Striano P, Lispi ML, Gennaro E, et al. Linkage analysis and disease models in benign familial infantile seizures: a study of 16 families. Epilepsia 2006; 47:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/15\">",
"      Weber YG, Jacob M, Weber G, Lerche H. A BFIS-like syndrome with late onset and febrile seizures: suggestive linkage to chromosome 16p11.2-16q12.1. Epilepsia 2008; 49:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/16\">",
"      Gardiner AR, Bhatia KP, Stamelou M, et al. PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology 2012; 79:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/17\">",
"      Riant F, Roze E, Barbance C, et al. PRRT2 mutations cause hemiplegic migraine. Neurology 2012; 79:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/18\">",
"      Caraballo R, Pavek S, Lemainque A, et al. Linkage of benign familial infantile convulsions to chromosome 16p12-q12 suggests allelism to the infantile convulsions and choreoathetosis syndrome. Am J Hum Genet 2001; 68:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/19\">",
"      Guipponi M, Rivier F, Vigevano F, et al. Linkage mapping of benign familial infantile convulsions (BFIC) to chromosome 19q. Hum Mol Genet 1997; 6:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/20\">",
"      Herlenius E, Heron SE, Grinton BE, et al. SCN2A mutations and benign familial neonatal-infantile seizures: the phenotypic spectrum. Epilepsia 2007; 48:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/21\">",
"      Striano P, Bordo L, Lispi ML, et al. A novel SCN2A mutation in family with benign familial infantile seizures. Epilepsia 2006; 47:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/22\">",
"      Misra SN, Kahlig KM, George AL Jr. Impaired NaV1.2 function and reduced cell surface expression in benign familial neonatal-infantile seizures. Epilepsia 2008; 49:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/23\">",
"      Zara F, Specchio N, Striano P, et al. Genetic testing in benign familial epilepsies of the first year of life: Clinical and diagnostic significance. Epilepsia 2013; 54:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/24\">",
"      Ohtahara S. Seizure disorders in infancy and childhood. Brain Dev 1984; 6:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/25\">",
"      Myoclonus and epilepsy in childhood. Commission on Pediatric Epilepsy of the International League Against Epilepsy. Epilepsia 1997; 38:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/26\">",
"      Lombroso CT. Early myoclonic encephalopathy, early infantile epileptic encephalopathy, and benign and severe infantile myoclonic epilepsies: a critical review and personal contributions. J Clin Neurophysiol 1990; 7:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/27\">",
"      Jansen FE, Sadleir LG, Harkin LA, et al. Severe myoclonic epilepsy of infancy (Dravet syndrome): recognition and diagnosis in adults. Neurology 2006; 67:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/28\">",
"      Sakakibara T, Nakagawa E, Saito Y, et al. Hemiconvulsion-hemiplegia syndrome in a patient with severe myoclonic epilepsy in infancy. Epilepsia 2009; 50:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/29\">",
"      Ragona F, Brazzo D, De Giorgi I, et al. Dravet syndrome: early clinical manifestations and cognitive outcome in 37 Italian patients. Brain Dev 2010; 32:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/30\">",
"      Ragona F, Granata T, Dalla Bernardina B, et al. Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients. Epilepsia 2011; 52:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/31\">",
"      Brunklaus A, Dorris L, Zuberi SM. Comorbidities and predictors of health-related quality of life in Dravet syndrome. Epilepsia 2011; 52:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/32\">",
"      Sakauchi M, Oguni H, Kato I, et al. Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome. Epilepsia 2011; 52:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/33\">",
"      Brunklaus A, Ellis R, Reavey E, et al. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 2012; 135:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/34\">",
"      Rodda JM, Scheffer IE, McMahon JM, et al. Progressive gait deterioration in adolescents with Dravet syndrome. Arch Neurol 2012; 69:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/35\">",
"      Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001; 68:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/36\">",
"      Claes L, Ceulemans B, Audenaert D, et al. De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy. Hum Mutat 2003; 21:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/37\">",
"      Fukuma G, Oguni H, Shirasaka Y, et al. Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB). Epilepsia 2004; 45:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/38\">",
"      Kearney JA, Wiste AK, Stephani U, et al. Recurrent de novo mutations of SCN1A in severe myoclonic epilepsy of infancy. Pediatr Neurol 2006; 34:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/39\">",
"      Mulley JC, Nelson P, Guerrero S, et al. A new molecular mechanism for severe myoclonic epilepsy of infancy: exonic deletions in SCN1A. Neurology 2006; 67:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/40\">",
"      Madia F, Striano P, Gennaro E, et al. Cryptic chromosome deletions involving SCN1A in severe myoclonic epilepsy of infancy. Neurology 2006; 67:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/41\">",
"      Mancardi MM, Striano P, Gennaro E, et al. Familial occurrence of febrile seizures and epilepsy in severe myoclonic epilepsy of infancy (SMEI) patients with SCN1A mutations. Epilepsia 2006; 47:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/42\">",
"      Ohmori I, Kahlig KM, Rhodes TH, et al. Nonfunctional SCN1A is common in severe myoclonic epilepsy of infancy. Epilepsia 2006; 47:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/43\">",
"      Zucca C, Redaelli F, Epifanio R, et al. Cryptogenic epileptic syndromes related to SCN1A: twelve novel mutations identified. Arch Neurol 2008; 65:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/44\">",
"      M&oslash;ller RS, Schneider LM, Hansen CP, et al. Balanced translocation in a patient with severe myoclonic epilepsy of infancy disrupts the sodium channel gene SCN1A. Epilepsia 2008; 49:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/45\">",
"      Wang JW, Kurahashi H, Ishii A, et al. Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy. Epilepsia 2008; 49:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/46\">",
"      Marini C, Scheffer IE, Nabbout R, et al. SCN1A duplications and deletions detected in Dravet syndrome: implications for molecular diagnosis. Epilepsia 2009; 50:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/47\">",
"      Escayg A, Goldin AL. Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia 2010; 51:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/48\">",
"      Zuberi SM, Brunklaus A, Birch R, et al. Genotype-phenotype associations in SCN1A-related epilepsies. Neurology 2011; 76:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/49\">",
"      Okumura A, Uematsu M, Imataka G, et al. Acute encephalopathy in children with Dravet syndrome. Epilepsia 2012; 53:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/50\">",
"      Tang S, Lin JP, Hughes E, et al. Encephalopathy and SCN1A mutations. Epilepsia 2011; 52:e26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/51\">",
"      Chipaux M, Villeneuve N, Sabouraud P, et al. Unusual consequences of status epilepticus in Dravet syndrome. Seizure 2010; 19:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/52\">",
"      Berkovic SF, Harkin L, McMahon JM, et al. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 2006; 5:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/53\">",
"      Specchio N, Balestri M, Trivisano M, et al. Electroencephalographic features in dravet syndrome: five-year follow-up study in 22 patients. J Child Neurol 2012; 27:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/54\">",
"      Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/55\">",
"      Kassa&iuml; B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia 2008; 49:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/56\">",
"      Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007; 69:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/57\">",
"      Kr&ouml;ll-Seger J, Portilla P, Dulac O, Chiron C. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics 2006; 37:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/58\">",
"      Nieto-Barrera M, Candau R, Nieto-Jimenez M, et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000; 9:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/59\">",
"      Ceulemans B, Boel M, Claes L, et al. Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol 2004; 19:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/60\">",
"      Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/61\">",
"      Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998; 29:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/62\">",
"      Striano P, Striano S, Minetti C, Zara F. Refractory, life-threatening status epilepticus in a 3-year-old girl. Lancet Neurol 2008; 7:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/63\">",
"      Akiyama M, Kobayashi K, Yoshinaga H, Ohtsuka Y. A long-term follow-up study of Dravet syndrome up to adulthood. Epilepsia 2010; 51:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/64\">",
"      McIntosh AM, McMahon J, Dibbens LM, et al. Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study. Lancet Neurol 2010; 9:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/65\">",
"      Tro-Baumann B, von Spiczak S, Lotte J, et al. A retrospective study of the relation between vaccination and occurrence of seizures in Dravet syndrome. Epilepsia 2011; 52:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/66\">",
"      Ottman R, Hirose S, Jain S, et al. Genetic testing in the epilepsies--report of the ILAE Genetics Commission. Epilepsia 2010; 51:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/67\">",
"      Brunklaus A, Dorris L, Ellis R, et al. The clinical utility of an SCN1A genetic diagnosis in infantile-onset epilepsy. Dev Med Child Neurol 2013; 55:154.",
"     </a>",
"    </li>",
"    <li>",
"     Noebels, JL, Tharp, BR. Absence seizures in developing brain. In: Brain Development in Epilepsy, Schwartzkroin, P, Mosh&eacute;, SL, Noebels, J, Swann, J (Eds), Oxford University Press 1995. p.66.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/69\">",
"      Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010; 362:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/70\">",
"      Hwang H, Kim H, Kim SH, et al. Long-term effectiveness of ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. Brain Dev 2012; 34:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/71\">",
"      Caplan R, Siddarth P, Stahl L, et al. Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities. Epilepsia 2008; 49:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/72\">",
"      Vega C, Vestal M, DeSalvo M, et al. Differentiation of attention-related problems in childhood absence epilepsy. Epilepsy Behav 2010; 19:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/73\">",
"      Conant LL, Wilfong A, Inglese C, Schwarte A. Dysfunction of executive and related processes in childhood absence epilepsy. Epilepsy Behav 2010; 18:414.",
"     </a>",
"    </li>",
"    <li>",
"     Tassinari, CA, Bureau, M, Thomas, P. Epilepsy with myoclonic absences. In: Epileptic syndromes in infancy, childhood and adolescence, 2nd ed, Roger, J, Bureau, M, Dravet, CH, et al (Eds), John Libbey and Co Ltd 1992. p.151.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/75\">",
"      Vierck E, Cauley R, Kugler SL, et al. Polyspike and waves do not predict generalized tonic-clonic seizures in childhood absence epilepsy. J Child Neurol 2010; 25:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/76\">",
"      Kleveland G, Engelsen BA. Juvenile myoclonic epilepsy: clinical characteristics, treatment and prognosis in a Norwegian population of patients. Seizure 1998; 7:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/77\">",
"      Grosso S, Galimberti D, Vezzosi P, et al. Childhood absence epilepsy: evolution and prognostic factors. Epilepsia 2005; 46:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/78\">",
"      Wheless JW, Constantinou JE. Lennox-Gastaut syndrome. Pediatr Neurol 1997; 17:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/79\">",
"      Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009; 8:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/80\">",
"      Autry AR, Trevathan E, Van Naarden Braun K, Yeargin-Allsopp M. Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms. J Child Neurol 2010; 25:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/81\">",
"      Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003; :CD003277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/82\">",
"      Hancock EC, Cross HH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2009; :CD003277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/83\">",
"      Hancock EC, Cross JH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2013; 2:CD003277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/84\">",
"      Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011; 77:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/85\">",
"      Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009; 50:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/86\">",
"      Freeman JM. The ketogenic diet: additional information from a crossover study. J Child Neurol 2009; 24:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/87\">",
"      Kostov K, Kostov H, Taub&oslash;ll E. Long-term vagus nerve stimulation in the treatment of Lennox-Gastaut syndrome. Epilepsy Behav 2009; 16:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/88\">",
"      Cukiert A, Burattini JA, Mariani PP, et al. Extended, one-stage callosal section for treatment of refractory secondarily generalized epilepsy in patients with Lennox-Gastaut and Lennox-like syndromes. Epilepsia 2006; 47:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/89\">",
"      Shahwan A, Bailey C, Maxiner W, Harvey AS. Vagus nerve stimulation for refractory epilepsy in children: More to VNS than seizure frequency reduction. Epilepsia 2009; 50:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/90\">",
"      LANDAU WM, KLEFFNER FR. Syndrome of acquired aphasia with convulsive disorder in children. Neurology 1957; 7:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/91\">",
"      Jayakar PB, Seshia SS. Electrical status epilepticus during slow-wave sleep: a review. J Clin Neurophysiol 1991; 8:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/92\">",
"      Maquet P, Hirsch E, Dive D, et al. Cerebral glucose utilization during sleep in Landau-Kleffner syndrome: a PET study. Epilepsia 1990; 31:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/93\">",
"      Takeoka M, Riviello JJ Jr, Duffy FH, et al. Bilateral volume reduction of the superior temporal areas in Landau-Kleffner syndrome. Neurology 2004; 63:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/94\">",
"      Bourgeois BF, Landau WM. Landau-Kleffner syndrome and temporal cortical volume reduction: cause or effect? Neurology 2004; 63:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/95\">",
"      Mikati MA, Shamseddine AN. Management of Landau-Kleffner syndrome. Paediatr Drugs 2005; 7:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/96\">",
"      Aeby A, Poznanski N, Verheulpen D, et al. Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12 cases. Epilepsia 2005; 46:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/97\">",
"      Morrell F, Whisler WW, Smith MC, et al. Landau-Kleffner syndrome. Treatment with subpial intracortical transection. Brain 1995; 118 ( Pt 6):1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/98\">",
"      Duran MH, Guimar&atilde;es CA, Medeiros LL, Guerreiro MM. Landau-Kleffner syndrome: long-term follow-up. Brain Dev 2009; 31:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33769/abstract/99\">",
"      Rapin I, Katzman R. Neurobiology of autism. Ann Neurol 1998; 43:7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6162 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33769=[""].join("\n");
var outline_f32_62_33769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16948835\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISTRIBUTION OF EPILEPSY SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SEIZURE SYNDROMES WITH ONSET IN THE FIRST YEAR OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NEONATAL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MYOCLONIC EPILEPSY OF INFANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Severe myoclonic epilepsy of infancy (Dravet syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ABSENCE SEIZURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LENNOX-GASTAUT SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LANDAU-KLEFFNER SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Relationship with autism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BENIGN PARTIAL EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      JUVENILE MYOCLONIC EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16948835\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6162\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6162|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/59/6078\" title=\"figure 1\">",
"      Incidence of absence epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6162|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/60/973\" title=\"table 1\">",
"      Classification of epileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/17/12571\" title=\"table 2\">",
"      Epilepsy syndromes in first year of life",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/921?source=related_link\">",
"      Benign partial epilepsies of childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/2/1063?source=related_link\">",
"      Clinical features and diagnosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3226?source=related_link\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/60/17354?source=related_link\">",
"      Hemiplegic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15849?source=related_link\">",
"      Juvenile myoclonic epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=related_link\">",
"      Neonatal epileptic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21912?source=related_link\">",
"      Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/54/38754?source=related_link\">",
"      Patient information: Epilepsy in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/26/419?source=related_link\">",
"      Patient information: Seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/5/19540?source=related_link\">",
"      Patient information: Treatment of seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_62_33770="Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis";
var content_f32_62_33770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33770/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33770/contributors\">",
"     Susan A Scherl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33770/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33770/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/62/33770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/62/33770/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/62/33770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scoliosis is defined as a lateral curvature of the spine that is usually accompanied by rotation. Scoliosis is not a diagnosis, but a description of a structural alteration that occurs in a variety of conditions. Progression of the curvature during periods of rapid growth may result in significant deformity, which may be accompanied by cardiopulmonary compromise.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and initial evaluation of adolescent idiopathic scoliosis will be reviewed here. The management and prognosis of adolescent idiopathic scoliosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37065?source=see_link\">",
"     \"Treatment and prognosis of adolescent idiopathic scoliosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scoliosis is defined as curvature of the spine in the coronal plane (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62029 \" href=\"mobipreview.htm?23/58/24494\">",
"     image 1",
"    </a>",
"    ). It is typically accompanied by a variable degree of rotation of the spinal column. By convention, 10&ordm; of curvature (as measured by the Cobb angle) defines a scoliosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62495 \" href=\"mobipreview.htm?28/39/29297\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/1\">",
"     1",
"    </a>",
"    ]. Curves with Cobb angle of less than 10&ordm; are referred to as spinal asymmetry and are of no long-term clinical significance.",
"   </p>",
"   <p>",
"    The direction (right or left) of a scoliotic curve is defined by the curve's convexity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62029 \" href=\"mobipreview.htm?23/58/24494\">",
"     image 1",
"    </a>",
"    ). The location is defined by the vertebra that is most deviated and rotated from midline, called the apical vertebra [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Radiographic evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Etiologic classification of scoliosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three broad categories of scoliosis: neuromuscular, congenital, and idiopathic (",
"    <a class=\"graphic graphic_table graphicRef50548 \" href=\"mobipreview.htm?7/13/7390\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Neuromuscular scoliosis",
"      </strong>",
"      occurs in patients with neurologic or musculoskeletal problems, such as cerebral palsy, myelomeningocele, or muscular dystrophy. It is the result of muscle imbalance and lack of trunk control.",
"      <br/>",
"      <br/>",
"      Neuromuscular scoliosis may be structural or nonstructural. Nonstructural scoliosis has no rotational component; it may be related to postural abnormalities, leg-length discrepancy, or pain (eg, splinting in patients with pneumonia or empyema). Most patients with neuromuscular scoliosis have additional findings related to the underlying disorder that help in making the diagnosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Congenital scoliosis",
"      </strong>",
"      results from asymmetry in the vertebrae secondary to congenital anomalies (eg, hemivertebrae, failure of segmentation). Congenital scoliosis usually manifests before adolescence.",
"     </li>",
"     <li>",
"      <strong>",
"       Syndromic scoliosis",
"      </strong>",
"      &ndash; Children with certain genetic disorders including connective tissue disorders such as Marfan syndrome and osteogenesis imperfecta and more generalized tissue disorders such as neurofibromatosis frequently develop scoliosis. Although these disorders are uncommon, it is important to be aware of them for two reasons: 1) Sometimes the first clinical manifestation of the disorder is a spinal deformity, and 2) the natural history and management often differs from that of idiopathic scoliosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Idiopathic scoliosis",
"      </strong>",
"      is scoliosis for which there is no definite etiology; it is therefore a diagnosis of exclusion. Idiopathic scoliosis is divided into three subcategories based upon the patient's age at presentation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infantile: 0 to 3 years",
"     </li>",
"     <li>",
"      Juvenile: 4 to 9 years",
"     </li>",
"     <li>",
"      Adolescent: &ge;10 years",
"      <br/>",
"      <br/>",
"      Infantile and juvenile idiopathic scoliosis are sometimes considered together and called \"early-onset\" idiopathic scoliosis; with this terminology, adolescent idiopathic scoliosis is called \"late-onset\" idiopathic scoliosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/3\">",
"       3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Adolescent idiopathic scoliosis (AIS) is the most common form of idiopathic scoliosis, accounting for between 80 and 85 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. AIS will be the focus of discussion in the remainder of this topic review.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of AIS with a Cobb angle &ge;10&ordm; is approximately 3 percent, but only 10 percent of adolescents with AIS require treatment (0.3 percent of the population) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Males and females are affected equally. However, the risk of curve progression and therefore the need for treatment is 10 times higher in females than in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence and female:male (F:M) ratio of AIS of varying degrees of severity is as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cobb angle &ge;10&ordm;: 2 to 3 percent, F:M 1.4 to 2.4:1",
"     </li>",
"     <li>",
"      Cobb angle &ge;20&ordm;: 0.3 to 0.5, F:M 5.4:1",
"     </li>",
"     <li>",
"      Cobb angle &ge;30&ordm;: 0.1 to 0.3, F:M 10:1",
"     </li>",
"     <li>",
"      Cobb angle &ge;40&ordm;: &le;0.1",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of AIS is unclear. Twin studies have shown a much higher concordance in the incidence and degree of scoliosis in monozygotic than dizygotic twins, supporting a genetic contribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The increased prevalence of scoliosis among individuals who have an affected sibling or parent provides additional support for the role of heritability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/6,13\">",
"     6,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, for example, the prevalence of scoliosis among first-, second-, and third-degree relatives of 52 girls with AIS was 6.9, 3.7, and 1.6 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/13\">",
"     13",
"    </a>",
"    ]. Another series evaluated the risk for subsequent siblings of index patients according to sex of the subsequent sibling and whether or not a parent was affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/6\">",
"     6",
"    </a>",
"    ]. If neither parent was affected, the risk for a subsequent sister was 7 percent and for a subsequent brother was 2 percent; if one parent was affected, the risk for a subsequent sister was 42 percent and for a subsequent brother was 7 percent.",
"   </p>",
"   <p>",
"    Genetic loci for AIS have been mapped to chromosomes 8, 9, 17, and 19 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/14-18\">",
"     14-18",
"    </a>",
"    ], but the inheritance pattern is unclear. It may be explained by either a multifactorial model or a dominant major gene diallele model with incomplete sex- and age-dependent penetrance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The expression of familial AIS may be linked to the X chromosome, with a dominant inheritance pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that have been proposed (but not definitively proved) to have a role in the pathogenesis of AIS include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/9,22,23\">",
"     9,22,23",
"    </a>",
"    ] abnormalities in growth hormone secretion, connective tissue structure, paraspinal musculature, vestibular function (as it relates to axial posture), melatonin secretion (as it relates to growth), and platelet microstructure, since the contractile system of platelets is similar to that of skeletal muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The studies describing the natural history of AIS have important limitations, including incorporation of patients with nonidiopathic etiologies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    early-onset scoliosis, lack of radiographic data, loss of patients, and small numbers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/25\">",
"     25",
"    </a>",
"    ]. Most of the patients included in these series were female and had thoracic curves. These limitations notwithstanding, these reports provide important observations regarding the natural history of untreated AIS.",
"   </p>",
"   <p>",
"    The natural history of untreated AIS is one of either stabilization or progression of the curve. Curves progress in approximately two-thirds of skeletally immature patients before they reach skeletal maturity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The magnitude of progression varies depending upon sex, curve magnitude at presentation, curve pattern, and remaining growth potential. These risk factors are discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Risk for progression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a review of 123 skeletally immature patients (mean age 14 years) with idiopathic scoliosis and Cobb angles less than 50&ordm; who were followed without treatment until skeletal maturity, the average curve measured 33&ordm; (range 10 to 49) at the time of diagnosis and 49&ordm; (range 12 to 97) at skeletal maturity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/26\">",
"     26",
"    </a>",
"    ]. The curves remained unchanged (progressed by &lt;5&ordm;) in 32 percent of patients and progressed by &ge;5&ordm; in 68 percent, &gt;10&ordm; in 34 percent, &gt;20&ordm; in 18 percent, and &gt;30&ordm; in only 8 percent.",
"   </p>",
"   <p>",
"    Scoliosis can continue to progress after skeletal maturity in untreated patients, particularly in those with curves measuring &gt;40&ordm; at the end of growth. Curves &gt;50&ordm; generally progress one degree per year after skeletal maturity. Curves measuring &le;30&ordm; at the end of growth typically do not progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. In a long-term study, 133 untreated curves in 102 patients were followed for an average of 40.5 years after skeletal maturity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/28\">",
"     28",
"    </a>",
"    ]. Two-thirds of the curves progressed, with an average rate of 0.75 to 1 degree per year. Factors related to progression after skeletal maturity included severity of curve at diagnosis (curves with Cobb angles &gt;30&ordm; tended to progress, whereas smaller curves did not) and curve location (increased risk with thoracic curves).",
"   </p>",
"   <p>",
"    Most patients with AIS have little, if any, functional limitation or pain in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/7,32-34\">",
"     7,32-34",
"    </a>",
"    ]. Back pain is slightly more common than in the general population but is rarely disabling, and the risk of neuropathy is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]. Mortality is not increased compared with the general population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37065?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment and prognosis of adolescent idiopathic scoliosis\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents with AIS may present in several ways. In some patients, scoliosis is noted as an incidental finding on physical examination. Others have complaints related to the deformity (eg, asymmetry of the shoulders, flank creases, hips, scapulae, or breasts). Some patients present because an abnormality was noted by the school nurse during scoliosis screening at school. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Scoliosis screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with severe thoracic curves (Cobb angle of &ge;70&ordm;) may have restrictive pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/30,35\">",
"     30,35",
"    </a>",
"    ]. However, such curves usually have onset before age 10 years (ie, infantile or juvenile idiopathic scoliosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the adolescent with scoliosis has several objectives, including identification of an underlying etiology (ie, excluding nonidiopathic causes) (",
"    <a class=\"graphic graphic_table graphicRef50548 \" href=\"mobipreview.htm?7/13/7390\">",
"     table 1",
"    </a>",
"    ), assessment of the magnitude of the curve and need for radiographs, and determining the risk of progression, which influences management decisions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37065?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prognosis of adolescent idiopathic scoliosis\", section on 'General guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Questions in the history are centered upon determining an underlying etiology and the risk for progression (based upon estimation of remaining potential for linear growth). Important aspects of the history include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/2,38\">",
"     2,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When was the deformity first noted, and who noted it?",
"     </li>",
"     <li>",
"      What is the rate of progression? Rapid progression of the curve is suggestive of nonidiopathic etiology (",
"      <a class=\"graphic graphic_table graphicRef50548 \" href=\"mobipreview.htm?7/13/7390\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Is there associated pain? The presence of significant pain (pain that limits activities or requires frequent analgesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/39\">",
"       39",
"      </a>",
"      ]) increases the likelihood of nonidiopathic etiology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/40\">",
"       40",
"      </a>",
"      ]. This was illustrated in a review of 2442 patients in which 23 percent complained of pain at the time of presentation; among these patients who complained of pain, 9 percent had an underlying pathologic condition (spondylolysis, spondylolisthesis, Scheuermann kyphosis, syrinx, herniated disc, hydromyelia, tethered cord, intraspinal tumor) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/41\">",
"       41",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients with significant pain may require additional evaluation, particularly those who have neurologic symptoms or signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a left thoracic curve, as discussed below. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Radiographic evaluation'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19162?source=see_link\">",
"       \"Back pain in children and adolescents: Overview of causes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2679?source=see_link\">",
"       \"Evaluation of the child with back pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Are there associated symptoms suggestive of a neuromuscular etiology (eg, muscle weakness, bowel or bladder problems, headache, neck pain)? Neurologic symptoms increase the likelihood of nonidiopathic causes and require additional evaluation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Radiographic evaluation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Does the patient have shortness of breath or difficulty breathing? Severe thoracic scoliosis may affect pulmonary function.",
"     </li>",
"     <li>",
"      What is the patient's growth trajectory, and has the pubertal growth spurt begun? This information helps to estimate remaining linear growth and need for intervention. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=see_link&amp;anchor=H11#H11\">",
"       \"Normal growth patterns in infants and prepubertal children\", section on 'Predicted height'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Has the patient entered puberty? Tanner grade 2 (the onset of puberty) precedes the peak height velocity (",
"      <a class=\"graphic graphic_figure graphicRef52047 graphicRef72046 \" href=\"mobipreview.htm?26/57/27543\">",
"       figure 1A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For female patients, has menarche occurred? If so, when? Peak height velocity usually occurs just before menarche (",
"      <a class=\"graphic graphic_figure graphicRef52047 \" href=\"mobipreview.htm?28/38/29283\">",
"       figure 1A",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/42\">",
"       42",
"      </a>",
"      ]. Girls continue to grow at decreased velocity for approximately one year after menarche and complete linear growth by 24 months after menarche [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=see_link&amp;anchor=H5#H5\">",
"       \"Normal puberty\", section on 'Peak height velocity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For male patients, have they started shaving (or do they need to)? Skeletal growth in boys is completed when they are (or should be) shaving every day.",
"     </li>",
"     <li>",
"      Is there a history of lower-limb fracture, joint infection, or arthritis (which may result in leg length discrepancy)?",
"     </li>",
"     <li>",
"      Is there a family history of scoliosis? AIS tends to run in families. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the general examination include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/2,38\">",
"     2,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of the patient's height, which should be plotted on a growth curve standardized for age and sex (",
"      <a class=\"graphic graphic_figure graphicRef63399 graphicRef77249 \" href=\"mobipreview.htm?43/30/44519\">",
"       figure 2A-B",
"      </a>",
"      ). This helps to estimate the remaining growth potential. Linear growth is near completion when there has been &lt;1 cm of change in standing height over a six-month period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=see_link&amp;anchor=H11#H11\">",
"       \"Normal growth patterns in infants and prepubertal children\", section on 'Predicted height'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measurement of the patient&rsquo;s arm span; an increased arm span to height ratio may be a clue to Marfan syndrome, a cause of syndromic scoliosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=see_link&amp;anchor=H28#H28\">",
"       \"Normal growth patterns in infants and prepubertal children\", section on 'Arm span to height'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiologic classification of scoliosis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Assessment of Tanner stage (",
"      <a class=\"graphic graphic_picture graphicRef72038 \" href=\"mobipreview.htm?10/43/10932\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef79782 \" href=\"mobipreview.htm?29/33/30227\">",
"       picture 2",
"      </a>",
"      ). The risk for curve progression is greatest during peak height velocity, the onset of which precedes Tanner stage 2 (",
"      <a class=\"graphic graphic_figure graphicRef52047 graphicRef72046 \" href=\"mobipreview.htm?26/57/27543\">",
"       figure 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=see_link\">",
"       \"Normal puberty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examination of the skin for caf&eacute;-au-lait spots and axillary freckling (suggestive of neurofibromatosis); vascular, hypopigmented, or hyperpigmented lesions or a patch of hair overlying the spine (which may be associated with spinal dysraphism); and dimpling in the lumbosacral area (which may be associated with intraspinal tumor). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=see_link\">",
"       \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excessive skin or joint laxity may be associated with Ehlers-Danlos or Marfan syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asymmetry on bilateral palpation of the iliac crests and posterior inferior iliac spines with the patient in the standing position with the hips and knees fully extended suggests leg-length discrepancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If a leg-length discrepancy is present, clinically apparent scoliosis may be compensatory. A compensatory scoliosis will usually correct when the leg lengths are evened out by placing a block under the shorter leg.",
"     </li>",
"     <li>",
"      If leg-length discrepancy is a possibility, the patient's leg lengths should be measured. Leg length is measured with the patient supine and the legs extended and held together in the midline; the measurement is taken from the anterior superior iliac spine to the medial malleolus, with the tape running medial to the patella. Most people have some asymmetry in leg length (on the order of 0.5 to 1 cm); up to 2 cm is typically well tolerated and can be treated with a shoe lift if necessary. Differences between 2 and 5 cm usually are treated with epiphysiodesis of the long leg, and differences &gt;5 cm usually are treated with surgical lengthening or shortening. Children with clinically significant leg-length discrepancy should be evaluated by an orthopedist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The feet should be examined for high arches (pes cavus) and hammer or claw toes, which are suggestive of neuromuscular disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15432?source=see_link\">",
"       \"Friedreich ataxia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21895?source=see_link\">",
"       \"Overview of hereditary neuropathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A full neurologic examination, including examination of the reflexes, should be performed. Balance and strength of the lower extremities can be assessed by watching the patient walk normally, toe and heel walk, squat deeply, and hop on each leg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The abdominal reflex is especially important, since an absent abdominal reflex is sometimes indicative of subtle intraspinal pathology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. Elicitation of the abdominal reflex involves lightly stroking the skin on one side of the upper, middle, and lower abdomen (above, at, and below the umbilicus, respectively); the normal response is contraction of the muscles, pulling the umbilicus and midline to the stimulated side.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Scoliosis examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination for scoliosis is facilitated by proper exposure of the trunk (ie, an examination gown that is open in the back, with undergarments that expose the iliac crests and posterior and anterior superior iliac spines) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the scoliosis examination is simple inspection. Though minor curves may not be immediately obvious when viewing a standing patient from behind, subtle differences in the height of the shoulders or scapulae, waistline symmetry, and the distance arms hang from the trunk may be appreciated on closer inspection (",
"    <a class=\"graphic graphic_picture graphicRef50532 \" href=\"mobipreview.htm?20/0/20495\">",
"     picture 3",
"    </a>",
"    ). The patient's head should appear \"balanced\" over the center of the sacrum and not shifted to one side or the other; a plumb line dropped from the spinous process of the seventh cervical vertebra should pass through the gluteal cleft.",
"   </p>",
"   <p>",
"    Viewed from the side, the patient should have the normal profile of thoracic kyphosis and lumbar lordosis; decreased thoracic kyphosis may be seen. The majority (90 percent) of curves in AIS are right thoracic curves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/47\">",
"     47",
"    </a>",
"    ]. Left thoracic curves have been associated with nonidiopathic causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/48-51\">",
"     48-51",
"    </a>",
"    ] and may require additional evaluation. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Radiographic evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Forward bend test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Adams forward bend test is performed by observing the patient from the back while he or she bends forward at the waist until the spine becomes parallel to the horizontal plane, with feet together, knees straight ahead, and arms hanging free. In a patient with scoliosis, a thoracic (rib) or lumbar (loin) prominence on one side will be evident (",
"    <a class=\"graphic graphic_figure graphicRef70408 \" href=\"mobipreview.htm?8/54/9071\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The Adams forward bend test actually demonstrates the rotational component of scoliosis, since the rib prominence is the result of the ribcage rotating along with the spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. If asymmetry is noted in the upper thoracic, midthoracic, thoracolumbar, or lumbar region, it should be measured with a scoliometer, as described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/38,54\">",
"     38,54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Use of a scoliometer'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Inability to bend forward at the waist or decreased range with forward or side bending may be secondary to pain, lumbar muscle spasm,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tightness of the hamstrings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/7,38\">",
"     7,38",
"    </a>",
"    ]. Any of these findings may indicate nonidiopathic etiology (",
"    <a class=\"graphic graphic_table graphicRef50548 \" href=\"mobipreview.htm?7/13/7390\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The location of the prominence in relation to the convexity of a lumbar curve may provide a clue to the underlying cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/38\">",
"     38",
"    </a>",
"    ]. In structural scoliosis (including AIS), the rotational prominence is on the same side as the convexity of the curve. In contrast, in leg-length discrepancy, the prominence is on the concave side of the curve. There is no rotational component, but the iliac crest and lumbar spine are more prominent on the side with the long leg, resulting in a long curve in the shape of the letter \"C\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/42\">",
"     42",
"    </a>",
"    ]. The prominence disappears if the pelvis is leveled by placement of an appropriately sized block (under the short leg) or during sitting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Adams forward bend test is the most sensitive of the clinical examination findings for scoliosis (using the radiographic Cobb angle as the gold standard) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/55\">",
"     55",
"    </a>",
"    ]. However, the ability of the forward bend test to correctly identify patients with and without scoliosis (sensitivity and specificity, respectively) varies depending upon the skills of the examiner, the location of the curve, and the magnitude of the curve used as the gold standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/55-58\">",
"     55-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The range of sensitivity and specificity of the forward bend test (performed by school-based screeners in most cases) for varying degrees of scoliosis are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thoracic scoliosis with Cobb angle &ge;10&ordm; &ndash; sensitivity 74 to 84 percent, specificity 78 to 93 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Thoracic scoliosis with Cobb angle &ge;20&ordm; &ndash; sensitivity: 92 to 100 percent; specificity 60 to 91 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/55,58\">",
"       55,58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lumbar scoliosis with Cobb angle &ge;20&ordm; &ndash; sensitivity 73 percent; specificity: 68 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Scoliosis with Cobb angle &ge;40&ordm; &ndash; sensitivity 83 percent; specificity 99 percent (with repeat screening by a more experienced screener in some cases) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Use of a scoliometer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A scoliometer (sometimes called an inclinometer) is a device used for scoliosis screening and quantification of trunk rotation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Scoliometer measurements can help in determining which patients need radiographs but should not be used in the absence of radiographs to make decisions regarding bracing or surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37065?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment and prognosis of adolescent idiopathic scoliosis\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A scoliometer is basically a version of a carpenter's level that measures the angle of trunk rotation. The scoliometer is run along the patient's spine from cephalad to caudad while the patient is in the position assumed for the Adams forward bend test (",
"    <a class=\"graphic graphic_picture graphicRef57756 \" href=\"mobipreview.htm?33/0/33806\">",
"     picture 4",
"    </a>",
"    ). If a rotational prominence (ie, rib or loin hump) is present, the ball in the scoliometer deviates from the center of the device. If there is a right rib prominence, for example, the right side of the scoliometer tips upward, and the ball deviates to the left.",
"   </p>",
"   <p>",
"    The degrees on a scoliometer do not correspond one-to-one to the degrees of curvature as measured using Cobb angles on a radiograph [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/61\">",
"     61",
"    </a>",
"    ]. Equations and algorithms have been developed to convert between scoliometer readings and Cobb angles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. As a general guideline, an angle of trunk rotation of 7&ordm; corresponds to a Cobb angle of 20&ordm; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/63\">",
"     63",
"    </a>",
"    ]. However, not all patients with radiographic scoliosis have rotation of the trunk, and not all patients with trunk rotation have radiographic scoliosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scoliometer use is, to some extent, operator dependent. In one study, the inter-rater errors for thoracic and lumbar curves were 2&ordm; and 2.2&ordm;, respectively (compared with an intra-rater error of 1.2&ordm; and 1.6&ordm;, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/60\">",
"     60",
"    </a>",
"    ]. Potential sources of error in scoliometer measurements include the size of the ball in relation to the markings for degree increments; inconsistent identification of the apex of the curve; and inconsistent performance of the forward bend test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity and specificity of the scoliometer to identify patients with scoliosis varies depending upon the threshold scoliometer value (ie, 5 versus 7 versus 10 degrees) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/55,61,64\">",
"     55,61,64",
"    </a>",
"    ]. The following observations illustrate the range of findings in different studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When scoliosis was defined by a Cobb angle of &ge;20&ordm;, the sensitivity was 94 to 100 percent, and specificity was 29 to 33 percent with a scoliometer threshold of 5&ordm; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/61\">",
"       61",
"      </a>",
"      ]. Increasing the scoliometer threshold to 10&ordm; reduced the sensitivity to 50 to 53 percent but increased the specificity to 94 to 100 percent.",
"     </li>",
"     <li>",
"      A scoliometer threshold of 7&ordm; was associated with a sensitivity of 83 percent and a specificity of 86 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity appears to be greater for thoracic curves. This was suggested in a study in which the sensitivity of a scoliometer threshold of 5&ordm; to detect curves of &ge;20&ordm; was 71 percent with thoracic curves and 51 percent with lumbar curves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/55\">",
"     55",
"    </a>",
"    ]. The specificity was the same (83 percent) at both sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs are required to confirm the diagnosis of scoliosis, to determine the type (congenital, neuromuscular, idiopathic) and severity, and to evaluate skeletal maturity (to determine the risk for progression) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/2,38,65-67\">",
"     2,38,65-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for plain radiographic evaluation in the patient with scoliosis may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scoliometer reading of &ge;7&ordm;, since curves of this magnitude may require treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/54,67\">",
"       54,67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Clinically evident scoliosis (eg, a large, unambiguous curve) on physical examination",
"     </li>",
"     <li>",
"      Thoracic or lumbar asymmetry on physical examination in skeletally immature children or in combination with a family history of scoliosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/68\">",
"       68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Monitoring progression in patients with previously diagnosed AIS (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37065?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment and prognosis of adolescent idiopathic scoliosis\", section on 'Monitoring'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, magnetic resonance (MR) imaging may be indicated in patients with scoliosis and clinical or plain radiographic findings suggestive of intraspinal pathology (tumor, dysraphism, infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/2,48-50,69-73\">",
"     2,48-50,69-73",
"    </a>",
"    ]. These findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Associated neurologic signs or symptoms, including headache, neck pain, intrinsic wasting of the hands (which can be associated with syringomyelia), absence of abdominal reflex, asymmetric lower-extremity atrophy, pes cavus, and midline skin lesions (vascular, pigmentary, hair patch)",
"     </li>",
"     <li>",
"      Complaints of significant associated pain: computed tomography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bone scan also may be indicated in these patients if bone tumors or infection are suspected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/40,41\">",
"       40,41",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H9\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=see_link&amp;anchor=H6#H6\">",
"       \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Imaging'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Early age of onset (before 10 years) with rapid progression",
"     </li>",
"     <li>",
"      Abnormalities on plain radiographs that suggest congenital scoliosis or intraspinal pathology (eg, widening of the interpediculate space, erosion of the pedicles, thickening of the paraspinal line) or increased kyphosis, particularly increased thoracic kyphosis (which can be associated with Arnold-Chiari malformation or syringomyelia) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/74-76\">",
"       74-76",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, some practitioners believe that MR imaging should be performed in all children with a left-sided thoracic curve regardless of neurologic status or progression rate, all children with a curve that rapidly progresses, and all boys with a curve that demonstrates any degree of progression. However, these criteria are controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/73,77\">",
"     73,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Views",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial radiographic evaluation for scoliosis should include standing, full-length posteroanterior (PA) and lateral views of the spine (C7 to the sacrum and iliac crest) exposed on a single long film cassette [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/67,78\">",
"     67,78",
"    </a>",
"    ]. Radiographs of the spine taken in the supine position will eliminate the effect of gravity on curves and cause underestimation of curve magnitude. The presence of an air fluid level in the stomach confirms a radiograph was taken with the patient upright. PA views minimize radiation to the breasts and thyroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/67\">",
"     67",
"    </a>",
"    ]. The lateral view assesses spinal curvature in the sagittal plane. It need not be repeated at subsequent visits if the initial film shows only the normal findings of scoliosis (eg, thoracic kyphosis within the typical range and lumbar lordosis).",
"   </p>",
"   <p>",
"    Discrepancy in leg length, if present, should be corrected by placing an appropriately sized block under the shorter leg before radiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/78\">",
"     78",
"    </a>",
"    ]. Another alternative to using blocks, which may not always be available, to level the pelvis is to obtain sitting radiographs of the spine. Long film cassettes may not be available at all facilities. If long film cassettes are not available, sending the patient to a facility where long film cassettes are available may be preferable to obtaining suboptimal radiographs on inappropriate cassettes.",
"   </p>",
"   <p>",
"    Lateral bending films, in which the patient actively bends as far as possible laterally to one side and then the other, demonstrate potential for surgical correction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/79\">",
"     79",
"    </a>",
"    ]. They are used for preoperative planning of fusion levels and hardware placement and are not necessary for diagnosis or at routine follow-up. Lateral bending radiographs should be obtained by the operating surgeon as he or she deems necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to spine radiographs, some centers obtain radiographs of the hand and wrist to assess skeletal maturity according to the methods of Tanner and Whitehouse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs are reviewed to obtain information about the etiology, the site of the deformity, the curve pattern, and the magnitude of the curve (by the method of Cobb), and evaluate skeletal maturity (with Risser sign or other methods) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/2,65-67\">",
"     2,65-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PA radiograph is viewed with the patient's heart on the examiner's left (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62029 \" href=\"mobipreview.htm?23/58/24494\">",
"     image 1",
"    </a>",
"    ), as if the examiner is standing behind the patient. This is the opposite of how one typically views a chest radiograph, in which the patient's heart is to the examiner's right.",
"   </p>",
"   <p>",
"    Spinal radiographs should be assessed for abnormalities that are suggestive of an underlying congenital or neuromuscular etiology (",
"    <a class=\"graphic graphic_table graphicRef50548 \" href=\"mobipreview.htm?7/13/7390\">",
"     table 1",
"    </a>",
"    ). These may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Soft tissue abnormalities (eg, paraspinal mass)",
"     </li>",
"     <li>",
"      Wedged vertebrae or hemivertebrae (indicative of congenital scoliosis)",
"     </li>",
"     <li>",
"      Vertebral body lucency or erosion of the pedicles (suggestive of bone tumor)",
"     </li>",
"     <li>",
"      Widening of the interpediculate space (suggestive of a spinal cord tumor, syringomyelia, diastematomyelia, or spinal dysraphism)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Curve pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;The direction of the curve (right or left) is defined by its convexity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62029 \" href=\"mobipreview.htm?23/58/24494\">",
"     image 1",
"    </a>",
"    ). The location is defined by the vertebra that is most deviated and rotated from midline (the apical vertebra) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cervical &ndash; C2 to C6",
"     </li>",
"     <li>",
"      Cervicothoracic &ndash; C7 to T1",
"     </li>",
"     <li>",
"      Thoracic &ndash; T2 to T11",
"     </li>",
"     <li>",
"      Thoracolumbar &ndash; T12 to L1",
"     </li>",
"     <li>",
"      Lumbar &ndash; L2 to L4",
"     </li>",
"     <li>",
"      Lumbosacral &ndash; L5 or below",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are many possible curve configurations. However, the typical curve in AIS is a right thoracic, left lumbar double curve. There are several classifications for curve patterns that are used in making decisions regarding surgery, which will not be discussed in this review. These include the King-Moe and the Lenke classification systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cobb angle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of curvature in the coronal plane is measured according to the method of Cobb. The Cobb angle is formed by the intersection of a line parallel to the superior end plate of the most cephalad vertebra in a particular curve, with the line parallel to the inferior end plate of the most caudad vertebra of the curve (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62495 \" href=\"mobipreview.htm?28/39/29297\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The superior (cephalad) end vertebra is the vertebra that has the greatest tilt from horizontal of its superior end plate. Similarly, the inferior (caudal) end vertebra is the vertebra that has the greatest tilt from horizontal of its inferior end plate. It may be helpful to draw lines along several vertebrae near each end of a curve to help decide which is the best one to choose.",
"   </p>",
"   <p>",
"    From a practical point of view, when these two lines are drawn, their intersection often is outside the border of the actual film. Thus, by convention, perpendiculars to the parallels are drawn, and the angle between their intersection is measured (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62495 \" href=\"mobipreview.htm?28/39/29297\">",
"     image 2",
"    </a>",
"    ). The size of the angle is the same, but the measurements can be performed within the physical parameters of the film. In a typical double curve, two Cobb angles are measured.",
"   </p>",
"   <p>",
"    The Cobb angle is the accepted standard for measuring scoliosis on radiographs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/67,84\">",
"     67,84",
"    </a>",
"    ]. However, it has some important limitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/84\">",
"     84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Cobb angle describes only one plane of the three-dimensional deformity",
"     </li>",
"     <li>",
"      The Cobb angle is not proportional to the severity of scoliosis in a linear fashion (ie, a curve with a Cobb angle of 40&ordm; is more than twice as severe as a curve with a Cobb angle of 20&ordm;)",
"     </li>",
"     <li>",
"      Measurement of the Cobb angle is associated with variation in inter- and intraobserver measurement error of approximately 5&ordm; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/85-90\">",
"       85-90",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When using digital images, one cannot accurately measure the Cobb angle by simply placing a goniometer on the computer screen. However, many digital imaging systems have an \"annotation\" feature with which the clinician can measure the Cobb angle semimanually (ie, by using the mouse to draw the lines).&nbsp;There is often a bit of a learning curve in using these features, as&nbsp;manipulating the mouse&nbsp;for this purpose is slightly different than drawing lines on a printed plain film and takes practice. To use these features, a large high-resolution monitor is helpful. Alternatively, the Cobb angles can be drawn manually on a paper printout of the digital image.",
"   </p>",
"   <p>",
"    The Cobb angle is the gold standard for quantitative monitoring of scoliosis. Clinicians who treat children with scoliosis&nbsp;must have training and experience in measuring Cobb angles and should have&nbsp;a digital system that includes measurement functions, access to traditional printed films, or, at the very least, a good-quality paper printout of the digital image to manually measure the Cobb angle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Skeletal maturity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal maturity is assessed to determine the risk for progression. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Risk for progression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Risser sign",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Risser sign, a visual grading of the degree to which the iliac apophysis has undergone ossification and fusion, is used to assess skeletal maturity on PA spinal radiographs. The iliac apophysis ossifies in a stepwise fashion from anterolateral to posteromedial along the iliac crest.",
"   </p>",
"   <p>",
"    The Risser grades are as follows (",
"    <a class=\"graphic graphic_figure graphicRef74751 \" href=\"mobipreview.htm?43/28/44481\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 &ndash; No ossification",
"     </li>",
"     <li>",
"      1 &ndash; Up to 25 percent ossification",
"     </li>",
"     <li>",
"      2 &ndash; 26 to 50 percent ossification",
"     </li>",
"     <li>",
"      3 &ndash; 51 to 75 percent ossification",
"     </li>",
"     <li>",
"      4 &ndash; Greater than 76 percent ossification",
"     </li>",
"     <li>",
"      5 &ndash; Full bony fusion of the apophysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lower the Risser grade, the more growth remaining, and the greater the risk for curve progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/91\">",
"     91",
"    </a>",
"    ]. However, Risser 1 usually occurs after peak height velocity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/92\">",
"     92",
"    </a>",
"    ]. Some reviews of Risser sign have found it no more useful in assessment of skeletal maturity than chronologic age and suggest that it not be used as the only indicator of maturity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Risk for progression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other methods of assessing skeletal maturity include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The method of Tanner and Whitehouse (or scoring systems adapted from Tanner and Whitehouse), which is based on the radiographic appearance of the epiphyses of the distal radius, ulna, and small bones of the hand [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/81,95\">",
"       81,95",
"      </a>",
"      ]. Assessment of the triradiate cartilage (peak height velocity occurs in girls with open triradiate cartilage before attainment of Risser 1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Assessment of ossification centers in the elbow. Two methods have been described: the Sauvegrain method, in which the appearance of four different elbow ossification centers (lateral condyle, trochlea, olecranon apophysis, and proximal radial epiphysis) are scored on a 27-point scale, which is then plotted on a graph, and the simpler olecranon method, in which only the olecranon apophysis is evaluated. The olecranon apophysis progresses through five radiographic stages at six-month intervals: appearance of two ossification nuclei, half-moon-shaped ossification center, rectangular-shaped ossification center, beginning of fusion, complete fusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/96,97\">",
"       96,97",
"      </a>",
"      ]. The appearance of the rectangular-shaped ossification center corresponds to closure of the triradiate cartilage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of AIS is made clinically and radiographically. Criteria for the diagnosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &ge;10 years (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiologic classification of scoliosis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Curvature of the spine in the coronal plain with a Cobb angle of &ge;10&ordm; (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Cobb angle'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Exclusion of other etiologies for scoliosis (congenital, neuromuscular) (",
"      <a class=\"graphic graphic_table graphicRef50548 \" href=\"mobipreview.htm?7/13/7390\">",
"       table 1",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiologic classification of scoliosis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     RISK FOR PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for progression has important implications for treatment. Unfortunately, it is impossible to predict with complete accuracy which curves will progress and which will not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H568342362\">",
"    <span class=\"h2\">",
"     Natural history studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural history studies provide some guidelines for predicting the risk for progression in relation to sex, magnitude of the curve, curve pattern, and skeletal maturity at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/66\">",
"     66",
"    </a>",
"    ]. For the most part, these studies defined progression as an increase in the Cobb angle of &ge;5&ordm;, which does not necessarily equal progression to the point that surgery is recommended.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sex &ndash; The risk for progression is increased 3 to 10 times in girls compared with boys [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/10,66\">",
"       10,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Curve magnitude &ndash; Curves with initial Cobb angle of 20 to 29&ordm; are more likely to increase by &ge;5&ordm; than curves with Cobb angle of 5 to 19&ordm;, independent of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/28,98,99\">",
"       28,98,99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Curve pattern &ndash; Double and thoracic curves have a threefold increased risk of progression compared with nonthoracic curves [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/23,27,66\">",
"       23,27,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maturity &ndash; Markers of maturity that are predictive of remaining growth potential and risk for progression include Risser sign, chronologic age, and menarchal status (in girls). If the markers of maturity are discordant, the risk for curve progression may differ from those described below [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/78\">",
"       78",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When the Risser sign is &le;1, the risk for progression of &ge;5&ordm; is 22 percent for curves with Cobb angle 5 to 19&ordm; and 68 percent for curves with Cobb angle 20 to 29&ordm; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/91\">",
"       91",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      When the Risser sign is &ge;2, the risk for progression of &ge;5&ordm; is 1.6 percent for curves with Cobb angle 5 to 19&ordm; and 23 percent for curves with Cobb angle 20 to 29&ordm; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/91\">",
"       91",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      When the Risser sign is 3, the risk for progression of &ge;5&ordm; is less than 10 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/27,91\">",
"       27,91",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients younger than 12 years have three times the risk for progression than older patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Among girls who have had menarche at the time of presentation, 32 percent have progression of Cobb angle of more than 5&ordm;, while 68 percent have no further progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/100\">",
"       100",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H568342369\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescent idiopathic scoliosis (AIS) is a complex disorder that appears to result from the interaction of multiple genetic loci and the environment, but the details of these interactions are not fully understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A group of investigators has developed an algorithm (AIS prognostic test [AIS-PT], marketed as ScoliScore&trade;) to predict the risk of scoliosis progression to a Cobb angle &gt;40&deg; in skeletally immature adolescents aged 9 to 13 years who present with a Cobb angle between 10 and 25&deg; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/102\">",
"     102",
"    </a>",
"    ]. The algorithm incorporates the initial Cobb angle and saliva-based DNA testing for 53 genetic markers of severe scoliosis progression. The genetic markers were identified in as yet unpublished case-control genome-wide association studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of the AIS-PT in clinical practice is evolving. It is expensive (approximately $2950), and, at present, results are applicable only to Caucasian patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents with curves with low risk for progression, and in whom an underlying congenital or neuromuscular cause has been excluded, may be followed by their primary care provider if the provider feels comfortable doing so. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37065?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prognosis of adolescent idiopathic scoliosis\", section on 'General guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications for referral to an orthopedic surgeon may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/47,52,54\">",
"     47,52,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angle of trunk rotation (as measured with the scoliometer) of &ge;7&ordm; and inability to obtain a Cobb angle",
"     </li>",
"     <li>",
"      Cobb angle between 20&ordm; and 29&ordm; in premenarchal girl or boy aged 12 to 14 years",
"     </li>",
"     <li>",
"      Cobb angle &gt;30&ordm; in any patient",
"     </li>",
"     <li>",
"      Progression of Cobb angle of more than 5&ordm; in any patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some orthopedic surgeons suggest referral of all patients with Cobb angle &gt;20&ordm;, particularly if the patient or parents have questions that are beyond the scope of the primary care provider.",
"   </p>",
"   <p>",
"    At the time of referral, it is important to specify which method of measurement (Cobb angle or scoliometer [angle of trunk rotation]) is being used to describe the curve since the risk for progression for a curve with a Cobb angle of 10&ordm; differs from that for a curve with an angle of trunk rotation of 10&ordm;. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Risk for progression'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37065?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prognosis of adolescent idiopathic scoliosis\", section on 'General guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings suggestive of neuromuscular scoliosis, which usually warrant MR imaging, include severe pain, left thoracic curve, and neurologic signs and symptoms, as discussed above. Depending upon the examination and MR findings, referral to a specialist (neurosurgeon, oncologist, orthopedic surgeon, neurologist) may be warranted.",
"   </p>",
"   <p>",
"    Orthopedic referral is not necessary for patients with an incidental finding of scoliosis on a chest radiograph or other imaging study if the Cobb angle of the curve is &lt;10&ordm;. Such curves do not meet the Scoliosis Research Society's definition of scoliosis (curves with Cobb angle &ge;10&ordm;). The family should be told that such a small curve is common and has no clinical significance; no follow-up other than routine screening at well-child visits is needed. Repeat imaging is NOT indicated unless other physical findings dictate otherwise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SCOLIOSIS SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many states in the United States have mandated or voluntary school-based scoliosis screening programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/78\">",
"     78",
"    </a>",
"    ]. However, the efficacy of such programs in preventing curve progression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the need for scoliosis surgery is unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supporters of screening programs suggest that earlier diagnosis permits conservative therapy (ie, bracing), preventing the need for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/66,100,104-106\">",
"     66,100,104-106",
"    </a>",
"    ]. Opponents of screening programs suggest that AIS lacks the characteristics that render a disease a good candidate for screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/56,65\">",
"     56,65",
"    </a>",
"    ]. These characteristics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High prevalence",
"     </li>",
"     <li>",
"      Substantial morbidity and mortality in untreated patients",
"     </li>",
"     <li>",
"      A preclinical phase that can be detected by a screening test that is highly sensitive and specific",
"     </li>",
"     <li>",
"      Benefit to preclinical detection (eg, ability to alter the natural history)",
"     </li>",
"     <li>",
"      Availability of effective treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limitations to the efficacy of school-based screening for AIS in asymptomatic patients include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/65,66,107\">",
"     65,66,107",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The low prevalence of AIS requiring intervention (0.3 to 0.4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/8,57,108-110\">",
"       8,57,108-110",
"      </a>",
"      ] increases the likelihood that a positive screen will be a false positive. In one review, nearly 450 children needed to be screened to detect one child who needed treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/108\">",
"       108",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22823?source=see_link&amp;anchor=H20#H20\">",
"       \"Glossary of common biostatistical and epidemiological terms\", section on 'Predictive values'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Potential harms of false positive screening include unnecessary anxiety, time lost from school or work for follow-up or specialty care, radiation exposure, and adverse psychosocial effects (particularly related to brace wear) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/47,65,107\">",
"       47,65,107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Untreated AIS does not result in substantial morbidity or mortality in most cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/32,34\">",
"       32,34",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Adams forward bend test has variable sensitivity and specificity depending upon the examiner and the curve magnitude used as the gold standard. The inter-rater error of scoliometer measurement is approximately 2&ordm;. In addition, there is not a one-to-one correlation between the scoliometer measurement and the Cobb angle (the gold standard for diagnosis). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Scoliosis examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of preclinical detection is unproven. Most curves detected through screening do not progress to the point of needing surgical intervention; most cases requiring surgical treatment are detected without screening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/56,65,111,112\">",
"       56,65,111,112",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacy of bracing for AIS is disputed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/56,65,84,113-116\">",
"       56,65,84,113-116",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37065?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment and prognosis of adolescent idiopathic scoliosis\", section on 'Efficacy of bracing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several strategies have been proposed to improve the efficacy of scoliosis screening programs. These include the development and use of more objective criteria for referral, screening only immature females (selective screening), and repeat screening rather than immediate referral for borderline cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/53,54,56,66\">",
"     53,54,56,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of these strategies (repeat screening, more objective criteria, increased threshold for referral) were incorporated into a screening program in Dublin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/56\">",
"     56",
"    </a>",
"    ]. The sensitivity and specificity of the forward bend test to detect patients with a Cobb angle of &ge;40&ordm; were 83 and 99 percent, respectively, with repeat screening. However, only 8 percent of patients with a positive screening test had Cobb angle of &ge;40&ordm; because of the low prevalence of AIS of this severity. The low prevalence of AIS with Cobb angle of &ge;40&ordm; cannot be changed by altering the logistics of school-based screening programs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22823?source=see_link&amp;anchor=H20#H20\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Predictive values'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Recommendations of expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that a spinal examination be included in the physical examination of children and adolescents at routine health supervision visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/117\">",
"     117",
"    </a>",
"    ]. Spinal examination is particularly important before the pubertal growth spurt (at approximately 10 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/110,118\">",
"     110,118",
"    </a>",
"    ]. In addition, pediatric health care providers should be prepared to evaluate patients for scoliosis when it is discovered incidentally or through a school-based screening program, or when the adolescent or parents express concern about scoliosis.",
"   </p>",
"   <p>",
"    Recommendations of other groups are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The United States Preventive Services Task Force (USPSTF) and the American Academy of Family Physicians (AAFP) recommend against the routine screening of asymptomatic adolescents for AIS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/65,119\">",
"       65,119",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Canadian Task Force on the Periodic Health Examination concluded that there is insufficient evidence on which to make a recommendation for or against routine scoliosis screening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American Academy of Orthopaedic Surgeons (AAOS), the Scoliosis Research Society (SRS), the Pediatric Orthopaedic Society of North America (POSNA), and the American Academy of Pediatrics (AAP) recognize the limitations of scoliosis screening but acknowledge that the potential benefits of early treatment of patients with AIS can be substantial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/106\">",
"       106",
"      </a>",
"      ]. They suggest that if scoliosis screening is undertaken, girls should be screened at ages 10 and 12 years and boys at age 13 or 14 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/106\">",
"       106",
"      </a>",
"      ]. The forward bend test should be included in screening, and screening personnel should be educated regarding the detection of spinal deformity. In addition, the AAOS, SRS, POSNA, and AAP suggest that not all children referred as a result of screening require spinal radiographs. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Bright Futures guidelines recommend noting the presence of scoliosis during the physical examination of children and adolescents &ge;8 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/62/33770/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/20/18754?source=see_link\">",
"       \"Patient information: Scoliosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scoliosis is a lateral curvature of the spine usually accompanied by rotation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62029 \" href=\"mobipreview.htm?23/58/24494\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three broad categories of scoliosis: congenital, neuromuscular, and idiopathic (",
"      <a class=\"graphic graphic_table graphicRef50548 \" href=\"mobipreview.htm?7/13/7390\">",
"       table 1",
"      </a>",
"      ). Idiopathic scoliosis is a diagnosis of exclusion and is classified according to the age of onset. Adolescent idiopathic scoliosis (AIS, also called late-onset idiopathic scoliosis) has onset after age 10 years and is the most common type of scoliosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiologic classification of scoliosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of AIS is approximately 3 percent, but only 10 percent of adolescents with AIS require treatment (0.3 percent of the population). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of untreated scoliosis is one of stabilization or progression. Untreated curves progress in approximately two-thirds of skeletally immature patients before they reach skeletal maturity and may continue to progress after skeletal maturity, but at a diminished rate. Most patients with untreated AIS have little, if any, functional limitation or pain in adulthood. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with scoliosis usually come to medical attention as a result of truncal asymmetry noted by the patient or parents, during school-based scoliosis screening, or as an incidental finding during physical examination. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evaluation for scoliosis centers on exclusion of an underlying etiology (",
"      <a class=\"graphic graphic_table graphicRef50548 \" href=\"mobipreview.htm?7/13/7390\">",
"       table 1",
"      </a>",
"      ), assessment of the magnitude of the curve, and the risk for progression. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the history include age of onset, rate of progression, associated findings (ie, pain, neuromuscular complaints, shortness of breath), family history of scoliosis, pubertal development, menarchal status (in girls), and past history of lower-limb trauma, infection, or arthritis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the general examination include assessment of height and pubertal stage, bilateral palpation of the iliac crests and posterior inferior iliac spines, measurement of leg length, examination of the skin, and neurologic examination, including assessment of abdominal reflexes. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'General examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination for scoliosis includes inspection (",
"      <a class=\"graphic graphic_picture graphicRef50532 \" href=\"mobipreview.htm?20/0/20495\">",
"       picture 3",
"      </a>",
"      ), the Adams forward bend test (",
"      <a class=\"graphic graphic_figure graphicRef70408 \" href=\"mobipreview.htm?8/54/9071\">",
"       figure 3",
"      </a>",
"      ), and, if asymmetry is noted, measurement of the angle of trunk rotation with a scoliometer (",
"      <a class=\"graphic graphic_picture graphicRef57756 \" href=\"mobipreview.htm?33/0/33806\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Scoliosis examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographs are indicated for patients with an angle of trunk rotation as measured with the scoliometer of &ge;7&ordm; and clinically obvious scoliosis. In addition, radiographs may be indicated in skeletally immature patients with asymmetry on examination and a family history of scoliosis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The initial radiographic evaluation for scoliosis should include standing, full-length posteroanterior and lateral views of the spine (C7 to the sacrum and iliac crest) exposed on a single long film cassette. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Views'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Important radiographic findings include assessment of the paravertebral soft tissues and the bony spine, the direction and magnitude of the curve(s) (as measured by the Cobb angle) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62495 \" href=\"mobipreview.htm?28/39/29297\">",
"       image 2",
"      </a>",
"      ), and skeletal maturity (ie, the Risser sign). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance (MR) imaging is indicated in patients with associated neurologic signs or symptoms, early age of onset with rapid progression, and abnormalities on plain radiographs that suggest congenital scoliosis or intraspinal pathology. MR imaging also may be indicated in patients with complaints of significant pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      left thoracic curves. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of AIS is made clinically and radiographically. Criteria for the diagnosis include age &ge;10 years at onset, Cobb angle of &ge;10&ordm;, and exclusion of other etiologies for scoliosis (",
"      <a class=\"graphic graphic_table graphicRef50548 \" href=\"mobipreview.htm?7/13/7390\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk for progression is directly related to the magnitude of the curve and indirectly related to skeletal maturity at the time of diagnosis. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Risk for progression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications for referral to an orthopedic surgeon include angle of trunk rotation (as measured with the scoliometer) of &ge;7&ordm;, Cobb angle &ge;20&ordm;, and progression of Cobb angle of &gt;5&ordm;. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A spinal examination should be included in the physical examination of children and adolescents at routine health supervision visits. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Scoliosis screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/1\">",
"      Kane WJ. Scoliosis prevalence: a call for a statement of terms. Clin Orthop Relat Res 1977; :43.",
"     </a>",
"    </li>",
"    <li>",
"     Tachdijan MO. The Spine. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management, Appleton and Lange, Stamford, CT 1997. p.325.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/3\">",
"      Stirling AJ, Howel D, Millner PA, et al. Late-onset idiopathic scoliosis in children six to fourteen years old. A cross-sectional prevalence study. J Bone Joint Surg Am 1996; 78:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/4\">",
"      McAlister WH, Shackelford GD. Classification of spinal curvatures. Radiol Clin North Am 1975; 13:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/5\">",
"      Goldstein LA, Waugh TR. Classification and terminology of scoliosis. Clin Orthop Relat Res 1973; :10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/6\">",
"      Riseborough EJ, Wynne-Davies R. A genetic survey of idiopathic scoliosis in Boston, Massachusetts. J Bone Joint Surg Am 1973; 55:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/7\">",
"      Roach JW. Adolescent idiopathic scoliosis. Orthop Clin North Am 1999; 30:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/8\">",
"      Gore DR, Passehl R, Sepic S, Dalton A. Scoliosis screening: results of a community project. Pediatrics 1981; 67:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/9\">",
"      Miller NH. Cause and natural history of adolescent idiopathic scoliosis. Orthop Clin North Am 1999; 30:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/10\">",
"      Weinstein SL. Adolescent idiopathic scoliosis: prevalence and natural history. Instr Course Lect 1989; 38:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/11\">",
"      Inoue M, Minami S, Kitahara H, et al. Idiopathic scoliosis in twins studied by DNA fingerprinting: the incidence and type of scoliosis. J Bone Joint Surg Br 1998; 80:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/12\">",
"      Kesling KL, Reinker KA. Scoliosis in twins. A meta-analysis of the literature and report of six cases. Spine (Phila Pa 1976) 1997; 22:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/13\">",
"      Wynne-Davies R. Familial (idiopathic) scoliosis. A family survey. J Bone Joint Surg Br 1968; 50:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/14\">",
"      Salehi LB, Mangino M, De Serio S, et al. Assignment of a locus for autosomal dominant idiopathic scoliosis (IS) to human chromosome 17p11. Hum Genet 2002; 111:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/15\">",
"      Chan V, Fong GC, Luk KD, et al. A genetic locus for adolescent idiopathic scoliosis linked to chromosome 19p13.3. Am J Hum Genet 2002; 71:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/16\">",
"      Clough M, Justice CM, Marosy B, Miller NH. Males with familial idiopathic scoliosis: a distinct phenotypic subgroup. Spine (Phila Pa 1976) 2010; 35:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/17\">",
"      Sharma S, Gao X, Londono D, et al. Genome-wide association studies of adolescent idiopathic scoliosis suggest candidate susceptibility genes. Hum Mol Genet 2011; 20:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/18\">",
"      Gao X, Gordon D, Zhang D, et al. CHD7 gene polymorphisms are associated with susceptibility to idiopathic scoliosis. Am J Hum Genet 2007; 80:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/19\">",
"      Axenovich TI, Zaidman AM, Zorkoltseva IV, et al. Segregation analysis of idiopathic scoliosis: demonstration of a major gene effect. Am J Med Genet 1999; 86:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/20\">",
"      Ward K, Ogilvie J, Argyle V, et al. Polygenic inheritance of adolescent idiopathic scoliosis: a study of extended families in Utah. Am J Med Genet A 2010; 152A:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/21\">",
"      Justice CM, Miller NH, Marosy B, et al. Familial idiopathic scoliosis: evidence of an X-linked susceptibility locus. Spine (Phila Pa 1976) 2003; 28:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/22\">",
"      Ahn UM, Ahn NU, Nallamshetty L, et al. The etiology of adolescent idiopathic scoliosis. Am J Orthop (Belle Mead NJ) 2002; 31:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/23\">",
"      Lonstein JE. Adolescent idiopathic scoliosis. Lancet 1994; 344:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/24\">",
"      Liebergall M, Floman Y, Eldor A. Functional, biochemical, and structural anomalies in platelets of patients with idiopathic scoliosis. J Spinal Disord 1989; 2:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/25\">",
"      Lonstein JE. Scoliosis: surgical versus nonsurgical treatment. Clin Orthop Relat Res 2006; 443:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/26\">",
"      Bunnell WP. The natural history of idiopathic scoliosis before skeletal maturity. Spine (Phila Pa 1976) 1986; 11:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/27\">",
"      Peterson LE, Nachemson AL. Prediction of progression of the curve in girls who have adolescent idiopathic scoliosis of moderate severity. Logistic regression analysis based on data from The Brace Study of the Scoliosis Research Society. J Bone Joint Surg Am 1995; 77:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/28\">",
"      Weinstein SL, Ponseti IV. Curve progression in idiopathic scoliosis. J Bone Joint Surg Am 1983; 65:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/29\">",
"      Ascani E, Bartolozzi P, Logroscino CA, et al. Natural history of untreated idiopathic scoliosis after skeletal maturity. Spine (Phila Pa 1976) 1986; 11:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/30\">",
"      Weinstein SL, Zavala DC, Ponseti IV. Idiopathic scoliosis: long-term follow-up and prognosis in untreated patients. J Bone Joint Surg Am 1981; 63:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/31\">",
"      Weinstein SL. Idiopathic scoliosis. Natural history. Spine (Phila Pa 1976) 1986; 11:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/32\">",
"      Asher MA, Burton DC. Adolescent idiopathic scoliosis: natural history and long term treatment effects. Scoliosis 2006; 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/33\">",
"      Cordover AM, Betz RR, Clements DH, Bosacco SJ. Natural history of adolescent thoracolumbar and lumbar idiopathic scoliosis into adulthood. J Spinal Disord 1997; 10:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/34\">",
"      Weinstein SL, Dolan LA, Spratt KF, et al. Health and function of patients with untreated idiopathic scoliosis: a 50-year natural history study. JAMA 2003; 289:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/35\">",
"      Pehrsson K, Bake B, Larsson S, Nachemson A. Lung function in adult idiopathic scoliosis: a 20 year follow up. Thorax 1991; 46:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/36\">",
"      Branthwaite MA. Cardiorespiratory consequences of unfused idiopathic scoliosis. Br J Dis Chest 1986; 80:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/37\">",
"      Dickson RA. Conservative treatment for idiopathic scoliosis. J Bone Joint Surg Br 1985; 67:176.",
"     </a>",
"    </li>",
"    <li>",
"     Newton PO, Wenger DR. Idiopathic scoliosis. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RJ, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.693.",
"    </li>",
"    <li>",
"     Sponseller PD. Bone, joint, and muscle problems. In: Oski's Pediatrics: Principles and Practice, 4th ed, McMillan JA, Feigin RD, DeAngelis CD, Jones MD Jr (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.2488.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/40\">",
"      Mehta MH. Pain provoked scoliosis. Observations on the evolution of the deformity. Clin Orthop Relat Res 1978; :58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/41\">",
"      Ramirez N, Johnston CE, Browne RH. The prevalence of back pain in children who have idiopathic scoliosis. J Bone Joint Surg Am 1997; 79:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/42\">",
"      Renshaw TS. Idiopathic scoliosis in children. Curr Opin Pediatr 1993; 5:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/43\">",
"      Richards BS, Bernstein RM, D'Amato CR, Thompson GH. Standardization of criteria for adolescent idiopathic scoliosis brace studies: SRS Committee on Bracing and Nonoperative Management. Spine (Phila Pa 1976) 2005; 30:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/44\">",
"      Charry O, Koop S, Winter R, et al. Syringomyelia and scoliosis: a review of twenty-five pediatric patients. J Pediatr Orthop 1994; 14:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/45\">",
"      Zadeh HG, Sakka SA, Powell MP, Mehta MH. Absent superficial abdominal reflexes in children with scoliosis. An early indicator of syringomyelia. J Bone Joint Surg Br 1995; 77:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/46\">",
"      Yngve D. Abdominal reflexes. J Pediatr Orthop 1997; 17:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/47\">",
"      Reamy BV, Slakey JB. Adolescent idiopathic scoliosis: review and current concepts. Am Fam Physician 2001; 64:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/48\">",
"      Barnes PD, Brody JD, Jaramillo D, et al. Atypical idiopathic scoliosis: MR imaging evaluation. Radiology 1993; 186:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/49\">",
"      Mejia EA, Hennrikus WL, Schwend RM, Emans JB. A prospective evaluation of idiopathic left thoracic scoliosis with magnetic resonance imaging. J Pediatr Orthop 1996; 16:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/50\">",
"      Schwend RM, Hennrikus W, Hall JE, Emans JB. Childhood scoliosis: clinical indications for magnetic resonance imaging. J Bone Joint Surg Am 1995; 77:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/51\">",
"      Wu L, Qiu Y, Wang B, et al. The left thoracic curve pattern: a strong predictor for neural axis abnormalities in patients with \"idiopathic\" scoliosis. Spine (Phila Pa 1976) 2010; 35:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/52\">",
"      Grossman TW, Mazur JM, Cummings RJ. An evaluation of the Adams forward bend test and the scoliometer in a scoliosis school screening setting. J Pediatr Orthop 1995; 15:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/53\">",
"      Huang SC. Cut-off point of the Scoliometer in school scoliosis screening. Spine (Phila Pa 1976) 1997; 22:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/54\">",
"      Bunnell WP. Outcome of spinal screening. Spine (Phila Pa 1976) 1993; 18:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/55\">",
"      C&ocirc;t&eacute; P, Kreitz BG, Cassidy JD, et al. A study of the diagnostic accuracy and reliability of the Scoliometer and Adam's forward bend test. Spine (Phila Pa 1976) 1998; 23:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/56\">",
"      Goldberg CJ, Dowling FE, Fogarty EE, Moore DP. School scoliosis screening and the United States Preventive Services Task Force. An examination of long-term results. Spine (Phila Pa 1976) 1995; 20:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/57\">",
"      Karachalios T, Sofianos J, Roidis N, et al. Ten-year follow-up evaluation of a school screening program for scoliosis. Is the forward-bending test an accurate diagnostic criterion for the screening of scoliosis? Spine (Phila Pa 1976) 1999; 24:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/58\">",
"      Viviani GR, Budgell L, Dok C, Tugwell P. Assessment of accuracy of the scoliosis school screening examination. Am J Public Health 1984; 74:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/59\">",
"      Bunnell WP. An objective criterion for scoliosis screening. J Bone Joint Surg Am 1984; 66:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/60\">",
"      Murrell GA, Coonrad RW, Moorman CT 3rd, Fitch RD. An assessment of the reliability of the Scoliometer. Spine (Phila Pa 1976) 1993; 18:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/61\">",
"      Amendt LE, Ause-Ellias KL, Eybers JL, et al. Validity and reliability testing of the Scoliometer. Phys Ther 1990; 70:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/62\">",
"      Sapkas G, Papagelopoulos PJ, Kateros K, et al. Prediction of Cobb angle in idiopathic adolescent scoliosis. Clin Orthop Relat Res 2003; :32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/63\">",
"      Korovessis PG, Stamatakis MV. Prediction of scoliotic cobb angle with the use of the scoliometer. Spine (Phila Pa 1976) 1996; 21:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/64\">",
"      Ashworth MA, Hancock JA, Ashworth L, Tessier KA. Scoliosis screening. An approach to cost/benefit analysis. Spine (Phila Pa 1976) 1988; 13:1187.",
"     </a>",
"    </li>",
"    <li>",
"     Screening for Idiopathic Scoliosis in Adolescents, Topic Page. June 2004. U.S. Preventive Services Task Force. www.ahrq.gov/clinic/uspstf/uspsaisc.htm (Accessed on February 28, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/66\">",
"      Bunnell WP. Selective screening for scoliosis. Clin Orthop Relat Res 2005; :40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/67\">",
"      Cassar-Pullicino VN, Eisenstein SM. Imaging in scoliosis: what, why and how? Clin Radiol 2002; 57:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/68\">",
"      Skaggs DL. Referrals from scoliosis screenings. Am Fam Physician 2001; 64:32, 34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/69\">",
"      Maenza RA. Juvenile and adolescent idiopathic scoliosis: magnetic resonance imaging evaluation and clinical indications. J Pediatr Orthop B 2003; 12:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/70\">",
"      Redla S, Sikdar T, Saifuddin A. Magnetic resonance imaging of scoliosis. Clin Radiol 2001; 56:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/71\">",
"      Davids JR, Chamberlin E, Blackhurst DW. Indications for magnetic resonance imaging in presumed adolescent idiopathic scoliosis. J Bone Joint Surg Am 2004; 86-A:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/72\">",
"      Malfair D, Flemming AK, Dvorak MF, et al. Radiographic evaluation of scoliosis: review. AJR Am J Roentgenol 2010; 194:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/73\">",
"      Diab M, Landman Z, Lubicky J, et al. Use and outcome of MRI in the surgical treatment of adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2011; 36:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/74\">",
"      Ouellet JA, LaPlaza J, Erickson MA, et al. Sagittal plane deformity in the thoracic spine: a clue to the presence of syringomyelia as a cause of scoliosis. Spine (Phila Pa 1976) 2003; 28:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/75\">",
"      Loder RT, Stasikelis P, Farley FA. Sagittal profiles of the spine in scoliosis associated with an Arnold-Chiari malformation with or without syringomyelia. J Pediatr Orthop 2002; 22:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/76\">",
"      Spiegel DA, Flynn JM, Stasikelis PJ, et al. Scoliotic curve patterns in patients with Chiari I malformation and/or syringomyelia. Spine (Phila Pa 1976) 2003; 28:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/77\">",
"      Goldberg CJ, Moore DP, Fogarty EE, Dowling FE. Left thoracic curve patterns and their association with disease. Spine (Phila Pa 1976) 1999; 24:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/78\">",
"      Greiner KA. Adolescent idiopathic scoliosis: radiologic decision-making. Am Fam Physician 2002; 65:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/79\">",
"      Beuerlein MJ, Raso VJ, Hill DL, et al. Changes in alignment of the scoliotic spine in response to lateral bending. Spine (Phila Pa 1976) 2003; 28:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/80\">",
"      Cheh G, Lenke LG, Lehman RA Jr, et al. The reliability of preoperative supine radiographs to predict the amount of curve flexibility in adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2007; 32:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/81\">",
"      Sanders JO, Khoury JG, Kishan S, et al. Predicting scoliosis progression from skeletal maturity: a simplified classification during adolescence. J Bone Joint Surg Am 2008; 90:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/82\">",
"      King HA, Moe JH, Bradford DS, Winter RB. The selection of fusion levels in thoracic idiopathic scoliosis. J Bone Joint Surg Am 1983; 65:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/83\">",
"      Lenke LG. Lenke classification system of adolescent idiopathic scoliosis: treatment recommendations. Instr Course Lect 2005; 54:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/84\">",
"      Dickson RA, Weinstein SL. Bracing (and screening)--yes or no? J Bone Joint Surg Br 1999; 81:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/85\">",
"      Oda M, Rauh S, Gregory PB, et al. The significance of roentgenographic measurement in scoliosis. J Pediatr Orthop 1982; 2:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/86\">",
"      Goldberg MS, Poitras B, Mayo NE, et al. Observer variation in assessing spinal curvature and skeletal development in adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 1988; 13:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/87\">",
"      Morrissy RT, Goldsmith GS, Hall EC, et al. Measurement of the Cobb angle on radiographs of patients who have scoliosis. Evaluation of intrinsic error. J Bone Joint Surg Am 1990; 72:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/88\">",
"      Pruijs JE, Hageman MA, Keessen W, et al. Variation in Cobb angle measurements in scoliosis. Skeletal Radiol 1994; 23:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/89\">",
"      Dang NR, Moreau MJ, Hill DL, et al. Intra-observer reproducibility and interobserver reliability of the radiographic parameters in the Spinal Deformity Study Group's AIS Radiographic Measurement Manual. Spine (Phila Pa 1976) 2005; 30:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/90\">",
"      Carman DL, Browne RH, Birch JG. Measurement of scoliosis and kyphosis radiographs. Intraobserver and interobserver variation. J Bone Joint Surg Am 1990; 72:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/91\">",
"      Lonstein JE, Carlson JM. The prediction of curve progression in untreated idiopathic scoliosis during growth. J Bone Joint Surg Am 1984; 66:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/92\">",
"      Sanders JO, Browne RH, Cooney TE, et al. Correlates of the peak height velocity in girls with idiopathic scoliosis. Spine (Phila Pa 1976) 2006; 31:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/93\">",
"      Bunch WH, Dvonch VM. Pitfalls in the assessment of skeletal immaturity: an anthropologic case study. J Pediatr Orthop 1983; 3:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/94\">",
"      Little DG, Sussman MD. The Risser sign: a critical analysis. J Pediatr Orthop 1994; 14:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/95\">",
"      Wang WW, Xia CW, Zhu F, et al. Correlation of Risser sign, radiographs of hand and wrist with the histological grade of iliac crest apophysis in girls with adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2009; 34:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/96\">",
"      Charles YP, Dim&eacute;glio A, Canavese F, Daures JP. Skeletal age assessment from the olecranon for idiopathic scoliosis at Risser grade 0. J Bone Joint Surg Am 2007; 89:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/97\">",
"      Dim&eacute;glio A, Charles YP, Daures JP, et al. Accuracy of the Sauvegrain method in determining skeletal age during puberty. J Bone Joint Surg Am 2005; 87:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/98\">",
"      Nachemson AL, Peterson LE. Effectiveness of treatment with a brace in girls who have adolescent idiopathic scoliosis. A prospective, controlled study based on data from the Brace Study of the Scoliosis Research Society. J Bone Joint Surg Am 1995; 77:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/99\">",
"      Tan KJ, Moe MM, Vaithinathan R, Wong HK. Curve progression in idiopathic scoliosis: follow-up study to skeletal maturity. Spine (Phila Pa 1976) 2009; 34:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/100\">",
"      Lonstein JE, Winter RB. The Milwaukee brace for the treatment of adolescent idiopathic scoliosis. A review of one thousand and twenty patients. J Bone Joint Surg Am 1994; 76:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/101\">",
"      Miller NH. Idiopathic scoliosis: cracking the genetic code and what does it mean? J Pediatr Orthop 2011; 31:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/102\">",
"      Ward K, Ogilvie JW, Singleton MV, et al. Validation of DNA-based prognostic testing to predict spinal curve progression in adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2010; 35:E1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/103\">",
"      Ogilvie JW. Update on prognostic genetic testing in adolescent idiopathic scoliosis (AIS). J Pediatr Orthop 2011; 31:S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/104\">",
"      Montgomery F, Willner S. The natural history of idiopathic scoliosis. A study of the incidence of treatment. Spine (Phila Pa 1976) 1988; 13:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/105\">",
"      Montgomery F, Willner S. Screening for idiopathic scoliosis. Comparison of 90 cases shows less surgery by early diagnosis. Acta Orthop Scand 1993; 64:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/106\">",
"      Richards BS, Vitale MG. Screening for idiopathic scoliosis in adolescents. An information statement. J Bone Joint Surg Am 2008; 90:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/107\">",
"      Screening for adolescent idiopathic scoliosis. Policy statement. US Preventive Services Task Force. JAMA 1993; 269:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/108\">",
"      Yawn BP, Yawn RA, Hodge D, et al. A population-based study of school scoliosis screening. JAMA 1999; 282:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/109\">",
"      Koukourakis I, Giaourakis G, Kouvidis G, et al. Screening school children for scoliosis on the island of Crete. J Spinal Disord 1997; 10:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/110\">",
"      Bremberg S, Nilsson-Berggren B. School screening for adolescent idiopathic scoliosis. J Pediatr Orthop 1986; 6:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/111\">",
"      Pruijs JE, van der Meer R, Hageman MA, et al. The benefits of school screening for scoliosis in the central part of The Netherlands. Eur Spine J 1996; 5:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/112\">",
"      Bunge EM, Juttmann RE, van Biezen FC, et al. Estimating the effectiveness of screening for scoliosis: a case-control study. Pediatrics 2008; 121:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/113\">",
"      Goldberg CJ, Dowling FE, Hall JE, Emans JB. A statistical comparison between natural history of idiopathic scoliosis and brace treatment in skeletally immature adolescent girls. Spine (Phila Pa 1976) 1993; 18:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/114\">",
"      Screening for adolescent idiopathic scoliosis. Review article. US Preventive Services Task Force. JAMA 1993; 269:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/115\">",
"      Dolan LA, Donnelly MJ, Spratt KF, Weinstein SL. Professional opinion concerning the effectiveness of bracing relative to observation in adolescent idiopathic scoliosis. J Pediatr Orthop 2007; 27:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/116\">",
"      Dolan LA, Weinstein SL. Surgical rates after observation and bracing for adolescent idiopathic scoliosis: an evidence-based review. Spine (Phila Pa 1976) 2007; 32:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/117\">",
"      Marsh JS. Screening for scoliosis. Pediatr Rev 1993; 14:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/62/33770/abstract/118\">",
"      Willner S. Development of trunk asymmetries and structural scoliosis in prepuberal school children in Malm&ouml;: follow-up study of children 10-14 years of age. J Pediatr Orthop 1984; 4:452.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Family Physicians (AAFP). Clinical preventive services. January 2010. www.aafp.org/online/en/home/clinical/exam.html (Accessed on August 31, 2011).",
"    </li>",
"    <li>",
"     Canadian Task Force on the Periodic Health Examination. In: Canadian Guide to Clinical Preventive Care, Canada Communication Group, Ottawa 1994. p.346.",
"    </li>",
"    <li>",
"     Bright Futures Encounter Forms for Health Professionals. www.brightfutures.org/encounter/provider/index.html (Accessed on June 13, 2006).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6286 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33770=[""].join("\n");
var outline_f32_62_33770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Etiologic classification of scoliosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Scoliosis examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Inspection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Forward bend test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Use of a scoliometer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RADIOGRAPHIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Views",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - General",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Curve pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cobb angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Skeletal maturity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Risser sign",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      RISK FOR PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H568342362\">",
"      Natural history studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H568342369\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SCOLIOSIS SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Recommendations of expert groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6286\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6286|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/58/24494\" title=\"diagnostic image 1\">",
"      Thoracolumbar scoliosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/39/29297\" title=\"diagnostic image 2\">",
"      Cobb angle measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6286|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/38/29283\" title=\"figure 1A\">",
"      Pubertal events girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/1/44048\" title=\"figure 1B\">",
"      Pubertal events boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/1/44050\" title=\"figure 2A\">",
"      CDC stature for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/10/29858\" title=\"figure 2B\">",
"      CDC stature for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/54/9071\" title=\"figure 3\">",
"      Adams forward bend test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/28/44481\" title=\"figure 4\">",
"      Risser sign",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6286|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/43/10932\" title=\"picture 1\">",
"      Sexual maturity rating of breast development in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/33/30227\" title=\"picture 2\">",
"      Sexual maturity rating of pubic hair in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/0/20495\" title=\"picture 3\">",
"      Scoliosis truncal asymmetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/0/33806\" title=\"picture 4\">",
"      Use of the scoliometer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6286|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/13/7390\" title=\"table 1\">",
"      Classification scoliosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19162?source=related_link\">",
"      Back pain in children and adolescents: Overview of causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2679?source=related_link\">",
"      Evaluation of the child with back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15432?source=related_link\">",
"      Friedreich ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=related_link\">",
"      Normal growth patterns in infants and prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21895?source=related_link\">",
"      Overview of hereditary neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/20/18754?source=related_link\">",
"      Patient information: Scoliosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37065?source=related_link\">",
"      Treatment and prognosis of adolescent idiopathic scoliosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_62_33771="Okuda staging system for HCC";
var content_f32_62_33771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Okuda staging system for hepatocellular carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive",
"       </td>",
"       <td class=\"subtitle1\">",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor size*",
"       </td>",
"       <td>",
"        &gt;50 percent",
"       </td>",
"       <td>",
"        &lt;50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascites",
"       </td>",
"       <td>",
"        Clinically detectable",
"       </td>",
"       <td>",
"        Clinically absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albumin",
"       </td>",
"       <td>",
"        &lt;3 mg/dL",
"       </td>",
"       <td>",
"        &gt;3 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilirubin",
"       </td>",
"       <td>",
"        &gt;3 mg/dL",
"       </td>",
"       <td>",
"        &lt;3 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Stage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        No positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        One or two positives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td colspan=\"2\">",
"        Three or four positives",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The Okuda system is commonly used for staging hepatocellular carcinoma. Survival correlates with the Okuda stage in untreated patients (8.3, 2.0, and 0.7 months for stages I, II, and III, respectively).",
"    <div class=\"footnotes\">",
"     * Largest cross-sectional area of tumor to largest cross-sectional area of the liver.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Okuda K, Ohtuiki T, Obata H, et al. Cancer 1985; 56:918.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33771=[""].join("\n");
var outline_f32_62_33771=null;
var title_f32_62_33772="15year prost CA surv rising PSA";
var content_f32_62_33772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    10 and 15-year likelihood of prostate cancer-specific survival after biochemical (PSA) recurrence following radical prostatectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        PSADT, months",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Risk",
"estimate, percent (95 percent confidence interval)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Recurrence",
"&gt;3 years after surgery",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Recurrence",
"      &le;3 years after",
"surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Gleason score &lt;8",
"       </td>",
"       <td class=\"subtitle3\">",
"        Gleason score &ge;8",
"       </td>",
"       <td class=\"subtitle3\">",
"        Gleason score &lt;8",
"       </td>",
"       <td class=\"subtitle3\">",
"        Gleason score &ge;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        10-year",
"estimate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;15.0",
"       </td>",
"       <td>",
"        98 (96-100)",
"       </td>",
"       <td>",
"        96 (93-98)",
"       </td>",
"       <td>",
"        93 (80-98)",
"       </td>",
"       <td>",
"        86 (61-96)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9.0-14.9",
"       </td>",
"       <td>",
"        95 (75-99)",
"       </td>",
"       <td>",
"        90 (58-98)",
"       </td>",
"       <td>",
"        85 (49-97)",
"       </td>",
"       <td>",
"        69 (30-92)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.0-8.9",
"       </td>",
"       <td>",
"        84 (62-94)",
"       </td>",
"       <td>",
"        68 (37-89)",
"       </td>",
"       <td>",
"        55 (25-82)",
"       </td>",
"       <td>",
"        26 (7-62)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;3.0",
"       </td>",
"       <td>",
"        59 (29-83)",
"       </td>",
"       <td>",
"        30 (10-63)",
"       </td>",
"       <td>",
"        15 (3-53)",
"       </td>",
"       <td>",
"        1 (&lt;1-55)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        15-year",
"estimate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;15.0",
"       </td>",
"       <td>",
"        94 (87-100)",
"       </td>",
"       <td>",
"        87 (79-92)",
"       </td>",
"       <td>",
"        81 (57-93)",
"       </td>",
"       <td>",
"        62 (32-85)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9.0-14.9",
"       </td>",
"       <td>",
"        86 (57-97)",
"       </td>",
"       <td>",
"        72 (35-92)",
"       </td>",
"       <td>",
"        59 (24-87)",
"       </td>",
"       <td>",
"        31 (7-72)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.0-8.9",
"       </td>",
"       <td>",
"        59 (32-81)",
"       </td>",
"       <td>",
"        30 (10-63)",
"       </td>",
"       <td>",
"        16 (4-49)",
"       </td>",
"       <td>",
"        1 (&lt;1-2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;3.0",
"       </td>",
"       <td>",
"        19 (5-51)",
"       </td>",
"       <td>",
"        2 (&lt;1-38)",
"       </td>",
"       <td>",
"        &lt;1 (&lt;1-26)",
"       </td>",
"       <td>",
"        &lt;1 (&lt;1-2)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PSADT: prostate specific antigen doubling time.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Freedland, SJ, et al. JAMA 2005; 294:437.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33772=[""].join("\n");
var outline_f32_62_33772=null;
var title_f32_62_33773="Prob PC death PSA doubling time";
var content_f32_62_33773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Probability of dying of prostate cancer according to number of PSA doublings per year",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 408px; background-image: url(data:image/gif;base64,R0lGODlh7QGYAcQAAP///4CAgAAAAMDAwEBAQP8AAP8QECAgIKCgoDAwMHBwcP/w8LCwsBAQEFBQUNDQ0PDw8ODg4JCQkP8gIP/Q0P9AQP/g4GBgYP+wsP8wMP9QUP+QkP9wcP/AwP+AgP+goCH5BAAAAAAALAAAAADtAZgBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ1OEAgBASKgAQgQnqmqhA8NAgQHIgmvAgmrt7h7BwIPIwwCDgAOAgy5xsdwDwIHu8EBAqPPo8jU1WYDtQOzodAA0iMDouID1uXmVMoE3tASAgoACgIS4OIBBNPn+fpKuwyzAxGWDdgVAYWofQgTDnkwqwECEQh2HXhoEJ/CixiZHMzIsWORjR5DitwBcqTJkzFK/6JcyfKEypYwWb6MSXPkzJo4Od7MyTPhzp5Az/0MSpTa0KJIcR1NytTT0qZQMz2NSpXS1KpYH13NylXR1q5gC30NSxbQ2LJo95xNy9bO2rZw47yNS5fN3Lp4z9zNy1fM3r6Au/wNTBjL4MKIpxxOzNjJ4saQkzyOTJnI5MqYf1zOzFnH5s6ga3wOTRrG6NKoV5xOzdrE6tawvVmMTdvH69qob+MmrXs36N6+OQMPjnk4ccrGj0NOrpwx8+aIn0OXQcFAAQMUqkqfDmNCge8TWFDwXmBCdpjbubv4zt7CCuvsDcRMr54F++/27xdYgH52fSzklccCfODN599/VlR33f95KowHHoMyHYigFfzB4B5N9E3YVoYapsVhh2V9CGJYIo7YVYkmZoViitpJyGJtK74IVYwyMkVjjUjdiCNROu4IVI8+8gRkkDgNSSSGLh4ZmpFKtsRkkys9CeVJUk5pU5JWVlZllh5tyaVOWH7ZmJdiXkRmmT6FiWZhZ66pT5tuCqVmnH3BSac1dt5p1Jx61pVnn8b8CahSfA66YaGGeohooiEuyiiJjj56YqSSqkhppS1iGgQGGFz0AECkhHJKCoJOt4AGBnSaygMFAcBqC610A8AsBNRC6qWanoCBARpUmMo9ItjTwizd/BLMMMW4hGuuI5ya6ioPENDAAQRIq47/ag3EE0033yjLLA679noLNgKUK0ADyaagDAPftCsrAOGIA+y3NDirai4KUNTCM+ay4w488tAj77KYhuurMZ8OMEAvKkSg8AUCXBBBQAcMJECrrhH8qL3VxGPutSx0G9Ey+mZMLwwGW3OuOCX3UCpsHJdzgMaq0dxnyuYoQIDCCwfxMmoxn1Prxz7bHCfO+YTCctEnnxD0PuxGEADDmhldJtL7eDyAAxcw3bQITyPUwAUJhAOybVZniXVCAgyw8wVnu5w2lGErREACBwwzDxA/R7a2p67UggrfcxNZN0c9C9F3Yh1MIK5IDtgSQQOFL07YAhw8axIxIujstaSNP755/7KeEy4p5pqj5EC28exd9aOhH3zSA7sI/jmgqN8LU+K36xk7TdV+VHiHuRcZt+m+Oy47TPFUS8A7yMdZPE9Dl3s8ScPX13gFFyZmOVmob0AUQ20f4Draa27fPVAJNNDAAKW/Lmb4SRGzs7DRZ6k+Uw1IQAADB+ha/uiWOfE1hV/lIscAlbS/qPjPAemSX5PoVxUI8G6BPmogVRBgrgQMToJBoiBWphWAeAgQhDvS4AgVGD/0+UiEXCnhwxxwQexlcALcI0v1iOZCGcEQLEqrR8s8kz3SqBA238PJD2OTRJockTZNbMkSYVTEyjwRLg8YFQa5M8W4YINyH+RBFE1yxf+6mC1tYwxJF+EygDD2DjpljIu0LkC1LQZnjXRBALHM50YbTieOeRlA4N4lxir2BY940WO5AkgtFPoGkHmp1QXSVUc/3rGAkWmj8IgDyb7kSwQSqJwh4YLIvlgwARdQmAOuR8TddLIv5OrXCXsIM0xiRmrUEoUE+mjJ1rwSCQuowHcqsLyQvMoyowxLKZcgTPZU4CQEeIDOnAc9R4bml0rQTwHW55G27ZCVOUhjLpbZBG3iRZy3wCYTmjnMk/DsnZUsJEsUhJ0rkPMJwRxmMTnSLx5aMyQBCk8V1BkFboqkHkuzY0f0Y9Am3PNF6ByDfqZAgQzkMDbRnGa1qklLkwT/VAoeMIABaePNfoETBxEVAz0hxISKXlRMKR3DPpMQ0pH6BgI6g6DikgkUlza0NjuMoNwaU1PodAMCCTjpDWL6CJ9O53/BUqoNmNqIoiLhA9YxwAfaUi28VStvb8REPgtAzBVg9TpbxYJTk0Ag+bCln9YL6yXYSdb3xAcLVs3mfYhD1R1o86cimGgVKpoBliKhrXF5wCo3KldLmFMFiKWCBwrggSecVatxIVZcFUoJuj5TBZdNaxQIa9gtrBQqAuAgAC4gSk+MtaxhmGxlWxBaKHy0KeWDn1RFw1M8ADYLpH1BZJ3A0KbMDGLAaGxXZBsDwRJ3r015wAMg4AAH8LKV/2kJbgyG24TbNsWC8RwqWpg7g9o+4bRN4WC5PKjcqGhXDTMNCglN2N6mkHdH7+vcbmnQ1zu8t0YPU8AM61uU++4Irq8gcE8zUNgjIVQUQ+wlVAz8NRL0Fw7/VRJ1z8XRjiKFwk2q1d0IKd6kZBhKnIPHfmdw4TWAeEqUAwB1g8HZmJzYSh4rl1DlSZQXQwG9lXngjnnckxtHwbuRQUCEPUwTH0uhuJRZ5SZzYuQpODfJFVNYeLFbEydTAcmQ+aaCO1Ll18a3CEBOshDHnBEvA8CzUThzYWpYY45UeQR/bRJSN9uCCIRyl6EyxXVl0xI34/nKROJgArbhgurZYla0eP+0t1By5xLAuUkBeHQC5sQACEBgFwMwljBSbLKTGLoEZoZSAGa26nss+QQEcZeEWpwgBpfWBb/FEQL9uYJ2vEPWAhPFvEJy6jvFa80soC8AfA0w1x3bHr2FRKUrPIJhsBogAiFIRTxSbGoDoJ+jGNlEbmVnW3sbmW2m7LmnnJBprzuc0UZEt9+91HgXwt30hvc+5p3veufDAubutxFoTQLz6mADBpitwAdu7y9w1wYWqECDF34Egh+aPTlAuMIpznBGPFwGEZ84xyvecC8YfAYaH7kSLL6DkN96CqmuFMsznvAuXFpSM4e4xF9ehTzjvORySPkXHvvzVETcPGG4+aP/ch4DhHNAzhRqJmyLvomjd+AMue4T01vgdKirnOSZsPrXq7D1FHR97GQHuhnEjva0V+LsbXe7JNged7lDAu51t3sj6J53vS8C7333OyL4HnjBGwLwhTf8IAifeMUHAvGNd7wfGB95yWOYPEgvAeQrb/k3EOg6JKA85zvvBm1WaPOjJ30bPh8e0ade9WxwUHkogPrXw94NFnC97W/fhtrvnvdq0P3vgY8G3w+f+GUQ/vGRPwbjL5/5YFD+86HvBedPn/pbkP71sZ8F62+f+1bQ/vfBTwXvj5/8Ba3ABK5+/jG0yfztR38TxB9/K3gJ/vWXfxLon3/7q50G+Nd/+lcE/8G0fgKoF/+HMgbwdAeIgGBwKgbYgA7oBbvCgBI4gVsAgex3gRiYBRXodRy4BSuigSGoBijygSVogglIAiTYAmmWglTwISjoAmAGg1KQIc6ygetxH1lng5KRgH+THxjngzGodofTAjVIhI4BdEHoAi+ohEvoBEcYAyAIheymBE1ohWYwHFOohVvYW1nohV8ITKiiO2JoF6MUhmc4hkTQhWvYgUCghm/IhkDghnMIhzwgh3dIhzxgh3uIh+DCK1VYcFklWn94BYfhhynwcYeoGDSjhyqAaI3oiDmgiHb1HW41idgHiSxwcpp4g5diiZ8IiC6gh544il+wFpwiXHeFiv9+YUiS6Ipc8BqMKIta8BqnaIu3uIK66H80IHuZ14ttcBafl4nCuAZnYXrHiIY0wHrLyIwzAIw894xhMBc9SI1RUApaNGnYOAe0Yivb1o1yIGrIEo7iCAfAxo3n6AbpCC/1UC0PFo/yOI/0WI/2eI/4mI/6uI/82I/++I8AGZACOZABqUDmwGytE2wEGY/wmI8NiY8PaY8RKZH34JAVCZEXSZH6OJH1yJH06JHyCJIhmZEaaZEmeZL5aJDlQDEWgzFXGDKFMhVXMZMxySc0aRo1+QI3qZM56QI7iRLi9mp1NgI/CZM4eZQ8mZRK6ZM9uS9N6ZRICZVLGRhFaZRMGZX/UnmVWrmVWdmVNYOVVsmVXzmVgFGVY+mVZ4mWKiCTTxmWammObwmXbpmWc1knbUmXa3mXeQmWe0mWeNmXcamOdQmYg0lubKKXhhmYpSaWfymXjemYhPmYgimZi1mYkBlIKskCCgMDm+kCnemZmbkCn9kCoymaoakCpWmanHmaKJCaqMmarQmbJ+Casbma63ibuJmburmbvNmbvvmbCaGNgwYDwlkCFsQzW+aZ4eVnATBknBlPx6llM8CcgFYCzOmcLECdbhSddPYCDxBK2zgC1zkD3yloxglPN/ApLikC40maPCMDz1MC8YkA0YQDCjBLl/CNkmYD+lkCsZRg5PkM/8czOQ0wCx3mnQJqAv+5YiTgaNbpPgY6Aw5KAgtaAyb1oAX6LzFwoRTKoTQQK7NBoBHKAv3iEDAAoCOQYOGwnjIQELxYBuRIajQQoxGEDWXTnS0wNMeTkK4wnCmgowqaDTi6Ap32aW1DAjwqAD56AkUKah16o8nJAg8REAJQAkm6pCUwpeXin0IapSxALLNxpSRapRHwDzKmM3QULBRhCt92D/OiogEwMc2pM9MAAXAjCuTwAHDjAPryDAURNQAQCqhAnwSwN4SqU1ITakLpFtxCYjLQjvByLgQgMTWADcdTK+SAqTRgqUHaAJPKojCgbSOgqZpKA6IqAl/0qTYAP/8kRqpHGgOsOhupSqn8lS2teqSlqgJbGqjJ1T6Z1gAFAaAJxmF606broDDW4woPYaAQE6e1EAAXQGMAAFa8Og/TAjAKUKwOoACrdjFfhKJ9AKks1qgWoaf2AI4zwKnyiauvKgPqSgLmWiv7GQPM1qDsKpsqUK8jEK/oOgP0qaGjeq8y8K8dxq/z6p3E0C0Bm6ntmgK7aqnK8A6/MA/Cqg4JBgHDqg7PgKyj8AsBgA1dgw1TswwKUJ2/kCwQUKATCwAklKBSAwttgw0HygcIGTA2ULPnQwK7mq7gKgLlOAtemgLvegI7GwPKRgI/ywszcLREW6U3kKujVgxASwNQq7P/Tvuo4Ia0nDO1K7CrHJRK3SCyxmqsFWusGyu2Iou2xSIt4HgBDUACEDMLqLAMLDM5CYAAEMOxgsCSp0oDfHsxZusA58qg8NoOZTO36sBBELQMH2q4mpRgASC4IjYD1oanxqq4vxALMlC5Hxu4g7upm+YxwZq4wJC5sBq65TK63iC5PfsCDjMAEEOpCYa5jDumA4AA7lMQ07I1SusK9zmsZQMxFKuxMRu20ICxFaMtsMsAgvS2GMtR5EJjw/CxoYANNISpYisIQZkD22usAFQu1kW1/UIOAKoArpAAQYsCO0S+6vC9wIClJpC15Xu+6Ru//TIKCea+4Tude5Qs81sL//Urnv0rAvlbO/srGrLyv+jbAv3iAAxDPuMWqO7TPN8WONADucU7CmKLu7QQp8SywO2wnv1ACm67Mqt1Lv+QvcC5BAigSjI6Ao1EAsi7wl+AXDNzAhDQuSTQDi9Kwz78w0AcxEI8xERcxEZ8xEicxEq8xEzcxE78xFAcxVL8ItppAu1ZqcsZStiJAsVpxeAJAK/7ni/QxSPAnQEsw6JyXQoDv4EWnqgqCukSL1uMxuZZAg8AYeIZSvVLxvuKxzKGnrHZKurpBC20AvRZR4d8DBMqnhAKsDFwx60roo78pZFmAhzkqc7QTzDQnx3Kay/AyVmaQJtcyZ1cLhp8v8NCyv9WWy7v0ArT8sIoAMopai7vUKEGcbHuw8YMzKC1opMNu7HH0KQNK6bwyWcjQMwsQKMkQDEf9LrxoLktoMzg0KUyIM2MLMouYM1gTA4cpA4Ow6tSpc2B6ipbiiwUk8zJVY4k8BDKUKU2Kp1c3A/PMA85TAA6pWKT2gvhkEXk4D/PgzEcNDMFIWQmwAD2vAsiwACrtDcr6o5SIw/V1QvAXM/3vAp966r4KrSti9E+Sa47XAuucD67sKgW5tHT7Km0ahomParV0rCqsdIjgACrky4yjS4hA9Piybi1UgxFe8vbciDnPKug6gvLAI6+OrUzY76x8AyuAK3ukGkGGQ+eKk3/7qDOCf2sCG0s8fBrR7qxAhoA7nOss0I5XJsK+ioCHM2zlyqw+wLTzzBJrtAqAa3SPw2vrCWvWFvXIyABwFq1a4nT8NA++qIAgn3Tel0C5XjJQ2PY63Ag5WiwKzA0vZAOTq3BOuMK65AswyC4mQmgBSpjyVVtgNvLw4AK7SPWXn2k8RAObUPZzaoKTOuzW6u0am0CSVu/OPvRo1CqIw0Dud20MvDbaN1PGQ1K/5KQwG21LCDcpFAr+sIu3bzcx22zZezc9iuaAGqp42As/lClwCxjZKNjOnstZRuwww0AvYze3t3VbQPMqY2sF1ncksC57MuriwvNj+y4iGvfpusC/3+ruhTDALm8DvjdZ9kGuJDLuoQLxgeuugkzC9WZnQ3uuda2upFbuw0z4QlWpq8gChPDAN09xwxeMdq24bTi4ZH7uaiJou7TwhLADc2J0N99ARLAqucjEBGALPNc0jFepTwsaobbrawtAQL+tsDc4gPw4qkgv9divgAsvuZS3/BAvzDQvQAqbr2QsrAspRJBEQUMvroc011OwGfj1ypg5e1bO/XpvvXJ5SRD5pE6vuSSACIOEWNurP/ZNvrro++qWIvUabPADOutQGDNYSXAL9M1DNlinLUi6J3jCuELAfI6DKztCgcg0Ufq58tQ51Pc6Z7+6aAe6qI+6qRe6qZ+6guonuqqvuqsfuohAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Albertsen, PC, Hanley, JA, Penson, DF, Fine, J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004; 171:2223.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33773=[""].join("\n");
var outline_f32_62_33773=null;
var title_f32_62_33774="Vaginal agenesis rudiment horns";
var content_f32_62_33774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vaginal agenesis with rudimentary uterine horns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Of note, in cases of vaginal agenesis the uterus may be normal or exhibit a variety of malformations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33774=[""].join("\n");
var outline_f32_62_33774=null;
var title_f32_62_33775="Pentax Airway Scope";
var content_f32_62_33775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Pentax Airway Scope&reg;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 473px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Pentax Airway Scope&reg; has a disposable L-shaped plastic blade with a video display integrated into the handle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: PENTAX Medical Company. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_62_33775=[""].join("\n");
var outline_f32_62_33775=null;
